+

US20100081670A1 - N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases - Google Patents

N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases Download PDF

Info

Publication number
US20100081670A1
US20100081670A1 US12/435,864 US43586409A US2010081670A1 US 20100081670 A1 US20100081670 A1 US 20100081670A1 US 43586409 A US43586409 A US 43586409A US 2010081670 A1 US2010081670 A1 US 2010081670A1
Authority
US
United States
Prior art keywords
pyrazinyl
methoxy
dichloro
benzenesulphonamide
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/435,864
Inventor
Andrew Baxter
Timothy Johnson
Nicholas Kindon
Bryan Roberts
Michael Stocks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200119A external-priority patent/SE0200119D0/en
Priority claimed from SE0201857A external-priority patent/SE0201857D0/en
Application filed by Individual filed Critical Individual
Priority to US12/435,864 priority Critical patent/US20100081670A1/en
Publication of US20100081670A1 publication Critical patent/US20100081670A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Definitions

  • the present invention relates to a sulphonamide compound, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
  • Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small-secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. At the present time, the chemokine superfamily comprises three groups exhibiting characteristic structural motifs, the Cys-X—Cys (C—X—C), Cys-Cys (C—C) and Cys-X 3 -Cys (C—X 3 —C) families.
  • the C—X—C and C—C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues.
  • the C—X 3 —C family is distinguished from the other two families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine residues.
  • the C—X—C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
  • IL-8 interleukin-8
  • NAP-2 neutrophil-activating peptide 2
  • the C—C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 ⁇ and 1 ⁇ (MIP-1 ⁇ and MIP-1 ⁇ ), Thymus and Activation Regulated Chemokine (TARC, CCL17) and Macrophage Derived Chemokine (MDC, CCL22).
  • MCP-1, MCP-2 and MCP-3 human monocyte chemotactic proteins 1-3
  • RANTES Registered on Activation, Normal T Expressed and Secreted
  • eotaxin and the macrophage inflammatory proteins 1 ⁇ and 1 ⁇ MIP-1 ⁇ and MIP-1 ⁇
  • TARC Thymus and Activation Regulated Chemokine
  • MDC Macrophage Derived Chemok
  • the C—X 3 —C chemokine (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.
  • chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C—C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C—X—C family) and CX 3 CR1 for the C—X 3 —C family.
  • These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.
  • the present invention therefore provides a compound of formula (I) and pharmaceutically acceptable salts, solvates or N-oxides thereof:
  • R 1 , R 2 and R 3 are independently hydrogen, halogen, cyano, CF 3 , OCF 3 , OC 1-6 alkyl or C 1-6 alkyl;
  • R 4 is halogen, CO 2 R 12 ,
  • alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
  • OC 1-6 alkylR 11 or OC 2-6 alkyl-X—R 11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR 14 R 15 , SR 13 , S(O) 2 R 13 , S(O)R 13 or COR 13 ;
  • R 5 and R 6 are independently hydrogen, cyano, halogen, CO 2 R 12 , CONR 14 R 15 ;
  • C 1-6 alkyl optionally substituted by hydroxy, NR 14 R 15 , or 1-3 fluorines;
  • NR 14 R 15 N(R 11 )R 11 ; X—(CH 2 )qNR 14 R 15 ; (CH 2 )nNR 14 R 15 ; NHC(O)C 1-6 alkyl optionally substituted by one or more hydroxy groups,
  • n 1, 2, 3, 4 or 5;
  • q 2, 3, 4, 5 or 6;
  • X is NR 13 , O, S, S(O), S(O) 2 ;
  • R 11 is an aryl group or a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur each of which can be optionally substituted by 1-3 groups selected from halogen, C(O)NR 14 R 15 , C(O)OR 12 , hydroxy, ⁇ O, ⁇ S, CN, NO 2 , COR 13 , NR 14 R 15 , X(CH 2 )qNR 14 R 15 , (CH 2 )nNR 14 R 15 , (CH 2 )nOH, SR 13 , S(O)R 13 , S(O) 2 R 13 C 1-6 alkyl-X—C 1-6 alkyl, C 1-6 alkyl or C 1-6 alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR 14 R 15 , SR 13 , S(O)R 13 , S(O) 2 R 13
  • R 12 and R 13 are independently hydrogen or C 1-6 alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;
  • R 14 and R 15 are independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl or (CH 2 )qOH,
  • R 14 and R 15 together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C 1-6 alkyl, C 1-6 alkyl-OH, or hydroxy; and
  • R 16 is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and ⁇ O,
  • aryl includes phenyl and naphthyl.
  • alkyl whether alone or as part of another group, includes straight chain and branched chain alkyl groups.
  • Examples of 5- to 7-membered heteroaromatic ring containing 1 to 4 heteroatoms include thienyl, furanyl, pyrrolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl.
  • saturated 4- to 8-membered rings containing 1 to 3 heteroatoms include morpholine, piperidine and azetidine. Substituents on any rings can be present in any suitable ring position including suitable substituents on nitrogen atoms.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.
  • R 1 , R 2 and R 3 are chloro, bromo and fluoro.
  • one of R 1 , R 2 and R 3 is hydrogen and the other is chloro, bromo or methyl. More preferably R 1 and R 2 are chloro at the 2- and 3-positions of the phenyl ring and R 3 is hydrogen (i.e. 2,3-dichlorophenyl), R 1 and R 3 are chloro at the 2- and 4-positions of the phenyl ring and R 2 is hydrogen (i.e.
  • R 1 is chloro at the 2-position and R 2 is methyl at the 3-position of the phenyl ring and R 3 is hydrogen (i.e 2-chloro-3-methylphenyl).
  • R 1 and R 2 are chloro at the 2- and 3-positions of the phenyl ring and R 3 is hydrogen (i.e. 2,3-dichlorophenyl).
  • the invention provides a compound of formula (I) as defined above but without the provisos where R 1 and R 2 are chloro at the 2- and 3-positions of the phenyl ring and R 3 is hydrogen (i.e. 2,3-dichlorophenyl), R 1 and R 3 are chloro at the 2- and 4-positions of the phenyl ring and R 2 is hydrogen (i.e. 2,4-dichlorophenyl) or R 1 is chloro at the 2-position and R 2 is methyl at the 3-position of the phenyl ring and R 3 is hydrogen (i.e 2-chloro-3-methylphenyl).
  • examples of C 3-6 alkenyloxy include OCH 2 CH ⁇ CH 2
  • examples of C 3-6 alkynyloxy include OCH 2 CCH
  • examples of OC 1-6 alkyl-O—C 1-6 alkyl include OCH 2 CH 2 OMe
  • examples of OC 1-6 alkylR 11 include OCH 2 R 11
  • examples of OC 1-6 alkylR 16 include OCH 2 pyrrolidine.
  • R 4 examples include C 1-6 alkoxy such as methoxy, 2-furanylmethoxy, bromo, chloro, 2-methoxyethoxy, (5-methyl-3-isoxazolyl)methoxy, 2-, 3- or 4-pyridylmethoxy, 3-pyridazinylmethoxy, methoxy, 2-(1-imidazolyl)ethoxy, (2-methyl-4-oxazolyl)methoxy and 4-methoxyphenylmethoxy. More preferably R 4 is methoxy.
  • NR 14 R 15 includes morpholine, pyrrolidine, NMe 2 , NHCH 2 CH 2 OMe, NHMe, and the groups below:
  • Examples of X—(CH 2 )qNR 14 R 15 include SCH 2 CH 2 NH 2 and SCH 2 CH 2 NMe 2 , examples of (CH 2 )nNR 14 R 15 include CH 2 morpholine, examples of X—R 12 includes SMe, OMe, OEt, OH, SO 2 Me, examples of X—C 1-6 alkylR 16 includes OCH 2 pyrrolidine, examples of X—(CH 2 )nCO 2 R 12 includes SCH 2 CO 2 H, SCH 2 CO 2 Me, SCH 2 CH 2 CO 2 Me, examples of X—(CH 2 )nCONR 14 R 15 includes SCH 2 CONH 2 , SCH 2 CONHMe, OCH 2 CONEt 2 , examples of X—(CH 2 )nR 11 includes the groups below:
  • Examples of NHC(O)C 1-6 alkyl optionally substituted by one or more hydroxy groups includes NHCOCH 2 OH.
  • R 5 examples include hydrogen, halogen such as bromo and chloro, phenyl, C 1-6 alkyl such as methyl, CH 2 OH, cyano and 2-aminothanethiol. More preferably R 5 is hydrogen, methyl, CH 2 OH or halogen such bromo or chloro.
  • Preferred groups for R 6 include hydrogen, C 1-6 alkyl, CH 2 OH and halogen, more preferably hydrogen, methyl, CH 2 OH or chloro.
  • R 1 , R 2 and R 3 are independently hydrogen, halogen, cyano, CF 3 , OCF 3 , C 1-6 alkenyl or C 1-6 alkyl;
  • R 4 is halogen, C 1-6 alkoxy or OR 9 ;
  • R 5 and R 6 are independently hydrogen, halogen, C 1-6 alkoxy, C 1-6 alkylthio, cyano, R 9 , OR 9 , NR 9 R 10 , SR 9 , S(CH2) n CO 2 H, S(CH2) n CO 2 R 12 , S(CH 2 ) n CONR 12 R 13 , S(CH2) n R 11 or a 5- to 7-membered heteroaromatic or saturated ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur;
  • n 1, 2 or 3;
  • R 9 and R 10 are independently hydrogen, C 1-6 alkyl optionally substituted by hydroxy, C 1-6 alkoxy or NHCOC 1-6 alkyl, or R 9 and R 10 are optionally substituted aryl, C 1-6 alkyl-aryl or C 1-6 alkyl-R 11 or R 9 and R 10 together with the nitrogen atom to which they are attached form a 4- to 8-membered saturated ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C 1-6 alkyl or C 1-6 alkyl-OH; and
  • R 11 is a 5- to 7-membered heteraromatic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C 1-6 alkyl;
  • R 12 and R 13 are independently hydrogen or C 1-6 alkyl.
  • R 1 , R 2 and R 3 are independently hydrogen, halogen, cyano, CF 3 , OCF 3 , C 1-6 alkenyl or C 1-6 alkyl, preferred halogen groups being chloro.
  • one of R 1 , R 2 and R 3 is methyl, ethenyl, cyano, chloro, fluoro, iodo or two are chloro or all three are fluoro. More preferred are compounds where R 1 -R 3 together with the phenyl group to which they are attached form a 3-chloro-2-methylphenyl or a 2,3-dichlorophenyl group.
  • R 4 preferred groups for R 4 include halogen such as bromo and chloro, C 1-6 alkoxy such as methoxy and ethoxy, C 1-6 alkyl or OR 9 where R 9 is CH 2 R 11 where R 11 is a 5- or 6-membered heteraromatic ring containing 1 or 2 heteroatoms.
  • R 4 is methoxy, halogen, such as chloro, or OR 9 where R 9 is CH 2 R 11 where R 11 is furanyl, 5-methyl-3-isoxazolyl, pyridyl optionally substituted by methyl, pyridazinyl, pyrazinyl, 1-methyl-6-oxo-1,6-dihydro-3-pyridinyl.
  • R 5 is hydrogen, methyl, bromo, chloro, methoxy, morpholinyl, pyrrolinyl, dimethylamino, hydroxy, 2-methoxyethoxy, pyrazinyl, pyrimidinyl, O-Ph-CO 2 H, 2-hydroxyethylamino, 2-methoxyethylamino, NHCH 2 CH 2 NHCOMe, cyano, 4-hydroxymethyl-1-piperidinyl, SMe, NHMe, or 2,4-difluorophenyl.
  • R 6 is hydrogen or chloro.
  • Preferred compounds of formula (I)/(IA) include those exemplified herein both in free base form and as pharmaceutically acceptable salts.
  • R 4 , R 5 and R 6 are as defined in formula (I) or are protected derivatives thereof with a compound of formula (III):
  • R 1 , R 2 and R 3 are as defined in formula (I) or are protected derivatives thereof and LG is a leaving group, and optionally thereafter
  • Preferred leaving groups LG include halogen such as chloro.
  • the reaction between compounds (II) and (III) is carried out by treating compound (II) with a base such as sodium hydride or potassium tert-butoxide in a suitable solvent such as 1,2-dimethoxyethane or tetrahydrofuran.
  • R 4 is C 1-6 alkoxy where the alkyl group may form a 3-6 membered saturated ring or to may be substituted with 1-3 fluorine atoms or a cyano group;
  • OC 1-6 alkylR 11 or OC 2-6 alkyl-X—R 11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR 14 R 15 , SR 13 , S(O) 2 R 13 , S(O)R 13 ; or
  • compounds of formula (II) can be prepared by treating a compound of the formula (IV), where LG is a leaving group (such as chlorine or bromine):
  • a suitable solvent such as 1,2-dimethoxyethane, N,N-dimethylformamide or tetrahydrofuran
  • a suitable base such as sodium hydride or potassium tert-butoxide
  • a suitable temperature such as 25° C. to 60° C.
  • R 4 is C 1-6 alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
  • OC 1-6 alkylR 11 or OC 2-6 alkyl-X—R 11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR 14 R 15 , SR 13 , S(O) 2 R 13 , S(O)R 13 ; or
  • compounds of formula (I) can be prepared by treating a compound of the formula (VI), where LG is a leaving group (such as chlorine or bromine):
  • a compound of formula (V) in a suitable solvent (such as 1,2-dimethoxyethane, N,N-dimethylformamide or tetrahydrofuran) with a suitable base such as sodium hydride or potassium tert-butoxide at a suitable temperature such as 25° C. to 60° C.
  • a suitable solvent such as 1,2-dimethoxyethane, N,N-dimethylformamide or tetrahydrofuran
  • a suitable base such as sodium hydride or potassium tert-butoxide
  • R 5 —H is a primary or secondary amine, thiol or alcohol as defined above (i.e. where R 5 is a group containing an X moiety where X is NR 13 , O or S), in a suitable solvent (such as tetrahydrofuran or acetonitrile) with or without a suitable base (such as sodium hydride, caesium carbonate or triethylamine) at a suitable temperature ranging from 25-85° C. to afford compound of the formula (X):
  • a suitable solvent such as tetrahydrofuran or acetonitrile
  • a suitable base such as sodium hydride, caesium carbonate or triethylamine
  • the protecting group (P) can then be removed by standard methods to afford compound of formula (I).
  • Compounds of structure (II) or (I), where R 5 is an optionally substituted aryl or heteroaryl ring as defined in the claims, can be prepared by taking a compound of formula (XI) or (VII) where LG is a suitable leaving group such as bromine, chlorine or iodine and reacting it with an aryl or heteroaryl boronic acid such as phenyl boronic acid, a palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium (II) chloride, a suitable base such as caesium fluoride, sodium acetate or caesium carbonate and a suitable solvent such as methanol or ethanol and heating between 40-80° C.
  • LG is a suitable leaving group such as bromine, chlorine or iodine
  • an aryl or heteroaryl boronic acid such as phenyl boronic acid
  • a palladium catalyst such as [1,1′-bis(diphen
  • Compounds of formula (II) and (I) where R 5 or R 6 is CO 2 R 13 can be prepared by reacting a compound of formula (II) or (I), where R 5 or R 6 is bromine or iodine, in a suitable solvent such as R 13 OH or dioxane containing R 13 OH, a suitable tertiary amine such as triethylamine, a suitable palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium (II) chloride under an atmosphere of carbon monoxide usually at 2-10 bar, ideally at 4-6 bar and at a temperature of 70-120° C.
  • a suitable solvent such as R 13 OH or dioxane containing R 13 OH
  • a suitable tertiary amine such as triethylamine
  • a suitable palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium (I
  • Compounds of formula (II) and (I) where R 5 or R 6 is CONR 14 R 15 can be prepared by reacting a compound of formula (II) or (I), where R 5 or R 6 is bromine or iodine, in a suitable solvent such as dioxane containing NHR 14 R 15 , a suitable tertiary amine such as triethylamine, a suitable palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium (II) chloride under an atmosphere of carbon monoxide usually at 2-10 bar, ideally at 4-6 bar and at a temperature of 70-120° C.
  • a suitable solvent such as dioxane containing NHR 14 R 15
  • a suitable tertiary amine such as triethylamine
  • a suitable palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium (II) chloride under an
  • Compounds of formula (I) where R 5 or R 6 is CHO can be prepared from compounds of formula (I) where R 5 or R 6 is CH 2 OH by oxidation using a suitable oxidising agent such as manganese dioxide or pyridinium chlorochromate (PCC) in a suitable solvent such as tetrahydrofuran or dichloromethane at a temperature of 0-50° C.
  • a suitable oxidising agent such as manganese dioxide or pyridinium chlorochromate (PCC) in a suitable solvent such as tetrahydrofuran or dichloromethane at a temperature of 0-50° C.
  • a compound of formula (XV) can be made by reacting a compound of formula (XIII), where R 4 is preferrably chloro, bromo or alkoxy and LG is a suitable leaving group such as chloro or bromo, with a compound of formula (XIV) using a suitable base such as potassium carbonate or caesium carbonate in a suitable solvent such as N,N-dimethylformamide at a temperature of 40-90° C.
  • a suitable base such as potassium carbonate or caesium carbonate
  • a suitable solvent such as N,N-dimethylformamide
  • the compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or p-toluenesulphonate.
  • a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine
  • an acid addition salt such as a hydrochloride, hydrobromide, phosphat
  • the compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or p-toluenesulphonate.
  • a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine
  • an acid addition salt such as a hydrochloride, hydrobromide, phosphat
  • the compounds of formula (I) has activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR4) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines.
  • conditions/diseases include:
  • the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
  • the compound of the invention are used to treat diseases in which the chemokine receptor belongs to the CC chemokine receptor subfamily, more preferably the target chemokine receptor is the CCR4 receptor.
  • Particular conditions which can be treated with the compound of the invention are asthma, rhinitis and inflammatory skin disorders, diseases in which there are raised TARC, MDC or CCR4 levels. It is preferred that the compound of the invention is used to treat asthma and rhinitis, especially asthma.
  • the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
  • the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity, particularly CCR4 activity, is beneficial.
  • the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
  • the terms “therapeutic” and “therapeutically” should be construed accordingly.
  • the invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CCR4) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • the invention also provides a method of treating a respiratory disease, such as asthma and rhinitis, especially asthma, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • a respiratory disease such as asthma and rhinitis, especially asthma
  • the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.
  • the compound of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99% w (percent by weight), more preferably from 0.05 to 80% w, still more preferably from 0.10 to 70% w, and even more preferably from 0.10 to 50% w, of active ingredient, all percentages by weight being based on total composition.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound is of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
  • the compound of the invention is administered orally.
  • the present invention provides the use of a compound or formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy in combination with drugs used to treat asthma and rhinitis (such as inhaled and oral steroids, inhaled ⁇ 2-receptor agonists and oral leukotriene receptor antagonists).
  • drugs used to treat asthma and rhinitis such as inhaled and oral steroids, inhaled ⁇ 2-receptor agonists and oral leukotriene receptor antagonists.
  • N-bromosuccinamide (6.9 g) was added portionwise over 0.5 h to a stirred solution of 6-chloro-2-pyrazinamine (5.0 g) in chloroform (200 mL) heated under reflux. After the addition was complete the reaction mixture was allowed to cool, washed with water and evaporated to give a 3:1 mixture of 5-bromo-6-chloro-2-pyrazinamine and the subtitle compound which were separated by silica gel chromatography eluting with dichloromethane. Yield 2.0 g. Used directly.
  • N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[ ⁇ 2-(trimethylsilanyl)ethoxy ⁇ methyl]benzenesulphonamide (0.30 g) in methanolic sodium methoxide (10 mL of 0.5 molar solution) was stirred at room temperature. After 16 h, the solution was evaporated to dryness and dichloromethane (10 mL) and trifluoroacetic acid (10 mL) added. After 2 h, the mixture was evaporated to dryness, dichloromethane added and the inorganic salts removed by filtration. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.1 g).
  • tetrabutylammonium hydroxide (0.28 g of 40% aqueous solution) was added to a solution of 2,3-dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ benzenesulfonamide (0.25 g) in 1,2-dimethoxyethane (3.0 mL) at room temperature. After 16 h, the solution was diluted with ethyl acetate (20 mL). The organic solution was washed with aqueous citric acid (10 mL) and brine, dried (MgSO 4 ) and evaporated.
  • N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[ ⁇ 2-(trimethylsilanyl)ethoxy ⁇ methyl]benzenesulphonamide (Example 55 part a) (0.70 g), tetrakis(triphenylphosphine)palladium(0) (0.1 g) and 2-(tributylstannanyl)pyrazine (0.50 g) in toluene (20 mL) was heated under nitrogen at 100° C. After 16 h, chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound protected with the SEM group as a white solid.
  • N-[5-Bromo-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide (Example 34) (0.15 g), tetrakis(triphenylphosphine)palladium(0) (0.04 g) and zinc cyanide (0.03 g) in N,N-dimethylformamide (5.0 mL) was heated at 70° C. After 5 h, the mixture was diluted with ethyl acetate (30 mL) and washed with 5% aqueous citric acid (5 mL), dried (MgSO 4 ) and evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures containing 1% acetic acid gave the title compound as a white solid (0.058 g).
  • Example 87 Prepared by the method of Example 86 using 2,3-dichloro-N-[5-chloro-3-(4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 87) (0.1 g). Yield 0.4 g.
  • Example 74 Prepared by the method of Example 31 using 1-butanol (0.05 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.1 g). Yield 0.037 g.
  • Example 89 Prepared by the method of Example 86 using 2,3-dichloro-N-[5-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 89) (0.2 g). Yield 0.1 g.
  • 3,5-Dichloro-2-pyrazinamine (1.0 g) was added to a stirred suspension of pyridine-3-methanol (1.3 g) and sodium hydride (0.70 g of 60% dispersion in oil) in 1,2-dimethoxyethane (10 mL). After 0.5 h, 5% aqueous citric acid was added and the mixture extracted with ethyl acetate. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound as a white solid (0.2 g). Used directly.
  • Example 95a 5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinamine (Example 95a) (0.1 g) and 3-chloro-2-methylbenzenesulphonyl chloride (0.09 g). Yield 0.012 g.
  • Example 95a 5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinamine (Example 95a) (0.1 g) and 3-chloro-2-fluorobenzenesulphonyl chloride (0.1 g). Yield 0.034 g.
  • Example 4a 3-bromo-5-chloro-2-pyrazinamine (Example 4a) (1.2 g) and 2,3-dichlorobenzenesulphonyl chloride (1.4 g). Yield 1.5 g.
  • Example 98 Prepared by the method of Example 31 using pyridine-3-methanol (0.22 g) and N-(3-bromo-6-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (Example 98) (0.2 g).
  • Example 36 Prepared by the method of Example 66a using 2,3-dichloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 36) (0.5 g). Yield 0.68 g. Used directly.
  • Example 74 Prepared by the method of Example 31 using (6-methoxy-3-pyridinyl)methanol (0.3 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.3 g). Yield 0.15 g.
  • Example 74 Prepared by the method of Example 31 using [3-(tetrahydro-2-pyranyloxymethyl)phenyl]methanol (1.99 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (1.0 g). Yield 1.0 g. Used directly.
  • Example 107b Prepared by the method of Example 107b using 2,3-dichloro-N-[5-chloro-3-(3-formylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 107a) (0.1 g) and 2-aminoethanol (0.05 g). Yield 0.035 g.
  • Example 109 2,3-dichloro-N-[5-chloro-3-(4-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide (0.65 g). Yield 0.64 g. Used directly.
  • Example 110a 2,3-dichloro-N-[5-chloro-4-(3-formylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 110a) (0.1 g) and 2-aminoethanol (0.05 g). Yield 0.028 g.
  • Methylmagnesium bromide (3 mL of a 3M solution in diethyl ether) was added over 3 minutes to a stirred solution of 5-(2,3-dichlorobenzenesuphonylamino)-6-methoxypyrazine-2-carboxylic acid, methyl ester (Example 113) (0.3 g) in tetrahydrofuran (10 mL) cooled in an ice/water bath. After a further 5 minutes, aqueous citric acid was added and the mixture extracted with ethyl acetate. The organic solution was evaporated to dryness. Chromatography on silica gel eluting with methanol/dichloromethane mixtures gave the title compound as a white solid (0.15 g).
  • Example 5 Prepared by the method of Example 66a using 2,3-dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide (Example 5) (7.0 g). Yield 9.8 g. Used directly.
  • Example 66a 2,3-dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ benzenesulphonamide (0.27 g). Yield 0.055 g.
  • Example 115a 2,3-dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-N- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ benzenesulphonamide (0.25 g) and 3-mercaptopropionic acid, methyl ester (0.06 mL). Yield 0.1 g.
  • Example 118b A solution of 3,5-dibromo-6-methyl-2-pyrazinamine (Example 118b) (0.9 g) was added to a solution of sodium (0.39 g) in methanol (30 mL) was heated at reflux for 18 h. After removal of solvent in vacuo, the residue was partitioned between water and dichloromethane, and the organic phase dried (MgSO 4 ), filtered and evaporated to give the title compound as a pale yellow solid (0.58 g).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

The invention provides N-pyrazinyl-phenyl-sulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.
Figure US20100081670A1-20100401-C00001

Description

  • The present invention relates to a sulphonamide compound, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
  • Certain sulphonamide compounds are known in the art, for example see GB2295616, US patent 2002143024, WO 01/44239, EP 749964 and Esche, J; Wojahn, H. Arch. Pharm. (1966), 299(2), 147-153.
  • Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small-secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. At the present time, the chemokine superfamily comprises three groups exhibiting characteristic structural motifs, the Cys-X—Cys (C—X—C), Cys-Cys (C—C) and Cys-X3-Cys (C—X3—C) families. The C—X—C and C—C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues. The C—X3—C family is distinguished from the other two families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine residues.
  • The C—X—C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
  • The C—C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1α and 1β (MIP-1α and MIP-1β), Thymus and Activation Regulated Chemokine (TARC, CCL17) and Macrophage Derived Chemokine (MDC, CCL22).
  • The C—X3—C chemokine (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.
  • Studies have demonstrated that the actions of chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C—C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C—X—C family) and CX3CR1 for the C—X3—C family. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.
  • The present invention therefore provides a compound of formula (I) and pharmaceutically acceptable salts, solvates or N-oxides thereof:
  • Figure US20100081670A1-20100401-C00002
  • in which:
  • R1, R2 and R3 are independently hydrogen, halogen, cyano, CF3, OCF3, OC1-6 alkyl or C1-6 alkyl;
  • R4 is halogen, CO2R12,
  • C1-6 alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
  • C3-6 alkenyloxy or C3-6 alkynyloxy where either may be optionally substituted with hydroxy or NR14R15;
  • OC1-6 alkyl-X—C1-6 alkyl where the alkyl groups may form a 3-6 membered saturated ring;
  • OC1-6 alkylR11, or OC2-6 alkyl-X—R11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR14R15, SR13, S(O)2R13, S(O)R13 or COR13;
  • OC1-6 alkylR16;
  • R5 and R6 are independently hydrogen, cyano, halogen, CO2R12, CONR14R15;
  • C1-6 alkyl optionally substituted by hydroxy, NR14R15, or 1-3 fluorines;
  • C1-6 alkylR11 or XCH(R11)C1-6 alkyl or XCH(R16)C1-6 alkyl where the alkyl group may be optionally substituted with 1-3 groups selected from hydroxy, and NR14R15;
  • NR14R15; N(R11)R11; X—(CH2)qNR14R15; (CH2)nNR14R15; NHC(O)C1-6 alkyl optionally substituted by one or more hydroxy groups,
  • C3-6 alkynyl or C3-6 alkenyl optionally branched and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and ═O;
  • R11; X—R11; X—R12; X—C1-6alkylR16; X—R16; X—(CH2)nCO2R12; X—(CH2)nCONR14R15;
  • X—(CH2)nR11; X—(CH2)nCN; X—(CH2)qOR12; (CH2)nOR12;
  • (CH2)n-X—R11; X—(CH2)qNHC(O)NHR12; X—(CH2)qNHC(O)R12;
  • X—(CH2)qNHS(O)2R12; X—(CH2)qNHS(O)2R11; X—C3-6 alkenyl; X—C3-6alkynyl;
  • n is 1, 2, 3, 4 or 5;
  • q is 2, 3, 4, 5 or 6;
  • X is NR13, O, S, S(O), S(O)2;
  • R11 is an aryl group or a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur each of which can be optionally substituted by 1-3 groups selected from halogen, C(O)NR14R15, C(O)OR12, hydroxy, ═O, ═S, CN, NO2, COR13, NR14R15, X(CH2)qNR14R15, (CH2)nNR14R15, (CH2)nOH, SR13, S(O)R13, S(O)2R13C1-6 alkyl-X—C1-6 alkyl, C1-6 alkyl or C1-6 alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR14R15, SR13, S(O)R13, S(O)2R13;
  • R12 and R13 are independently hydrogen or C1-6 alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;
  • R14 and R15 are independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl or (CH2)qOH,
  • or R14 and R15 together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C1-6 alkyl, C1-6 alkyl-OH, or hydroxy; and
  • R16 is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and ═O,
  • provided that:
      • when R4 is halogen or C1-4alkoxy and R5 is hydrogen, halogen, C1-4 alkyl, C1-2alkoxy, C1-2alkylthio, trifluoromethyl or ethynyl and when one of R1, R2 or R3 is C1-6alkyl or C1-6alkoxy and is meta to the sulphonamide group then the group ortho to both the sulphonamide group and the C1-6alkyl or C1-6alkoxy group is not hydrogen,
      • when R4 is halogen or C1-4alkoxy and R5 is hydrogen, halogen, C1-4alkyl, C1-2alkoxy, C1-2alkylthio, trifluoromethyl or ethynyl and when one of R1, R2 or R3 is C1-6alkyl or C1-6alkoxy and is ortho to the sulphonamide group then the group ortho to the C1-6Alkyl or C1-6alkoxy and also meta to the sulphonamide group is not hydrogen,
      • when two of R1, R2, R3 are hydrogen and the other is a methyl group para to the sulphonamide and R4 is methoxy then R5 is not hydrogen or bromo, and
      • when R5 is methyl and R6 is methoxy and one of R1, R2 or R3 is bromo or iodo and the other two are both hydrogen, then the bromo or iodo group is not ortho to the sulphonamide group.
  • The term aryl includes phenyl and naphthyl. The term alkyl, whether alone or as part of another group, includes straight chain and branched chain alkyl groups. Examples of 5- to 7-membered heteroaromatic ring containing 1 to 4 heteroatoms include thienyl, furanyl, pyrrolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl. Examples of saturated 4- to 8-membered rings containing 1 to 3 heteroatoms include morpholine, piperidine and azetidine. Substituents on any rings can be present in any suitable ring position including suitable substituents on nitrogen atoms.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.
  • Preferred halogen groups for R1, R2 and R3 are chloro, bromo and fluoro. Preferably one of R1, R2 and R3 is hydrogen and the other is chloro, bromo or methyl. More preferably R1 and R2 are chloro at the 2- and 3-positions of the phenyl ring and R3 is hydrogen (i.e. 2,3-dichlorophenyl), R1 and R3 are chloro at the 2- and 4-positions of the phenyl ring and R2 is hydrogen (i.e. 2,4-dichlorophenyl) or R1 is chloro at the 2-position and R2 is methyl at the 3-position of the phenyl ring and R3 is hydrogen (i.e 2-chloro-3-methylphenyl). Most preferably R1 and R2 are chloro at the 2- and 3-positions of the phenyl ring and R3 is hydrogen (i.e. 2,3-dichlorophenyl).
  • In a further aspect the invention provides a compound of formula (I) as defined above but without the provisos where R1 and R2 are chloro at the 2- and 3-positions of the phenyl ring and R3 is hydrogen (i.e. 2,3-dichlorophenyl), R1 and R3 are chloro at the 2- and 4-positions of the phenyl ring and R2 is hydrogen (i.e. 2,4-dichlorophenyl) or R1 is chloro at the 2-position and R2 is methyl at the 3-position of the phenyl ring and R3 is hydrogen (i.e 2-chloro-3-methylphenyl).
  • For the group R4 examples of C3-6 alkenyloxy include OCH2CH═CH2, examples of C3-6 alkynyloxy include OCH2CCH, examples of OC1-6 alkyl-O—C1-6 alkyl include OCH2CH2OMe, examples of OC1-6 alkylR11 include OCH2R11, and examples of OC1-6 alkylR16 include OCH2pyrrolidine.
  • Preferred groups for R4 include C1-6 alkoxy such as methoxy, 2-furanylmethoxy, bromo, chloro, 2-methoxyethoxy, (5-methyl-3-isoxazolyl)methoxy, 2-, 3- or 4-pyridylmethoxy, 3-pyridazinylmethoxy, methoxy, 2-(1-imidazolyl)ethoxy, (2-methyl-4-oxazolyl)methoxy and 4-methoxyphenylmethoxy. More preferably R4 is methoxy.
  • For R5 and R6 examples of NR14R15 includes morpholine, pyrrolidine, NMe2, NHCH2CH2OMe, NHMe, and the groups below:
  • Figure US20100081670A1-20100401-C00003
  • Examples of X—(CH2)qNR14R15 include SCH2CH2NH2 and SCH2CH2NMe2, examples of (CH2)nNR14R15 include CH2morpholine, examples of X—R12 includes SMe, OMe, OEt, OH, SO2Me, examples of X—C1-6alkylR16 includes OCH2pyrrolidine, examples of X—(CH2)nCO2R12 includes SCH2CO2H, SCH2CO2Me, SCH2CH2CO2Me, examples of X—(CH2)nCONR14R15 includes SCH2CONH2, SCH2CONHMe, OCH2CONEt2, examples of X—(CH2)nR11 includes the groups below:
  • Figure US20100081670A1-20100401-C00004
  • Examples of X—(CH2)nCN, includes SCH2CN, examples of X—(CH2)qOR12 includes OCH2CH2OMe, examples of (CH2)nOR12 includes CH2OH, CH2OMe, examples of X—(CH2)qNHC(O)NHR12 includes SCH2CH2NHC(O)NHEt, and examples of X—(CH2)qNHC(O)R12 includes NHCH2CH2NHC(O)Me. Examples of NHC(O)C1-6 alkyl optionally substituted by one or more hydroxy groups includes NHCOCH2OH.
  • Preferred groups for R5 include hydrogen, halogen such as bromo and chloro, phenyl, C1-6 alkyl such as methyl, CH2OH, cyano and 2-aminothanethiol. More preferably R5 is hydrogen, methyl, CH2OH or halogen such bromo or chloro.
  • Preferred groups for R6 include hydrogen, C1-6 alkyl, CH2OH and halogen, more preferably hydrogen, methyl, CH2OH or chloro.
  • In a further aspect the invention provides a compound of formula (IA):
  • Figure US20100081670A1-20100401-C00005
  • in which
  • R1, R2 and R3 are independently hydrogen, halogen, cyano, CF3, OCF3, C1-6 alkenyl or C1-6 alkyl;
  • R4 is halogen, C1-6 alkoxy or OR9;
  • R5 and R6 are independently hydrogen, halogen, C1-6 alkoxy, C1-6 alkylthio, cyano, R9, OR9, NR9R10, SR9, S(CH2)nCO2H, S(CH2)nCO2R12, S(CH2)nCONR12R13, S(CH2)nR11 or a 5- to 7-membered heteroaromatic or saturated ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur;
  • n is 1, 2 or 3;
  • R9 and R10 are independently hydrogen, C1-6 alkyl optionally substituted by hydroxy, C1-6 alkoxy or NHCOC1-6 alkyl, or R9 and R10 are optionally substituted aryl, C1-6 alkyl-aryl or C1-6 alkyl-R11 or R9 and R10 together with the nitrogen atom to which they are attached form a 4- to 8-membered saturated ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C1-6 alkyl or C1-6 alkyl-OH; and
  • R11 is a 5- to 7-membered heteraromatic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C1-6 alkyl; and
  • R12 and R13 are independently hydrogen or C1-6 alkyl.
  • For compounds (IA) R1, R2 and R3 are independently hydrogen, halogen, cyano, CF3, OCF3, C1-6 alkenyl or C1-6 alkyl, preferred halogen groups being chloro. Preferably one of R1, R2 and R3 is methyl, ethenyl, cyano, chloro, fluoro, iodo or two are chloro or all three are fluoro. More preferred are compounds where R1-R3 together with the phenyl group to which they are attached form a 3-chloro-2-methylphenyl or a 2,3-dichlorophenyl group.
  • For compounds (IA) preferred groups for R4 include halogen such as bromo and chloro, C1-6 alkoxy such as methoxy and ethoxy, C1-6 alkyl or OR9 where R9 is CH2R11 where R11 is a 5- or 6-membered heteraromatic ring containing 1 or 2 heteroatoms.
  • More preferably R4 is methoxy, halogen, such as chloro, or OR9 where R9 is CH2R11 where R11 is furanyl, 5-methyl-3-isoxazolyl, pyridyl optionally substituted by methyl, pyridazinyl, pyrazinyl, 1-methyl-6-oxo-1,6-dihydro-3-pyridinyl.
  • For compounds (IA) preferably R5 is hydrogen, methyl, bromo, chloro, methoxy, morpholinyl, pyrrolinyl, dimethylamino, hydroxy, 2-methoxyethoxy, pyrazinyl, pyrimidinyl, O-Ph-CO2H, 2-hydroxyethylamino, 2-methoxyethylamino, NHCH2CH2NHCOMe, cyano, 4-hydroxymethyl-1-piperidinyl, SMe, NHMe, or 2,4-difluorophenyl.
  • For compounds (IA) preferably R6 is hydrogen or chloro.
  • Preferred compounds of formula (I)/(IA) include those exemplified herein both in free base form and as pharmaceutically acceptable salts.
  • According to the invention there is also provided a process for the preparation of compound (I) which comprises reaction of a compound of formula (II):
  • Figure US20100081670A1-20100401-C00006
  • where R4, R5 and R6 are as defined in formula (I) or are protected derivatives thereof with a compound of formula (III):
  • Figure US20100081670A1-20100401-C00007
  • where R1, R2 and R3 are as defined in formula (I) or are protected derivatives thereof and LG is a leaving group,
    and optionally thereafter
      • removing any protecting groups,
      • forming a pharmaceutically acceptable salt.
  • Preferred leaving groups LG include halogen such as chloro. Preferably the reaction between compounds (II) and (III) is carried out by treating compound (II) with a base such as sodium hydride or potassium tert-butoxide in a suitable solvent such as 1,2-dimethoxyethane or tetrahydrofuran.
  • Where R4 is C1-6 alkoxy where the alkyl group may form a 3-6 membered saturated ring or to may be substituted with 1-3 fluorine atoms or a cyano group;
  • C3-6 alkenyloxy or C3-6 alkynyloxy where either may be optionally substituted with hydroxy or NR14R15;
  • OC1-6 alkyl-X—C1-6 alkyl where the alkyl groups may form a 3-6 membered saturated ring;
  • OC1-6 alkylR11, or OC2-6 alkyl-X—R11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR14R15, SR13, S(O)2R13, S(O)R13; or
  • OC1-6 alkylR16;
  • compounds of formula (II) can be prepared by treating a compound of the formula (IV), where LG is a leaving group (such as chlorine or bromine):
  • Figure US20100081670A1-20100401-C00008
  • with a compound of formula (V)

  • R4—H  (V)
  • in a suitable solvent (such as 1,2-dimethoxyethane, N,N-dimethylformamide or tetrahydrofuran) with a suitable base such as sodium hydride or potassium tert-butoxide at a suitable temperature such as 25° C. to 60° C.
  • Where R4 is C1-6 alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
  • C3-6 alkenyloxy or C3-6 alkynyloxy where either may be optionally substituted with hydroxy or NR14R15;
  • OC1-6 alkyl-X—C1-6 alkyl where the alkyl groups may form a 3-6 membered saturated ring;
  • OC1-6 alkylR11, or OC2-6 alkyl-X—R11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR14R15, SR13, S(O)2R13, S(O)R13; or
  • OC1-6 alkylR16;
  • compounds of formula (I) can be prepared by treating a compound of the formula (VI), where LG is a leaving group (such as chlorine or bromine):
  • Figure US20100081670A1-20100401-C00009
  • with a compound of formula (V)
    in a suitable solvent (such as 1,2-dimethoxyethane, N,N-dimethylformamide or tetrahydrofuran) with a suitable base such as sodium hydride or potassium tert-butoxide at a suitable temperature such as 25° C. to 60° C.
  • Compounds of structure (VIII) can be prepared by taking a compound of formula (VII) where LG is a leaving group (such as chlorine or bromine) and protecting the sulfonamide as for example the trimethylsilyethoxymethyl ether (SEM) or methoxymethyl ether (MOM) by the standard literature methods (such as SEM-chloride or MOM-chloride) in a suitable solvent (such as tetrahydrofuran) with a suitable base (such as triethylamine) at a suitable temperature (such as 0-20° C.) to afford compound of the formula (VIII):
  • Figure US20100081670A1-20100401-C00010
  • Compound of formula (VIII) could then be treated with compounds of formulae (IX):

  • R5—H  (IX)
  • where R5—H is a primary or secondary amine, thiol or alcohol as defined above (i.e. where R5 is a group containing an X moiety where X is NR13, O or S), in a suitable solvent (such as tetrahydrofuran or acetonitrile) with or without a suitable base (such as sodium hydride, caesium carbonate or triethylamine) at a suitable temperature ranging from 25-85° C. to afford compound of the formula (X):
  • Figure US20100081670A1-20100401-C00011
  • The protecting group (P) can then be removed by standard methods to afford compound of formula (I).
  • Compounds of structure (II) or (I), where R5 is an optionally substituted aryl or heteroaryl ring as defined in the claims, can be prepared by taking a compound of formula (XI) or (VII) where LG is a suitable leaving group such as bromine, chlorine or iodine and reacting it with an aryl or heteroaryl boronic acid such as phenyl boronic acid, a palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium (II) chloride, a suitable base such as caesium fluoride, sodium acetate or caesium carbonate and a suitable solvent such as methanol or ethanol and heating between 40-80° C.
  • Figure US20100081670A1-20100401-C00012
  • Compounds of formula (II) and (I) where R5 or R6 is CO2R13 can be prepared by reacting a compound of formula (II) or (I), where R5 or R6 is bromine or iodine, in a suitable solvent such as R13OH or dioxane containing R13OH, a suitable tertiary amine such as triethylamine, a suitable palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium (II) chloride under an atmosphere of carbon monoxide usually at 2-10 bar, ideally at 4-6 bar and at a temperature of 70-120° C. Compounds of formula (II) and (I) where R5 or R6 is CONR14R15 can be prepared by reacting a compound of formula (II) or (I), where R5 or R6 is bromine or iodine, in a suitable solvent such as dioxane containing NHR14R15, a suitable tertiary amine such as triethylamine, a suitable palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium (II) chloride under an atmosphere of carbon monoxide usually at 2-10 bar, ideally at 4-6 bar and at a temperature of 70-120° C. Compounds of formula (I) where R5 or R6 is CH2OH can be prepared from compounds of formula (I) where R5 or R6 is CO2R13 by reduction using a suitable reducing agent such as lithium triethylborohydride in a suitable solvent such as tetrahydrofuran at a temperature of 0-10° C.
  • Compounds of formula (I) where R5 or R6 is CHO can be prepared from compounds of formula (I) where R5 or R6 is CH2OH by oxidation using a suitable oxidising agent such as manganese dioxide or pyridinium chlorochromate (PCC) in a suitable solvent such as tetrahydrofuran or dichloromethane at a temperature of 0-50° C.
  • Compounds of formula (I) where R5 or R6 is CH(OH)R11 or CH(OH)(C1-5)alkyl can be prepared from compounds of formula (I) where R5 or R6 is CHO by reaction with a compound of formula (XII) where M is a metal such as magnesium or lithium in a suitable solvent such as tetrahydrofuran or diethyl ether at a temperature of 0-10° C.
  • C1-5 alkylM or R11M
  • Figure US20100081670A1-20100401-C00013
  • A compound of formula (XV) can be made by reacting a compound of formula (XIII), where R4 is preferrably chloro, bromo or alkoxy and LG is a suitable leaving group such as chloro or bromo, with a compound of formula (XIV) using a suitable base such as potassium carbonate or caesium carbonate in a suitable solvent such as N,N-dimethylformamide at a temperature of 40-90° C.
  • Intermediate compounds of formula (II) and (III) can be prepared using standard chemistry or are available commercially.
  • It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compound may need to be protected by protecting groups. Thus, the preparation of the compound of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in ‘Protective Groups in Organic Chemistry’, edited by J. W. F. McOmie, Plenum Press (1973), and ‘Protective Groups in Organic Synthesis’, 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).
  • The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or p-toluenesulphonate.
  • Certain compounds of formula (II) and (III) are believed to be novel and form a further aspect of the invention.
  • The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or p-toluenesulphonate.
  • The compounds of formula (I) has activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR4) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include:
      • (1) (the respiratory tract) obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
      • (2) (bone and joints) gout, rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
      • (3) (skin) pruritis, scleroderma, otitus, psoriasis, atopical dermatitis, contact dermatitis and other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis, lupus;
      • (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, inflammatory bowel diseases such as Crohn's disease, ulcerative colitis, ileitis and enteritis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
      • (5) (central and peripheral nervous system) Neurodegenerative diseases and dementia disorders, e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntington's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g. multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis; neuromuscular disorders, e.g. myasthenia gravis and Lambert-Eaton syndrome; spinal diorders, e.g. tropical spastic paraparesis, and stiff-man syndrome: paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis; CNS trauma; migraine; stroke and correctum diseases such as meningitis
      • (6) (other tissues and systemic disease) hepatitis, vasculitis, spondyloarthopathies, vaginitis, glomerulonephritis, myositis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, and idiopathic thrombocytopenia pupura; post-operative adhesions, and sepsis.
      • (7) (allograft and xenograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
      • (8) Cancer, carcinoma & tumour metastasis, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin, especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma. Hematopoietic tumors of lymphoid lineage, including acute lymphocytic leukemia, B cell lymphoma and Burketts lymphoma, Hodgkins Lymphoma, Acute Lymphoblastic Leukemia. Hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia. Tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma, and other tumors, including melanoma, seminoma, tetratocarcinoma, neuroblastoma and glioma.
      • (9) All diseases that result from a general inbalance of the immune system and resulting in increased atopic inflammatory reactions.
      • (10) Cystic fibrosis, re-perfusion injury in the heart, brain, peripheral limbs and other organs.
      • (11) Burn wounds & chronic skin ulcers
      • (12) Reproductive Diseases (e.g. Disorders of ovulation, menstruation and implantation, Pre-term labour, Endometriosis)
      • (13) thrombosis
      • (14) infectious diseases such as HIV infection and other viral infections, bacterial infections.
  • Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
  • Preferably the compound of the invention are used to treat diseases in which the chemokine receptor belongs to the CC chemokine receptor subfamily, more preferably the target chemokine receptor is the CCR4 receptor.
  • Particular conditions which can be treated with the compound of the invention are asthma, rhinitis and inflammatory skin disorders, diseases in which there are raised TARC, MDC or CCR4 levels. It is preferred that the compound of the invention is used to treat asthma and rhinitis, especially asthma.
  • In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
  • In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity, particularly CCR4 activity, is beneficial.
  • In the context of the present specification, the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary. The terms “therapeutic” and “therapeutically” should be construed accordingly.
  • The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CCR4) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • The invention also provides a method of treating a respiratory disease, such as asthma and rhinitis, especially asthma, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.
  • The compound of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99% w (percent by weight), more preferably from 0.05 to 80% w, still more preferably from 0.10 to 70% w, and even more preferably from 0.10 to 50% w, of active ingredient, all percentages by weight being based on total composition.
  • The present invention also provides a pharmaceutical composition comprising a compound is of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Preferably the compound of the invention is administered orally.
  • In a further aspect, the present invention provides the use of a compound or formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy in combination with drugs used to treat asthma and rhinitis (such as inhaled and oral steroids, inhaled β2-receptor agonists and oral leukotriene receptor antagonists).
  • The following examples illustrate the invention.
    • EXAMPLE 1 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide
  • Figure US20100081670A1-20100401-C00014
  • Sodium hydride (0.1 g of 60%) was added to 3-methoxy-5-methyl-2-pyrazinamine (0.07 g) in 1,2-dimethoxyethane (3 mL) under nitrogen at room temperature. After 1 hour at 50°, 2,3-dichlorobenzenesuphonyl chloride (0.15 g) was added. After stirring for 30 minutes, 5% aqueous citric acid was added and the product extracted with ethyl acetate (X3). The combined extracts were washed with saturated brine, dried (MgSO4) and the solvent was evaporated. Chromatography on silica eluting with dichloromethane/methanol mixtures gave the title compound as a white solid (0.08 g).
  • m/e 346/8/350 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.27 (1H, s), 8.06 (1H, d), 7.93 (1H, d), 7.60-7.55 (1H, br s), 7.58 (1H, t), 3.87 (3H, s), 2.28 (3H, s).
    • EXAMPLE 2 N-(6-Chloro-3-methoxy-2-pyrazinyl)-2,3,4-trifluorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00015
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 6-chloro-3-methoxy-2-pyrazinamine (0.16 g) and 2,3,4-trifluorobenzenesulphonyl chloride (0.25 g). Yield 0.08 g.
  • m/e 352/4 (M-1+, 100%).
  • 1H NMR (D6-DMSO) δ 7.93-7.80 (1H, m), 7.89 (1H, s), 7.60-7.50 (1H, m), 3.91 (3H, s).
    • EXAMPLE 3 3-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-methylbenzenesulphonamide
  • Figure US20100081670A1-20100401-C00016
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 6-chloro-3-methoxy-2-pyrazinamine (0.16 g) and 3-chloro-2-methylbenzenesulphonyl chloride (0.23 g). Yield 0.15 g.
  • m/e 346/8/50 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.05 (1H, d), 7.85 (1H, s), 7.75 (1H, d), 7.47 (1H, t), 3.92 (3H, s), 2.66 (3H, s).
    • EXAMPLE 4 2,3-Dichloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide a) 3-Bromo-6-chloro-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00017
  • N-bromosuccinamide (6.9 g) was added portionwise over 0.5 h to a stirred solution of 6-chloro-2-pyrazinamine (5.0 g) in chloroform (200 mL) heated under reflux. After the addition was complete the reaction mixture was allowed to cool, washed with water and evaporated to give a 3:1 mixture of 5-bromo-6-chloro-2-pyrazinamine and the subtitle compound which were separated by silica gel chromatography eluting with dichloromethane. Yield 2.0 g. Used directly.
    • b) 6-Chloro-3-methoxy-2-pyrazinamine and 3-bromo-6-methoxy-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00018
  • 3-Bromo-6-chloro-2-pyrazinamine (1.0 g), sodium methoxide (3 mL of 25% solution in methanol) and methanol (10 mL) were heated at reflux for 3 hours. The solvent was evaporated and the residue was dissolved in ethyl acetate and brine. The organic layer was separated dried (MgSO4) and the solvent was evaporated to give a mixture of the sub-title compounds (ratio 10:1). Purification was by silica gel chromatography eluting with dichloromethane. Yield 0.5 g. Used directly.
    • c) 2,3-Dichloro-N-(6-Chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00019
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 6-chloro-3-methoxy-2-pyrazinamine (0.24 g) and 2,3-dichlorobenzenesulphonyl chloride (0.32 g). Yield 0.24 g.
  • m/e 366/8/370/2 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.14 (1H, d), 7.96 (1H, d), 7.89 (1H, s), 7.62 (1H, t), 3.91 (3H, s).
    • EXAMPLE 5 2,3-Dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00020
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-chloro-3-methoxy-2-pyrazinamine (0.1 g) and 2,3-dichlorobenzenesulphonyl chloride (0.15 g). Yield 0.05 g.
  • m/e 366/8/370/2 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.15 (1H, d), 7.93 (1H, d), 7.79 (1H, s), 7.58 (1H, t), 3.93 (3H, s).
    • EXAMPLE 6 N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,5-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00021
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.2 g) and 2,5-dichlorobenzenesulphonyl chloride (0.24 g). Yield 0.14 g.
  • m/e 410/2/4/6 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.04 (1H, d), 7.86 (1H, s), 7.73 (1H, dd), 7.66 (1H, dd), 3.91 (3H, s).
    • EXAMPLE 7 N-(5-Bromo-3-methoxy-2-pyrazinyl)-3,5-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00022
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.2 g) and 3,5-dichlorobenzenesulphonyl chloride (0.24 g). Yield 0.012 g.
  • m/e 410/2/4/6 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 7.96-7.91 (4H, m), 3.93 (3H, s).
    • EXAMPLE 8 N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00023
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.1 g) and 2,3-dichlorobenzenesulphonyl chloride (0.2 g). Yield 0.045 g.
  • m/e 410/2/4/6 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.06 (1H, dd), 7.93 (1H, dd), 7.82 (1H, s), 7.57 (1H, t), 3.92 (3H, s).
    • EXAMPLE 9 N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,4-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00024
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.2 g) and 2,4-dichlorobenzenesulphonyl chloride (0.24 g). Yield 0.059 g.
  • m/e 410/2/4/6 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.07 (1H, d), 7.85 (2H, d), 7.64 (1H, dd), 3.92 (3H, s).
    • EXAMPLE 10 N-(5-Bromo-3-methoxy-2-pyrazinyl)-3,4-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00025
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.15 g) and 3,4-dichlorobenzenesulphonyl chloride (0.15 g). Yield 0.09 g.
  • m/e 410/2/4/6 (M-1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.14 (1H, s), 8.00-7.85 (3H, m), 3.94 (3H, s).
    • EXAMPLE 11 N-(5-Bromo-3-methoxy-2-pyrazinyl)-4-chlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00026
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.1 g) and 4-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.13 g.
  • m/e 376/8/380 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.3 (1H, br s), 7.97 (2H, d), 7.91 (1H, s), 7.66 (2H, d), 3.93 (3H, s).
    • EXAMPLE 12 N-(5-Bromo-3-methoxy-2-pyrazinyl)-3-chlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00027
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.1 g) and 3-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.14 g.
  • m/e 376/8/380 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.00-7.90 (3H, m), 7.75 (1H, d), 7.64 (1H, t), 3.94 (3H, s).
    • EXAMPLE 13 N-(3-Methoxy-5-methyl-2-pyrazinyl)-2-fluorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00028
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine and 2-fluorobenzenesulphonyl chloride.
  • m/e 298 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.05 (1H, br s), 7.85-7.95 (1H, m), 7.65-7.75 (1H, m), 7.50-7.60 (1H, m), 7.35-7.45 (1H, m), 3.90 (3H, s), 2.30 (3H, s).
  • MP 150-152° C.
    • EXAMPLE 14 N-(3-Methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00029
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine and benzenesulphonyl chloride
  • MP 138-139° C.
    • EXAMPLE 15 N-(3-Methoxy-5-methyl-2-pyrazinyl)-2-iodobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00030
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine and 2-iodobenzenesulphonyl chloride.
  • 1H NMR (D6-DMSO) δ 10.75 (1H, br s), 8.05-8.15 (2H, m), 7.65-7.75 (2H, m), 7.30 (1H, dt), 3.90 (3H, s), 2.30 (3H, s).
  • MP 140-141° C.
    • EXAMPLE 16 N-(3-Methoxy-5-methyl-2-pyrazinyl)-3-fluorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00031
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine and 3-fluorobenzenesulphonyl chloride.
  • MP 95-97° C.
    • EXAMPLE 17 2-[[(3-Methoxy-5-methyl-2-pyrazinyl)amino]sulphonyl]benzonitrile
  • Figure US20100081670A1-20100401-C00032
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine and 2-cyanobenzenesulphonyl chloride.
  • m/e 305 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.15 (1H, dd), 8.05 (1H, dd), 7.85 (1H, dt), 7.80 (1H, dt), 7.60 (1H, s), 3.85 (3H, s), 2.30 (3H, s).
    • EXAMPLE 18 N-(5-Bromo-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00033
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine and benzenesulphonyl chloride
  • m/e 344 (M+1+, 100%).
    • EXAMPLE 19 N-(5-Bromo-3-methoxy-2-pyrazinyl)2-iodobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00034
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine and 2-iodobenzenesulphonyl chloride.
  • m/e 470 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.30 (1H, br s), 8.0-8.1 (2H, m), 7.80 (1H, s), 7.60 (1H, dt), 7.30 (1H, dt), 3.95 (3H, s).
    • EXAMPLE 20 2,3-Dichloro-N-[3-(2-furanylmethoxy)-5-methyl-2-pyrazinyl]benzenesulphonamide a) N-(3-Bromo-5-methyl-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00035
  • Prepared by the method of Example 1 using 3-bromo-5-methyl-2-pyrazinamine (0.84 g) and 2,3-dichlorobenzenesulphonyl chloride (1.1 g). Yield 0.92 g.
    • b) 2,3-Dichloro-N-[3-(2-furanylmethoxy)-5-methyl-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00036
  • Sodium hydride (0.04 g of a 60% dispersion in oil) was added to furfurylalcohol (0.034 g) in 1,2-dimethoxyethane (1 mL). After 5 minutes N-(3-Bromo-5-methyl-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (Example 20 part a) (0.1 g) was added and the mixture heated at 40° C. After 16 h, 5% aqueous citric acid (10 mL) was added and the mixture extracted with ethyl acetate (2×50 mL). The combined extracts were washed with brine, dried (MgSO4) and the solvent evaporated. Chromatography on silica gel eluting with dichloromethane gave the title compound as a white solid (0.02 g)
  • m/e 412 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.33 (1H, br s), 8.01 (1H, d), 7.90 (1H, d), 7.70 (1H, s), 7.62 (1H, br s), 7.54 (1H, t), 6.61-6.58 (1H, m), 6.50-6.45 (1H, m), 5.33 (2H, s), 2.32 (3H, s).
  • MP 127-129° C.
    • EXAMPLE 21 2,3-Dichloro-N-[5-methyl-3-(5-methyl-3-isoxazolylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00037
  • Prepared by the method of Example 20 using (5-methyl-3-isoxazolyl)methanol (0.05 g) and N-(3-bromo-5-methyl-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (0.1 g). Yield 0.05 g.
  • m/e 429 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.39 (1H, br s), 8.03 (1H, d), 7.91 (1H, d), 7.64 (1H, br s), 7.47 (1H, t), 6.33 (1H, s), 5.37 (2H, s), 2.41 (3H, s), 2.29 (3H, s).
  • MP 155-156° C.
    • EXAMPLE 22 2,3-Dichloro-N-[5-methyl-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00038
  • Prepared by the method of Example 20 using pyridine-2-methanol (0.05 g) and N-(3-bromo-5-methyl-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (0.1 g). Yield 0.07 g.
  • m/e 425 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.57-8.54 (1H, m), 8.05 (1H, d), 7.89 (1H, d), 7.83 (1H, dt), 7.65-7.50 (2H, m), 7.56 (1H, t), 7.35-7.30 (1H, m), 5.44 (2H, s), 2.26 (3H, s).
    • EXAMPLE 23 2,3-Dichloro-N-[5-methyl-3-(6-methyl-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00039
  • Prepared by the method of Example 20 using 6-methylpyridine-2-methanol (0.05 g) and N-(3-bromo-5-methyl-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (0.1 g). Yield 0.023 g.
  • m/e 439 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.05 (1H, dd), 7.89 (1H, dd), 7.70 (1H, t), 7.59 (1H, br s), 7.54 (1H, t), 7.34 (1H, d), 7.19 (1H, d), 5.39 (2H, s), 2.47 (3H, s), 2.26 (3H, s).
  • MP 164-165° C.
    • EXAMPLE 24 2,3-Dichloro-N-[5-methyl-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00040
  • Prepared by the method of Example 20 using pyridine-3-methanol (0.05 g) and N-(3-bromo-5-methyl-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (0.1 g). Yield 0.023 g.
  • m/e 425 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.74 (1H, d), 8.55 (1H, dd), 8.03 (1H, dd), 7.95-7.85 (2H, m), 7.59 (1H, br s), 7.54 (1H, t), 7.42 (1H, dd), 5.41 (2H, s), 2.29 (3H, s).
  • MP 160-161° C.
    • EXAMPLE 25 2,3-Dichloro-N-[5-methyl-3-(4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00041
  • Prepared by the method of Example 20 using pyridine-4-methanol (0.05 g) and N-(3-bromo-5-methyl-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (0.1 g). Yield 0.009 g.
  • m/e 425 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.57 (2H, d), 8.05 (1H, dd), 7.89 (1H, dd), 7.60 (1H, s), 7.55 (1H, t), 7.50 (2H, d), 5.43 (2H, s), 2.26 (3H, s).
  • MP 183-184° C.
    • EXAMPLE 26 2,3-Dichloro-N-[5-methyl-3-(3-methyl-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00042
  • Prepared by the method of Example 20 using 3-methylpyridine-2-methanol (0.05 g) and N-(3-bromo-5-methyl-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (0.1 g). Yield 0.021 g.
  • m/e 439 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.36 (1H, d), 8.05 (1H, dd), 7.83 (1H, dd), 7.64 (1H, d), 7.60 (1H, br s), 7.49 (1H, t), 7.31 (1H, dd), 5.40 (2H, s), 2.33 (3H, s), 2.29 (3H, s).
  • MP 137-138° C.
    • EXAMPLE 27 2,3-Dichloro-N-[5-methyl-3-(3-pyridazinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00043
  • Prepared by the method of Example 20 using pyridazine-3-methanol (0.1 g) and N-(3-bromo-5-methyl-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (0.15 g). Yield 0.038 g.
  • m/e 424 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.47 (1H, br s), 9.21 (1H, dd), 8.05 (1H, dd), 8.00-7.95 (1H, m), 7.88 (1H, d), 7.80-7.75 (1H, m), 7.62 (1H, br s), 7.54 (1H, t), 5.65 (2H, s), 2.27 (3H, s).
  • MP 119-124° C.
    • EXAMPLE 28 2,3-Dichloro-N-[3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide a) 2,3-Dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00044
  • 2,3-Dichloropyrazine (2.6 g), 2,3-dichlorobenzenesulphonamide (4.0 g) and potassium carbonate (10.0 g) in N,N-dimethylformamide (50 mL) was heated at 75° C.
  • After 16 h, 5% aqueous citric acid (30 mL) was added and the mixture extracted with ethyl acetate (2×100 mL). The combined extracts were washed with brine, dried (MgSO4) and the solvent evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound (1.5 g).
    • b) 2,3-Dichloro-N-[3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00045
  • Sodium hydride (0.05 g of a 60% dispersion in oil) was added to pyridine-2-methanol (0.088 g) in 1,2-dimethoxyethane (3.0 mL). After 5 minutes, 2,3-dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (0.1 g) was added and the mixture heated at 70° C. After 4 h, 5% aqueous citric acid (10 mL) was added and the mixture extracted with ethyl acetate (2×50 mL). The combined extracts were washed with brine, dried (MgSO4) and the solvent evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.06 g).
  • m/e 411 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.57 (1H, d), 8.13 (1H, d), 7.93 (1H, d), 7.90-7.75 (2H, m), 7.75-7.65 (1H, m), 7.65-7.55 (2H, m), 7.40-7.30 (1H, m), 5.49 (2H, s).
  • MP 167-168° C.
    • EXAMPLE 29 2,3-Dichloro-N-[3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00046
  • Prepared by the method of Example 28 using pyridine-3-methanol (0.09 g) and 2,3-dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (0.1 g). Yield 0.042 g.
  • m/e 409 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.70 (1H, s), 8.65 (1H, d), 8.28 (1H, dd), 7.79 (1H, d), 7.70-7.67 (2H, m), 7.61 (1H, d), 7.40-7.35 (2H, m), 5.45 (2H, s).
  • MP 138-139° C.
    • EXAMPLE 30 2,3-Dichloro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00047
  • 2,3-Dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (Example 28 part a) (0.2 g) in 10% sodium methoxide in methanol (10 mL) was heated at 85° C. After 4 h, 5% aqueous citric acid (50 mL) was added and the mixture extracted with ethyl acetate (2×150 mL). The combined extracts were washed with brine, dried (MgSO4) and the solvent evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.12 g)
  • m/e 334 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.54 (1H, br s), 8.10 (1H, d), 7.94 (1H, d), 7.85-7.75 (1H, m), 7.70-7.55 (1H, m), 7.59 (1H, t), 3.90 (3H, s).
  • MP 183-184° C.
    • EXAMPLE 31 N-[5-Bromo-3-(2-pyrazinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide a) 2,3-Dichloro-N-(3,5-dibromo-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00048
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 3,5-dibromo-2-pyrazinamine (2.9 g) and 2,3-dichloro benzenesulphonyl chloride (2.8 g). Yield 4.4 g.
    • b) N-[5-Bromo-3-(2-pyrazinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00049
  • Sodium hydride (0.05 g of a 60% dispersion in oil) was added to pyrazine-2-methanol (0.04 g) in 1,2-dimethoxyethane (3 ml). After 5 minutes, 2,3-Dichloro-N-(3,5-dibromo-2-pyrazinyl)benzenesulphonamide
  • (0.12 g) was added. After 0.5 h, 5% aqueous citric acid (10 mL) was added and the mixture extracted with ethyl acetate (2×30 mL). The combined extracts were washed with brine, dried (MgSO4) and the solvent evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.06 g).
  • m/e 489 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 9.00 (1H, s), 8.66 (2H, s), 8.08 (1H, dd), 7.92 (1H, dd), 7.91 (1H, s), 7.56 (1H, t), 5.53 (2H, s).
  • MP 207-209° C.
    • EXAMPLE 32 N-[5-Bromo-3-(1-methyl-6-oxo-1,6-dihydro-3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00050
  • Prepared by the method of Example 31 using 5-hydroxymethyl-1-methyl-1H-pyridin-2-one (0.1 g) and 2,3-dichloro-N-(3,5-dibromo-2-pyrazinyl)benzenesulphonamide (0.16 g). Yield 0.035 g.
  • m/e 521 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.04 (1H, dd), 7.91 (1H, dd), 7.90-7.87 (2H, m), 7.60-7.50 (2H, m), 6.42 (1H, d), 5.10 (2H, s), 3.41 (3H, s).
  • MP 169-170° C.
    • EXAMPLE 33 N-[5-Bromo-3-(3-pyrazinyllmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00051
  • Prepared by the method of Example 31 using pyridazine-3-methanol (0.07 g) and 2,3-dichloro-N-(3,5-dibromo-2-pyrazinyl)benzenesulphonamide (0.15 g). Yield 0.06 g.
  • m/e 489 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 9.23 (1H, d), 8.08 (1H, dd), 7.99 (1H, dd), 7.92 (1H, dd), 7.91 (1H, s), 7.80 (1H, dd), 7.56 (1H, t), 5.67 (2H, s).
  • MP 115-120° C.
    • EXAMPLE 34 N-[5-Bromo-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00052
  • Prepared by the method of Example 31 using pyridine-3-methanol (0.44 g) and 2,3-dichloro-N-(3,5-dibromo-2-pyrazinyl)benzenesulphonamide (1.0 g). Yield 0.6 g.
  • m/e 491 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.78 (1H, d), 8.58 (1H, dd), 8.06 (1H, d), 7.99 (1H, dt), 7.91 (1H, d), 7.88 (1H, s), 7.55 (1H, t), 7.55-7.50 (1H, m), 5.44 (2H, s).
  • MP 204-206° C.
    • EXAMPLE 35 N-[5-Bromo-3-(5-pyrimidinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00053
  • Prepared by the method of Example 31 using pyrimidine-5-methanol (0.035 g) and 2,3-dichloro-N-(3,5-dibromo-2-pyrazinyl)benzenesulphonamide (0.16 g). Yield 0.028 g.
  • m/e 490 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 9.21 (1H, s), 9.02 (2H, s), 8.07 (1H, dd), 7.92 (1H, dd), 7.91 (1H, s), 7.56 (1H, t), 5.45 (2H, s).
  • MP 208-209° C.
    • EXAMPLE 36 N-[5-Chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00054
  • Prepared by the method of Example 31 using pyridine-3-methanol (0.13 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.3 g). Yield 0.19 g.
  • m/e 447 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.78 (1H, s), 8.59 (1H, dd), 8.06 (1H, dd), 7.96 (1H, dt), 7.91 (1H, dd), 7.83 (1H, s), 7.55 (1H, t), 7.47 (1H, dd), 5.44 (2H, s).
  • MP 200-204° C.
    • EXAMPLE 37 N-[5-Chloro-3-(5-pyrimidinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00055
  • Prepared by the method of Example 31 using pyrimidine-5-methanol (0.035 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.07 g). Yield 0.015 g.
  • m/e 448 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 9.21 (1H, s), 9.02 (2H, s), 8.08 (1H, dd), 7.92 (1H, dd), 7.86 (1H, s), 7.56 (1H, t), 5.46 (2H, s).
  • MP 205-206° C.
    • EXAMPLE 38 2-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00056
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 6-chloro-3-methoxy-2-pyrazinamine (0.1 g) and 2-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.11 g.
  • m/e 332 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.15 (1H, d), 7.86 (1H, s), 7.70-7.50 (3H, m), 3.91 (3H, s).
  • MP 172-173° C.
    • EXAMPLE 39 3-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00057
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 6-chloro-3-methoxy-2-pyrazinamine (0.1 g) and 3-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.14 g.
  • m/e 332 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.05 (1H, d), 7.93 (1H, dd), 7.90 (1H, s), 7.76 (1H, dd), 7.65 (1H, t) 3.92 (3H, s).
  • MP 126-127° C.
    • EXAMPLE 40 4-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00058
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 6-chloro-3-methoxy-2-pyrazinamine (0.1 g) and 4-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.13 g.
  • m/e 332 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 7.99 (2H, dt), 7.89 (1H, s), 7.70 (2H, dt), 3.92 (3H, s).
  • MP 174-175° C.
    • EXAMPLE 41 N-(6-Chloro-3-methoxy-2-pyrazinyl)-2,4-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00059
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 6-chloro-3-methoxy-2-pyrazinamine (0.05 g) and 2,4-dichlorobenzenesulphonyl chloride (0.1 g). Yield 0.07 g.
  • m/e 368 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.13 (1H, d), 7.86 (1H, s), 7.85 (1H, d), 7.70 (1H, dd), 3.91 (3H, s).
  • MP 189-190° C.
    • EXAMPLE 42 N-(6-Chloro-3-methoxy-2-pyrazinyl)-3,4-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00060
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 6-chloro-3-methoxy-2-pyrazinamine (0.05 g) and 3,4-dichlorobenzenesulphonyl chloride (0.09 g). Yield 0.08 g.
  • m/e 368 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.21 (1H, s), 7.93-7.90 (3H, m), 3.92 (3H, s).
  • MP 176-177° C.
    • EXAMPLE 43 3-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-2-methylbenzenesulphonamide
  • Figure US20100081670A1-20100401-C00061
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine (0.1 g) and 3-chloro-2-methylbenzenesulphonyl chloride (0.19 g). Yield 0.08 g.
  • m/e 328 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.09 (1H, br s), 7.95 (1H, d), 7.72 (1H, d), 7.54 (1H, br s), 7.41 (1H, t), 3.88 (3H, s), 2.64 (3H, s), 2.27 (3H, s).
  • MP 133-135° C.
    • EXAMPLE 44 2-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00062
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine (0.1 g) and 2-chlorobenzenesulphonyl chloride (0.15 g). Yield 0.06 g.
  • m/e 314 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.07 (1H, br s), 8.06 (1H, d), 7.69-7.46 (4H, m), 3.90 (3H, s), 2.24 (3H, s).
    • EXAMPLE 45 3-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00063
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine (0.1 g) and 3-chlorobenzenesulphonyl chloride (0.18 g). Yield 0.042 g.
  • m/e 314 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.89 (1H, br s), 7.97 (1H, d), 7.92 (1H, d), 7.73 (1H, d), 7.65-7.58 (2H, m), 3.90 (3H, s), 2.29 (3H, s).
  • MP 123-125° C.
    • EXAMPLE 46 4-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00064
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine (0.1 g) and 4-chlorobenzenesulphonyl chloride (0.18 g). Yield 0.06 g.
  • m/e 314 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.83 (1H, br s), 7.96 (2H, d), 7.65 (2H, d), 7.60 (1H, s), 3.88 (3H, s), 2.28 (3H, s).
  • MP 155-156° C.
    • EXAMPLE 47 2,4-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00065
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine (0.1 g) and 2,4-dichlorobenzenesulphonyl chloride (0.21 g). Yield 0.041 g.
  • m/e 348 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.05 (1H, d), 7.83 (1H, d), 7.64 (1H, dd), 7.54 (1H, br s), 3.87 (3H, s), 2.27 (3H, s).
  • MP 135-136° C.
    • EXAMPLE 48 3,4-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00066
  • Prepared by the method of Example 1 using 3-methoxy-5-methyl-2-pyrazinamine (0.1 g) and 3,4-dichlorobenzenesulphonyl chloride (0.21 g). Yield 0.046 g.
  • m/e 348 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.97 (1H, s), 8.14 (1H, d), 7.91 (1H, dd), 7.88 (1H, d), 7.63 (1H, s), 3.89 (3H, s), 2.27 (3H, s).
  • MP 148-149° C.
    • EXAMPLE 49 N-(5-Bromo-3-methoxy-2-pyrazinyl)-2-trifluoromethoxybenzenesulphonamide
  • Figure US20100081670A1-20100401-C00067
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.1 g) and 2-trifluoromethoxybenzenesulphonyl chloride (0.13 g). Yield 0.097 g
  • m/e 428 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.03 (1H, dd), 7.87 (1H, s), 7.82-7.74 (1H, m), 7.60-7.52 (2H, m), 3.92 (3H, s).
  • MP 156-157° C.
    • EXAMPLE 50 3-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-methylbenzenesulphonamide
  • Figure US20100081670A1-20100401-C00068
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-chloro-3-methoxy-2-pyrazinamine (0.1 g) and 3-chloro-2-methylbenzenesulphonyl chloride (0.15 g). Yield 0.085 g.
  • m/e 346 (M-1+, 100%).
  • 1H NMR (CDCl3) δ 8.17 (1H, d), 7.69 (1H, br s), 7.64 (1H, s), 7.61 (2H, d), 7.30 (1H, t), 4.04 (3H, s), 2.73 (3H, s).
  • MP 150-152° C.
    • EXAMPLE 51 2-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00069
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-chloro-3-methoxy-2-pyrazinamine (0.1 g) and 2-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.082 g.
  • m/e 332 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.33 (1H, d), 7.82 (1H, s), 7.64-7.62 (1H, m), 7.61 (1H, s), 7.50-7.42 (2H, m), 4.04 (3H, s).
  • MP 190-192° C.
    • EXAMPLE 52 3-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00070
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-chloro-3-methoxy-2-pyrazinamine (0.1 g) and 3-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.095 g.
  • m/e 332 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.14 (1H, s), 8.03 (1H, d), 7.76 (1H, s), 7.68-7.53 (2H, m), 7.46 (1H, t), 4.02 (3H, s).
  • MP 129-130° C.
    • EXAMPLE 53 4-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00071
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-chloro-3-methoxy-2-pyrazinamine (0.1 g) and 4-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.05 g.
  • m/e 332 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.07 (2H, d), 7.75 (1H, s), 7.56 (1H, s), 7.49 (2H, d), 4.02 (3H, s).
  • MP 179-180° C.
    • EXAMPLE 54 N-(5-Chloro-3-methoxy-2-pyrazinyl)-2,4-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00072
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-chloro-3-methoxy-2-pyrazinamine (0.1 g) and 2,4-dichlorobenzenesulphonyl chloride (0.13 g). Yield 0.045 g.
  • m/e 368 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.27 (1H, d), 7.78 (1H, s), 7.63 (1H, s), 7.48 (1H, s), 7.43 (1H, d), 4.05 (3H, s).
  • MP 170-171° C.
    • EXAMPLE 55 2,3-Dichloro-N-[3-methoxy-5-(4-morpholinyl)-2-pyrazinyl]benzenesulphonamide a) N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-{[2-(trimethylsilanyl)ethoxy]methyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00073
  • A mixture of N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (Example 8) (0.40 g), diisopropylethylamine (0.26 g) and [2-(chloromethoxy)ethyl]trimethylsilane (0.25 g) in dichloromethane (50 mL) was stirred at room temperature. After 2 h, the solution was washed with water, dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.40 g).
  • 1H NMR (CDCl3) δ 8.09 (1H, s), 7.96 (1H, dd), 7.68 (1H, dd), 7.29 (1H, t), 5.24 (2H, s), 3.92 (3H, s), 3.77-3.73 (2H, m), 0.86-0.82 (2H, m), 0.00 (9H, s).
    • b) 2,3-Dichloro-N-[3-methoxy-5-(4-morpholinyl)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00074
  • N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (0.30 g) and morpholine (0.45 g) in acetonitrile (10 mL) was heated at 50° C. After 16 h, the solution was evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound with SEM group attached, as a white solid. The solid was dissolved in trifluoroacetic acid (5.0 mL) and dichloromethane (5.0 mL). After 2 h, the solution was evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.06 g).
  • m/e 417 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.17 (1H, d), 7.65 (1H, d), 7.41 (1H, s), 7.34 (1H, t), 7.16 (1H, s), 3.89 (3H, s), 3.80-3.75 (4H, m), 3.40-3.35 (4H, m).
  • MP 167-168° C.
    • EXAMPLE 56 2,3-Dichloro-N-[3,5-dimethoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00075
  • N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (0.30 g) in methanolic sodium methoxide (10 mL of 0.5 molar solution) was stirred at room temperature. After 16 h, the solution was evaporated to dryness and dichloromethane (10 mL) and trifluoroacetic acid (10 mL) added. After 2 h, the mixture was evaporated to dryness, dichloromethane added and the inorganic salts removed by filtration. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.1 g).
  • m/e 364 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.21 (1H, d), 7.67 (1H, d), 7.50 (1H, s), 7.37 (1H, t), 7.26 (1H, s), 3.98 (3H, s), 3.87 (3H, s).
  • MP 138-139° C.
    • EXAMPLE 57 2,3-Dichloro-N-[3-methoxy-5-(1-pyrrolinyl)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00076
  • Prepared by the method of Example 55 using pyrrolidine (0.4 g) and N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (0.3 g). Yield 0.045 g.
  • m/e 403 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.08 (1H, d), 7.64 (1H, d), 7.30 (1H, t), 7.21 (1H, s), 6.99 (1H, s), 3.81 (3H, s), 3.40-3.35 (4H, m), 2.00-1.95 (4H, m).
  • MP 179-180° C.
    • EXAMPLE 58 3-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-2-methylbenzenesulphonamide
  • Figure US20100081670A1-20100401-C00077
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5,6-dichloro-3-methoxy-2-pyrazinamine (0.1 g) and 3-chloro-2-methylbenzenesulphonyl chloride (0.14 g). Yield 0.13 g.
  • m/e 381 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.25 (1H, d), 7.65 (1H, br s), 7.62 (1H, d), 7.35 (1H, t), 4.04 (3H, s), 2.73 (3H, s).
  • MP 177-178° C.
    • EXAMPLE 59 2,3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00078
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5,6-dichloro-3-methoxy-2-pyrazinamine (0.1 g) and 2,3-dichlorobenzenesulphonyl chloride (0.15 g). Yield 0.12 g.
  • m/e 402 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.31 (1H, d), 7.81 (1H, br s), 7.72 (1H, d), 7.45 (1H, t), 4.05 (3H, s).
  • MP 172-173° C.
    • EXAMPLE 60 2-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00079
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5,6-dichloro-3-methoxy-2-pyrazinamine (0.1 g and 2-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.096 g.
  • m/e 367 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.39 (1H, d), 7.79 (1H, br s), 7.58-7.45 (3H, m), 4.04 (3H, s).
  • MP 217-218° C.
    • EXAMPLE 61 3-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00080
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5,6-dichloro-3-methoxy-2-pyrazinamine (0.1 g) and 3-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.047 g.
  • m/e 367 (M-1+, 100%).
  • 1H NMR (CDCl3) δ 8.19 (1H, s), 8.07 (1H, d), 7.61 (1H, d), 7.59 (1H, br s), 7.50 (1H, t), 4.02 (3H, s).
  • MP 171-172° C.
    • EXAMPLE 62 4-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00081
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5,6-dichloro-3-methoxy-2-pyrazinamine (0.1 g) and 4-chlorobenzenesulphonyl chloride (0.13 g). Yield 0.09 g.
  • m/e 367 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.11 (2H, d), 7.57 (1H, br s), 7.50 (2H, d), 4.02 (3H, s).
  • MP 186-187° C.
    • EXAMPLE 63 2,4-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00082
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5,6-dichloro-3-methoxy-2-pyrazinamine (0.1 g) and 2,4-dichlorobenzenesulphonyl chloride (0.15 g). Yield 0.076 g.
  • m/e 402 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.30 (1H, d), 7.76 (1H, br s), 7.50 (1H, s), 7.48 (1H, d), 4.05 (3H, s).
  • MP 171-172° C.
    • EXAMPLE 64 3,4-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00083
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5,6-dichloro-3-methoxy-2-pyrazinamine (0.1 g) and 3,4-dichlorobenzenesulphonyl chloride (0.15 g). Yield 0.11 g.
  • m/e 402 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.30 (1H, s), 8.01 (1H, d), 7.63 (1H, d), 7.58 (1H, br s), 4.03 (3H, s).
  • MP 189-191° C.
    • EXAMPLE 65 2,3-Dichloro-N-(3-methoxy-5,6-dimethyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00084
  • Prepared by the method of Example 1 using 3-methoxy-5,6-dimethyl-2-pyrazinamine (0.07 g) and 2,3-dichlorobenzenesulphonyl chloride (0.12 g). Yield 0.04 g.
  • m/e 360 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.32 (1H, d), 7.67 (1H, s), 7.65 (1H, d), 7.39 (1H, t), 3.95 (3H, s), 2.28 (3H, s), 2.14 (3H, s).
  • MP 165-166° C.
    • EXAMPLE 66 2,3-Dichloro-N-(6-chloro-3,5-dimethoxy-2-pyrazinyl)benzenesulphonamide a) 2,3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00085
  • To a stirred solution of 2,3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide (0.68 g) in dichloromethane (20 mL) was added triethylamine (0.491 mL) followed by 2-(trimethylsilyl)ethoxymethyl chloride (0.328 g) and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was poured into water (50 mL) and extracted into ethyl acetate (3×20 mL). The combined extracts were dried (MgSO4), filtered and concentrated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the sub-title compound as a white solid (0.74 g).
  • 1H NMR (CDCl3) δ 8.02 (1H, dd), 7.70 (1H, dd), 7.34 (1H, t), 5.22 (2H, s), 3.96 (3H, s), 3.73 (2H, dd), 0.91-0.79 (2H, m), −0.03 (9H, s).
    • b) 2,3-Dichloro-N-(6-chloro-3,5-dimethoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00086
  • 2,3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulfonamide (0.10 g) was dissolved in methanol (1.0 mL) and a solution of sodium methoxide in methanol (0.1 mL of a 25% solution in methanol) was added. The reaction was stirred at room temperature for 30 min and was concentrated. The residue was dissolved in trifluoroacetic acid (2.0 mL) and was stirred at room temperature for 30 min. The reaction mixture was concentrated and chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.028 g).
  • m/e 397 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.26 (1H, d), 7.69 (1H, d), 7.41 (1H, t), 7.41 (1H, br s), 4.02 (3H, s), 3.91 (3H, s).
  • MP 163-165° C.
    • EXAMPLE 67 2,3-Dichloro-N-[6-chloro-3-methoxy-5-(4-morpholinyl)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00087
  • 2,3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (Example 66 part a) (0.10 g) was dissolved in THF (1.0 mL) and a solution of morpholine (0.05 g) in THF (0.1 mL) was added. The reaction was stirred at room temperature for 30 min and was concentrated. The residue was dissolved in trifluoroacetic acid (2.0 mL) and dichloromethane (2.0 mL) and was stirred at room temperature for 30 min. The reaction mixture was concentrated and chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.042 g).
  • m/e 452 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.28 (1H, dd), 7.69 (1H, dd), 7.49 (1H, br s), 7.43 (1H, t), 3.96 (3H, s), 3.79 (4H, dd), 3.28 (4H, dd).
  • MP 150-151° C.
    • EXAMPLE 68 2,3-Dichloro-N-[6-chloro-5-(2-hydroxyethylamino)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00088
  • Prepared by the method of Example 67 using 2-aminoethanol (0.05 g) and 2,3-dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulfonamide (0.1 g). Yield 0.015 g.
  • m/e 426 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.31 (1H, s), 7.91 (2H, dd), 7.52 (1H, t), 6.89 (1H, br s), 4.71 (1H, t), 3.63 (3H, s), 3.53 (2H, dd), 3.40 (2H, dd).
    • EXAMPLE 69 2,3-Dichloro-N-[6-chloro-5-dimethylamino-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00089
  • Prepared by the method of Example 67 using dimethylamine (5 mL of a 2M solution in tetrahydrofuran) and 2,3-dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulfonamide (0.1 g). Yield 0.015 g.
  • m/e 410 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 7.99-7.93 (2H, m), 7.56 (1H, t), 3.74 (3H, s), 2.99 (6H, s).
  • MP 145-146° C.
    • EXAMPLE 70 2,3-Dichloro-N-[6-chloro-3-methoxy-5-(2-methoxyethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00090
  • Sodium hydride (0.019 g of 60% dispersion in oil) was added to a solution of 2,3-dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulfonamide (0.25 g) in 2-methoxyethanol (3.0 mL) at room temperature. After 16 h, the solvent was evaporated and trifluoroacetic acid (2.0 mL) added. After 1 h, the reaction mixture was concentrated and chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.08 g).
  • m/e 442 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.24 (1H, dd), 7.70 (1H, dd), 7.41 (1H, t), 4.50-4.40 (2H, m), 3.96 (3H, s), 3.80-3.70 (2H, m), 3.42 (3H, s).
  • MP 193-194° C.
    • EXAMPLE 71 2,3-Dichloro-N-[6-chloro-5-hydroxy-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00091
  • tetrabutylammonium hydroxide (0.28 g of 40% aqueous solution) was added to a solution of 2,3-dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulfonamide (0.25 g) in 1,2-dimethoxyethane (3.0 mL) at room temperature. After 16 h, the solution was diluted with ethyl acetate (20 mL). The organic solution was washed with aqueous citric acid (10 mL) and brine, dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound containing the SEM group, as a white solid (0.08 g). The solid was dissolved in trifluoroacetic acid (2.0 mL) and dichloromethane (2.0 mL) and stirred at room temperature for 1 h. The reaction mixture was concentrated and chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.027 g).
  • m/e 384 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 12.56 (1H, s), 10.87 (1H, s), 7.96 (2H, t), 7.56 (1H, t), 3.74 (3H, s).
    • EXAMPLE 72 2,3-Dichloro-N-[6-methoxy-5-([2,2′]bipyrazinylyl)]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00092
  • N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55 part a) (0.70 g), tetrakis(triphenylphosphine)palladium(0) (0.1 g) and 2-(tributylstannanyl)pyrazine (0.50 g) in toluene (20 mL) was heated under nitrogen at 100° C. After 16 h, chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound protected with the SEM group as a white solid. The solid was dissolved in trifluoroacetic acid (2.0 mL) and dichloromethane (2.0 mL) and stirred at room temperature for 1 h. The reaction mixture was concentrated, toluene added and evaporated. The title compound crystallised from acetonitrile to give a white solid (0.38 g).
  • m/e 410 (M−1+, 100%).
  • 1H NMR (D6 DMSO) δ 9.35 (1H, s), 8.69 (1H, d), 8.67 (1H, d), 8.40 (1H, br s), 8.14 (1H, d), 7.96 (1H, d), 7.61 (1H, t), 4.07 (3H, s).
  • MP 199-200° C.
    • EXAMPLE 73 4-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinyloxy]benzoic acid
  • Figure US20100081670A1-20100401-C00093
  • 4-Hydroxybenzoic acid tert butyl ester (0.13 g), N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55 part a) (0.35 g) and caesium carbonate (0.42 g) in acetonitrile (10 mL) was heated at 50° C. After 12 h, the mixture was diluted with ethyl acetate, washed with water, dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound protected with the SEM group and tert butyl group as an oil. The oil was dissolved in trifluoroacetic acid (2.0 mL) and stirred at room temperature for 3 h. The reaction mixture was concentrated, toluene added and evaporated to give the title compound as a white solid (0.19 g).
  • m/e 468 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.28 (1H, d), 8.11 (2H, d), 7.80 (1H, br s), 7.71 (1H, d), 7.45 (2H, m), 7.12 (2H, d), 3.89 (3H, s).
  • MP 186-187° C.
    • EXAMPLE 74 2,3-Dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00094
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 3,5-dichloro-2-pyrazinamine (2.0 g) and 2,3-dichloro benzenesulphonyl chloride (2.94 g). Yield 3.0 g.
  • m/e 372 (M−1+, 100%).
  • 1H NMR (D6 DMSO) δ 8.29 (1H, s), 8.06 (1H, dd), 7.94 (1H, dd), 7.57 (1H, t).
  • MP 181-182° C.
    • EXAMPLE 75 2,3-Dichloro-N-{6-chloro-3-methoxy-5-([2-methoxyethyl)amino]-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00095
  • Prepared by the method of Example 67 using 2-methoxyethylamine (3 mL) and 2,3-dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (0.24 g). Yield 0.08 g.
  • m/e 439 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.33 (1H, s), 7.92 (2H, dd), 7.52 (1H, t), 7.00 (1H, s), 3.64 (3H, s), 3.47 (4H, s), 3.24 (2H, dd).
  • MP 177-178° C.
    • EXAMPLE 76 N-{2-[3-Chloro-5-(2,3-dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylamino]ethyl}acetamide
  • Figure US20100081670A1-20100401-C00096
  • 2,3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-[{2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (Example 66 part a) (0.26 g) was dissolved in acetonitrile (1.0 mL) and N-acetylethylenediamine (0.055 mL) and triethylamine (0.19 mL) added. After 48 h, the reaction mixture was concentrated and chromatography on silica gel eluting with ethyl acetate gave the title compound protected with the SEM group, as an oil (0.13 g). The oil was dissolved in dichloromethane (2.0 mL) and boron trifluoride etherate (0.14 ml) added. After 2 h, ethyl acetate (20 mL) was added and the mixture washed with 5% aqueous citric acid (5 mL), dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate gave the title compound as a solid (0.031 g).
  • m/e 470 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.32 (1H, s), 7.93-7.88 (2H, m), 7.52 (1H, t), 7.10 (1H, s), 3.65 (3H, s), 3.40-3.10 (4H, m), 1.75 (3H, s).
  • MP 150-152° C.
    • EXAMPLE 77 2,3-Dichloro-N-[5-(4-hydroxymethyl-1-piperidinyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00097
  • Prepared by the method of Example 55 using 4-(hydroxymethyl)piperidine (0.4 g) and N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy]methyl}benzenesulphonamide (0.3 g). Yield 0.012 g.
  • m/e 447 (M+1+, 100%).
  • 1H NMR (CDCl3)
    Figure US20100081670A1-20100401-P00001
    8.14 (1H, dd), 7.65 (1H, dd), 7.33 (1H, t), 7.20 (1H, s), 4.20-4.10 (2H, m), 3.86 (3H, s), 3.60-3.50 (2H, m), 2.90-2.70 (2H, m), 1.90-1.70 (3H, m), 1.40-1.20 (3H, m).
    • EXAMPLE 78 2,3-Dichloro-N-[5-cyano-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00098
  • N-[5-Bromo-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide (Example 34) (0.15 g), tetrakis(triphenylphosphine)palladium(0) (0.04 g) and zinc cyanide (0.03 g) in N,N-dimethylformamide (5.0 mL) was heated at 70° C. After 5 h, the mixture was diluted with ethyl acetate (30 mL) and washed with 5% aqueous citric acid (5 mL), dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures containing 1% acetic acid gave the title compound as a white solid (0.058 g).
  • m/e 436 (M+1+, 100%).
  • 1H NMR (D6 DMSO)
    Figure US20100081670A1-20100401-P00001
    8.70-7.65 (2H, m), 8.29 (1H, dd), 7.99 (1H, s), 7.78 (1H, d), 7.73 (1H, dd), 7.46 (1H, t), 7.40-7.35 (1H, m), 5.45 (2H, s).
  • MP 222-224° C.
    • EXAMPLE 79 2,3-Dichloro-N-(6-chloro-3-methoxy-5-methylamino-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00099
  • 3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (Example 66 part a) (0.25 g) was dissolved in methanol (1.0 mL) and methylamine (2.0 mL of 40% aqueous solution) was added. After 16 h, the solution was partitioned between water and ethyl acetate. The organic layer was dried (MgSO4) and evaporated. The residue was dissolved in dichloromethane (2.0 mL) and boron trifluoride etherate (0.25 mL) added. After 1 h, ethyl acetate (20 mL) was added and the solution washed with 5% aqueous citric acid (5 mL), dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.05 g).
  • m/e 395 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.27 (1H, s), 7.95-7.87 (2H, m), 7.51 (1H, dd), 7.10-7.00 (1H, m), 3.64 (3H, s), 2.84 (3H, s).
  • MP 185-186° C.
    • EXAMPLE 80 2,3-Dichloro-N-(3-methoxy-5-methylsulphanyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00100
  • N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-{[2-(trimethylsilanyl)ethoxy]methyl}benzenesulphonamide (0.30 g) and sodium thiomethoxide (0.05 g) in acetonitrile (10 mL) was stirred at room temperature. After 2 h, the solution was evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound with SEM group attached. The compound was dissolved in trifluoroacetic acid (5 mL). After 2 h, toluene (20 mL) was added and the solution evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.16 g).
  • m/e 380 (M+1+, 100%).
  • 1H NMR (CDCl3)
    Figure US20100081670A1-20100401-P00001
    8.25 (1H, d), 7.70 (1H, s), 7.68 (1H, d), 7.52 (1H, s), 7.39 (1H, t), 4.03 (3H, s), 2.48 (3H, s).
  • MP 141-142° C.
    • EXAMPLE 81 2,3-Dichloro-N-[5-(2,4-difluorophenyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide a) 5-(2,4-difluorophenyl)-3-methoxy-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00101
  • 5-Bromo-3-methoxy-2-pyrazinamine (0.3 g), cesium fluoride (0.8 g), 2,4-difluorobenezeneboronic acid (0.4 g) and [1,1′-bis(diphenylphosphino)ferrocene]palladium (II) chloride (0.04 g) in methanol (20 mL) was heated at 70° C. After 6 h, the solvent was evaporated and the residue purified by chromatography on silica eluting with ethyl acetate/isohexane mixtures to give the sub-title compound (0.2 g).
    • b) 2,3-Dichloro-N-[5-(2,4-difluorophenyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00102
  • Prepared by the method of Example 1 using 5-(2,4-difluorophenyl)-3-methoxy-2-pyrazinamine (0.2 g) and 2,3-dichlorobenzenesulphonyl chloride (0.2 g). Yield 0.06 g.
  • m/e 444 (M−1+, 100%).
  • 1H NMR (D6-DMSO)
    Figure US20100081670A1-20100401-P00001
    8.15 (1H, d), 8.05-7.95 (2H, m), 7.93 (1H, d), 7.60 (1H, t), 7.45-7.35 (1H, m), 7.30-7.20 (1H, m), 4.03 (3H, s).
  • MP 169-170° C.
    • EXAMPLE 82 [5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetic acid methyl ester
  • Figure US20100081670A1-20100401-C00103
  • N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (0.40 g), mercaptoacetic acid methyl ester (0.1 g) and caesium carbonate (0.6 g) in acetonitrile (10 mL) was stirred at room temperature. After 16 h, the solution was diluted with dichloromethane, filtered and evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound with SEM group attached. The compound was dissolved in trifluoroacetic acid (5 mL). After 2 h, toluene (20 mL) was added and the solution evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.15 g).
  • m/e 438 (M+1+, 100%).
  • 1H NMR (CDCl3)
    Figure US20100081670A1-20100401-P00001
    8.26 (1H, dd), 7.73 (1H, s), 7.68 (1H, dd), 7.59 (1H, s), 7.41 (1H, t), 3.99 (3H, s), 3.80 (2H, s), 3.71 (3H, s).
  • MP 152-153° C.
    • EXAMPLE 83 [5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetic acid
  • Figure US20100081670A1-20100401-C00104
  • [5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetic acid methyl ester (Example 82) (0.1 g) and lithium hydroxide (0.04 g) in methanol (5 mL) and water (1 mL) was stirred at room temperature. After 2 h, the mixture was evaporated and saturated aqueous citric acid (5 mL) added. The white solid was collected, washed with water and dried. Yield 0.07 g.
  • m/e 424 (M+1+, 100%).
  • 1H NMR (CDCl3)
    Figure US20100081670A1-20100401-P00001
    8.27 (1H, dd), 7.90 (1H, br s), 7.70 (1H, dd), 7.61 (1H, s), 7.40 (1H, t), 3.98 (3H, s), 3.80 (2H, s).
  • MP 138-140° C.
    • EXAMPLE 84 2,3-Dichloro-N-[5-(2-chlorobenzylsulphanyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00105
  • Prepared by the method of Example 82 using 2-chlorobenzylmercaptan (0.15 g) and N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (0.4 g). Yield 0.18 g.
  • m/e 492 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.26 (1H, dd), 7.73 (1H, s), 7.69 (1H, dd), 7.53 (1H, s), 7.40-7.30 (3H, m), 7.20-7.10 (2H, m), 4.39 (2H, s), 4.02 (3H, s).
  • MP 119-120° C.
    • EXAMPLE 85 2,3-Dichloro-N-[6-chloro-5-(3-hydroxy-1-azetidinyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00106
  • 2,3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (Example 66 part a) (0.20 g), azetidin-3-ol hydrochloride (0.082 g) and triethylamine (0.25 mL) in acetonitrile (3 mL) and water (0.5 mL) was stirred at room temperature. After 2 h, the mixture was evaporated and triturated with diethyl ether. The ethereal solution was evaporated and the residue dissolved in a 1 molar solution of tetrabutylammonium fluoride in THF (6 mL). After 16 h, the reaction mixture was concentrated and chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.024 g).
  • m/e 442 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.58 (1H, s), 7.92 (2H, d), 7.54 (1H, t), 5.66 (1H, s), 4.49 (1H, s), 4.36 (2H, t), 3.88 (2H, m), 3.67 (3H, s).
  • MP 93-95° C.
    • EXAMPLE 86 2,3-Dichloro-N-[5-methyl-3-(1-oxy-3-pyrazinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00107
  • 2,3-Dichloro-N-[5-methyl-3-(3-pyridinylmethoxy)-2-pyrazinyl)benzenesulphonamide (Example 24) (0.2 g) and 3-chloroperbenzoic acid (0.35 g) in dichloromethane (4 mL) was stirred at room temperature. After 0.5 h, chromatography on silica gel eluting with 5% methanol in ethyl acetate containing 1% acetic acid gave the title compound as a white solid (0.16 g).
  • m/e 441 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.56 (1H, br s), 8.60 (1H, br s), 8.18 (1H, dt), 8.06 (1H, dd), 7.90 (1H, dd), 7.61 (1H, br s), 7.56 (1H, t), 7.50-7.40 (2H, m), 5.36 (2H, s), 2.28 (3H, s).
  • MP 223-228° C.
    • EXAMPLE 87 2,3-Dichloro-N-[5-chloro-3-(4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00108
  • Prepared by the method of Example 31b using pyridine-4-methanol (0.4 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.4 g). Yield 0.47 g.
  • m/e 445 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.63 (2H, d), 8.08 (1H, dd), 7.91 (1H, dd), 7.83 (1H, s), 7.60 (2H, d), 7.55 (1H, t), 5.47 (2H, s).
  • MP 226-229° C. decomposes.
    • EXAMPLE 88 2,3-Dichloro-N-[5-chloro-3-(1-oxy-4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00109
  • Prepared by the method of Example 86 using 2,3-dichloro-N-[5-chloro-3-(4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 87) (0.1 g). Yield 0.4 g.
  • m/e 462 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.27 (2H, dt), 8.07 (1H, dd), 7.92 (1H, dd), 7.85 (1H, s), 7.60 (2H, d), 7.57 (1H, t), 5.38 (2H, s).
  • MP 208-211° C. decomposes.
    • EXAMPLE 89 2,3-Dichloro-N-[5-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]
  • Figure US20100081670A1-20100401-C00110
  • Prepared by the method of Example 31b using pyridine-2-methanol (0.2 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.2 g). Yield 0.1 g.
  • m/e 445 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.58 (1H, dt), 8.08 (1H, dd), 7.92 (1H, dd), 7.80-7.90 (2H, m), 7.64 (1H, d), 7.56 (1H, t), 7.18-7.20 (1H, m), 5.47 (2H, s).
  • MP 147-148° C.
    • EXAMPLE 90 2,3-Dichloro-N-[5-chloro-3-(2-methylsulphanylethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00111
  • Prepared by the method of Example 31 using 2-methylsulphanylethanol (0.05 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.1 g). Yield 0.06 g.
  • m/e 427 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.50-12.00 (1H, br s), 8.09 (1H, d), 7.95 (1H, d), 7.81 (1H, s), 7.60 (1H, t), 4.47 (2H, t), 2.86 (2H, t), 2.14 (3H, s).
  • MP 140-141° C.
    • EXAMPLE 91 N-(3-Butoxy-5-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00112
  • Prepared by the method of Example 31 using 1-butanol (0.05 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.1 g). Yield 0.037 g.
  • m/e 410 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.08 (1H, d), 7.96 (1H, d), 7.79 (1H, s), 7.57 (1H, t), 4.29 (2H, t), 1.60-1.75 (2H, m), 1.40-1.50 (2H, m), 0.95 (3H, t).
  • MP 133-134° C.
    • EXAMPLE 92 2,3-Dichloro-N-[5-chloro-3-(2-methyl-3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00113
  • Prepared by the method of Example 31 using (2-methyl-3-pyridinyl)methanol (0.15 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.15 g).
  • Yield 0.06 g
  • m/e 458 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.45 (1H, dd), 8.05 (1H, dd), 7.94 (1H, dd), 7.88 (1H, dd), 7.80 (1H, s), 7.53 (1H, t), 7.32 (1H, dd), 5.40 (2H, s), 2.56 (3H, s).
  • MP 214-216° C. decomposes.
    • EXAMPLE 93 2,3-Dichloro-N-[5-chloro-3-(6-methyl-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00114
  • Prepared by the method of Example 31 using (6-methyl-2-pyridinyl)methanol (0.15 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.15 g). Yield 0.06 g.
  • m/e 461 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.08 (1H, dd), 7.91 (1H, dd), 7.84 (1H, s), 7.75 (1H, t), 7.55 (1H, t), 7.42 (1H, d), 7.24 (1H, d), 5.42 (2H, s), 2.52 (3H, s).
  • MP 158-159° C.
    • EXAMPLE 94 2,3-Dichloro-N-[5-chloro-3-(1-oxy-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00115
  • Prepared by the method of Example 86 using 2,3-dichloro-N-[5-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 89) (0.2 g). Yield 0.1 g.
  • m/e 462 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.35-8.40 (1H, m), 8.09 (1H, dd), 7.80-7.90 (2H, m), 7.88 (1H, s), 7.58 (1H, t), 7.40-7.50 (2H, m), 5.51 (2H, s).
  • MP 222-224° C. decomposes.
    • EXAMPLE 95 3-Chloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-methylbenzenesulphonamide a) 5-Chloro-3-(3-pyridinylmethoxy)-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00116
  • 3,5-Dichloro-2-pyrazinamine (1.0 g) was added to a stirred suspension of pyridine-3-methanol (1.3 g) and sodium hydride (0.70 g of 60% dispersion in oil) in 1,2-dimethoxyethane (10 mL). After 0.5 h, 5% aqueous citric acid was added and the mixture extracted with ethyl acetate. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound as a white solid (0.2 g). Used directly.
    • b) 3-Chloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-methylbenzenesulphonamide
  • Figure US20100081670A1-20100401-C00117
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinamine (Example 95a) (0.1 g) and 3-chloro-2-methylbenzenesulphonyl chloride (0.09 g). Yield 0.012 g.
  • m/e 425 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.78 (1H, d), 8.58 (1H, dd), 7.96 (2H, dt), 7.83 (1H, s), 7.72 (1H, d), 7.46 (1H, dd), 7.40 (1H, t), 5.44 (2H, s), 2.63 (3H, s).
  • MP 192-193° C.
    • EXAMPLE 96 3-Chloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-fluorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00118
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinamine (Example 95a) (0.1 g) and 3-chloro-2-fluorobenzenesulphonyl chloride (0.1 g). Yield 0.034 g.
  • m/e 429 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.78 (1H, d), 8.60 (1H, dd), 7.99 (1H, dt), 7.80-7.90 (3H, m), 7.48 (1H, dd), 7.40 (1H, t), 5.43 (2H, s).
  • MP 177-178° C.
    • EXAMPLE 97 2,3-Dichloro-N-[5-chloro-3-(4-methoxyphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00119
  • Prepared by the method of Example 31 using 4-methoxybenzylalcohol (0.3 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.5 g). Yield 0.4 g.
  • m/e 475 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.05 (1H, dd), 7.91 (1H, dd), 7.81 (1H, s), 7.58 (1H, t), 7.42 (2H, d), 6.94 (2H, d), 5.32 (2H, s), 3.77 (3H, s).
  • MP 163-164° C.
    • EXAMPLE 98
  • N-[5-Bromo-6-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00120
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 3-bromo-5-chloro-2-pyrazinamine (Example 4a) (1.2 g) and 2,3-dichlorobenzenesulphonyl chloride (1.4 g). Yield 1.5 g.
  • m/e 418 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.07 (1H, dd), 7.90-7.80 (2H, m), 7.53 (1H, t).
  • MP 123-124° C.
    • EXAMPLE 99 2,3-Dichloro-N-[6-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00121
  • Prepared by the method of Example 31 using pyridine-3-methanol (0.22 g) and N-(3-bromo-6-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (Example 98) (0.2 g).
  • Yield 0.04 g.
  • m/e 445 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.77 (1H, br s), 8.59 (1H, dd), 8.12 (1H, dd), 8.00 (1H, dt), 7.92 (1H, dd), 7.84 (1H, s), 7.58 (1H, t), 7.55-7.50 (1H, m), 5.44 (2H, s).
  • MP 203-204° C.
    • EXAMPLE 100 2,3-Dichloro-N-[6-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00122
  • Prepared by the method of Example 31 using pyridine-2-methanol (0.22 g) and N-(3-s bromo-6-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (Example 98) (0.2 g). Yield 0.13 g.
  • m/e 445 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.56 (1H, dd), 8.15 (1H, dd), 7.94 (1H, dd), 7.90-7.80 (2H, m), 7.65-7.60 (1H, m), 7.58 (1H, s), 7.40-7.35 (1H, m), 5.48 (2H, s).
  • MP 201-203° C.
    • EXAMPLE 101 N-[5-(2-Aminoethylsulphanyl)-3-(2-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide a) 2,3-Dichloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-N-[2-trimethylsilanylethoxymethyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00123
  • Prepared by the method of Example 66a using 2,3-dichloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 36) (0.5 g). Yield 0.68 g. Used directly.
    • b) N-[5-(2-Aminoethylsulphanyl)-3-(2-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00124
  • A mixture of 2,3-dichloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-N-[2-trimethylsilanylethoxymethyl]benzenesulphonamide (Example 101a) (0.68 g), caesium carbonate (1.9 g) and 2-aminoethanethiol hydrochloride (0.2 g) in acetonitrile (5 mL) was stirred at room temperature for 5 h. Ethyl acetate was added and the mixture washed with water and brine. The organic layer was dried (MgSO4) and evaporated. The residue was dissolved in trifluoracetic acid. After 1 h, toluene was added and the mixture evaporated to dryness. HCl (1M in dioxane) was added and the solid collected by filtration (0.2 g).
  • m/e 484 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.65 (1H, s), 8.52 (1H, d), 8.20-7.60 (2H, br s), 7.96 (1H, dd), 7.82 (1H, d), 7.62 (1H, d), 7.42-7.38 (1H, m), 7.35 (1H, t), 7.30 (1H, s), 5.24 (2H, s), 3.05-3.00 (2H, m), 2.85-2.80 (2H, m).
    • EXAMPLE 102 2,3-Dichloro-N-[5-chloro-3-(6-methoxy-3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00125
  • Prepared by the method of Example 31 using (6-methoxy-3-pyridinyl)methanol (0.3 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.3 g). Yield 0.15 g.
  • m/e 474 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.32 (1H, d), 8.04 (1H, dd), 7.91 (1H, dd), 7.85-7.80 (2H, m), 7.86 (1H, d), 7.55 (1H, t), 6.86 (1H, dd), 5.33 (2H, s), 3.87 (3H, s).
    • EXAMPLE 103 N-[3-(3-Bromophenylmethoxy)-5-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00126
  • Prepared by the method of Example 31b using 3-bromobenzylalcohol (1.3 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (1.1 g). Yield 1.1 g.
  • m/e 522 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.07 (1H, dd), 7.92 (1H, dd), 7.85 (1H, s), 7.78 (1H, s), 7.60-7.50 (3H, m), 7.37 (1H, t), 5.40 (2H, s).
    • EXAMPLE 104 3-[6-Chloro-3-(2,3-dichlorobenzenesulphonylamino)-2-pyrazinyloxymethyl]benzoic acid methyl ester
  • Figure US20100081670A1-20100401-C00127
  • N-[3-(3-Bromophenylmethoxy)-5-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide (Example 103) (1.0 g) and bis(triphenylphosphine)palladium dichloride (0.4 g) in methanol (15 mL) and triethylamine (7 mL) was heated at 100° C. under an atmosphere of carbon monoxide (6 barr). After 20 h, the mixture was filtered and evaporated. The residue was dissolved in ethyl acetate. The organic solution was washed with brine, aqueous citric acid, dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound as a white solid (0.65 g).
  • m/e 503 (m+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.11 (1H, s), 8.05 (1H, dd), 7.95 (1H, d), 7.90 (1H, dd), 7.84 (1H, s), 7.80 (1H, d), 7.60-7.50 (2H, m), 5.46 (2H, s), 3.88 (3H, s).
  • MP 175-176° C.
    • EXAMPLE 105 3-[6-Chloro-3-(2,3-dichlorobenzenesulphonylamino)-2-pyrazinyloxymethyl]benzoic acid
  • Figure US20100081670A1-20100401-C00128
  • A mixture of 3-[6-chloro-3-(2,3-dichlorobenzenesulphonylamino)-2-pyrazinyloxymethyl]benzoic acid methyl ester (Example 104) (0.3 g) and lithium hydroxide hydrate (0.2 g) in water (5 mL) and methanol (5 mL) was stirred at room temperature. After 3 h, hydrochloric acid (2M) was added to acidify the mixture and the solid product was collected by filtration and dried (0.25 g).
  • m/e 489 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 13.10-13.00 (1H, br s), 12.00-11.80 (1H, br s), 8.10 (1H, s), 8.05 (1H, dd), 7.85-7.95 (2H, m), 7.82 (1H, s), 7.76 (1H, d), 7.54 (2H, t), 5.46 (2H, s).
  • MP 218-224° C. decomposes.
    • EXAMPLE 106 2,3-Dichloro-N-[5-chloro-3-(3-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide a) 2,3-Dichloro-N-{5-chloro-3-[3-(tetrahydro-2-pyranyloxymethyl)phenylmethoxy]-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00129
  • Prepared by the method of Example 31 using [3-(tetrahydro-2-pyranyloxymethyl)phenyl]methanol (1.99 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (1.0 g). Yield 1.0 g. Used directly.
    • b) 2,3-Dichloro-N-[5-chloro-3-(3-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00130
  • 2,3-Dichloro-N-{5-chloro-3-[3-(tetrahydro-2-pyranyloxymethyl)phenylmethoxy]-2-pyrazinyl}benzenesulphonamide (Example 106a) (1.0 g) in acetic acid (40 mL), water (10 mL) and tetrahyrofuran (20 mL) was heated at 45° C. for 16 h and the solution was evaporated to dryness. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound as a white solid (0.6 g).
  • m/e 475 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.05 (1H, dd), 7.91 (1H, dd), 7.82 (1H, s), 7.55 (1H, t), 7.43 (1H, s), 7.40-7.25 (3H, m), 5.39 (2H, s), 4.52 (2H, s).
  • MP 162-163° C.
    • EXAMPLE 107 2,3-Dichloro-N-[5-chloro-3-(3-methylaminomethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide a) 2,3-Dichloro-N-[5-chloro-3-(3-formylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00131
  • 2,3-Dichloro-N-[5-chloro-3-(3-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 106) (0.6 g) and manganese dioxide (1.0 g) in tetrahydrofuran (5 mL) was stirred at room temperature for 16 h. The mixture was diluted with dichloromethane and filtered through celite. The solution was evaporated to dryness and the product crystallised from diethyl ether (0.4 g). Used directly.
    • b) 2,3-Dichloro-N-[5-chloro-3-(3-methylaminomethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00132
  • A mixture of 2,3-dichloro-N-[5-chloro-3-(3-formylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 107a) (0.1 g), methylamine (2 mL of a 2M solution in tetrahydrofuran) and acetic acid (0.2 mL) in methanol (2 mL) was stirred at room temperature. After 2 h, sodium cyanoborohydride (0.03 g) was added. After 0.5 h, water (2 mL) was added and the mixture evaporated to dryness. Chromatography on silica gel eluting with methanol/dichloromethane mixtures gave the title compound as a white solid (0.035 g).
  • m/e 487 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.90-8.60 (2H, br s), 8.02 (1H, d), 7.90-7.80 (1H, m), 7.80-7.60 (1H, m), 7.59 (1H, d), 7.55-7.40 (4H, m), 5.40 (2H, s), 4.08 (2H, s), 2.59 (3H, s).
  • MP 167-168° C.
    • EXAMPLE 108 2,3-Dichloro-N-[5-chloro-3-{3-([2-hydroxyethylamino]methyl)phenylmethoxy}-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00133
  • Prepared by the method of Example 107b using 2,3-dichloro-N-[5-chloro-3-(3-formylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 107a) (0.1 g) and 2-aminoethanol (0.05 g). Yield 0.035 g.
  • m/e 517 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 9.00-8.80 (2H, br s), 7.93 (1H, d), 7.80-7.20 (7H, m), 5.28 (2H, s), 5.21 (1H, t), 4.20 (2H, s), 3.80-3.60 (2H, m), 3.05-2.95 (2H, m).
  • MP 196-198° C.
    • EXAMPLE 109 2,3-Dichloro-N-[5-chloro-3-(4-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00134
  • Prepared by the method of Examples 106a and 106b using [4-(tetrahydro-2-pyranyloxymethyl)phenyl]methanol (2.0 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (1.0 g). Yield 0.7 g.
  • m/e 474 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.05 (1H, dd), 7.91 (1H, dd), 7.83 (1H, s), 7.55 (1H, t), 7.46 (2H, d), 7.33 (2H, d), 5.38 (2H, s), 4.51 (2H, s).
  • MP 177-178° C.
    • EXAMPLE 110 2,3-Dichloro-N-[5-chloro-3-{4-([2-hydroxyethylamino]methyl)phenylmethoxy}-2-pyrazinyl]benzenesulphonamide a) 2,3-Dichloro-N-[5-chloro-3-(4-formylphenylmethoxy)-2-parazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00135
  • Prepared by the method of Example 107a using 2,3-dichloro-N-[5-chloro-3-(4-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 109) (0.65 g). Yield 0.64 g. Used directly.
    • b) 2,3-Dichloro-N-(5-chloro-3-{4-[(2-hydroxyethylamino)methyl]phenylmethoxy}-2-parazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00136
  • Prepared by the method of Example 107b using 2,3-dichloro-N-[5-chloro-4-(3-formylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 110a) (0.1 g) and 2-aminoethanol (0.05 g). Yield 0.028 g.
  • m/e 517 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.75 (2H, br s), 7.93 (1H, dd), 7.61 (1H, dd), 7.54 (4H, s), 7.35 (1H, t), 7.26 (1H, s), 5.26 (2H, s), 5.18 (1H, t), 4.18 (2H, s), 3.70-3.60 (2H, m), 3.00-2.95 (2H, m).
  • MP 202-205° C.
    • EXAMPLE 111 2,3-Dichloro-N-[3-(4-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide a) 2,3-Dichloro-N-{3-[4-(tetrahydro-2-pyranyloxymethyl)phenylmethoxy]-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00137
  • 2,3-Dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (Example 28a) (0.1 g), [4-(tetrahydro-2-pyranyloxymethyl)phenyl]methanol (0.27 g) and potassium tert-butoxide (2 mL of a 1M solution in tetrahydrofuran) in N-methylpyrrolidinone (1 mL) was stirred at 50° C. After 2 h, aqueous citric acid was added and the mixture extracted with ethyl acetate. The organic solution was washed with water and brine and evaporated to dryness. Used directly.
    • b) 2,3-Dichloro-N-[3-(4-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00138
  • 2,3-Dichloro-N-{3-[4-(tetrahydro-2-pyranyloxymethyl)phenylmethoxy]-2-pyrazinyl}benzenesulphonamide (Example 111a) in acetic acid (10 mL), water (2.5 mL) and tetrahydrofuran (5 mL) was heated at 45° C. for 16 h and the solution was evaporated to dryness. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound as a white solid (0.022 g).
  • m/e 440 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.08 (1H, dd), 7.91 (1H, dd), 7.90-7.70 (1H, br s), 7.70-7.60 (1H, br s), 7.55 (1H, t), 7.42 (2H, d), 7.31 (2H, d), 5.39 (2H, s), 5.20-5.05 (1H, br s), 4.49 (2H, s).
  • MP 160-161° C.
    • EXAMPLE 112 2,3-Dichloro-N-[5-chloro-3-(2-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00139
  • 2,3-Dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74). (0.15 g), (2-hydroxymethylphenyl)methanol (0.27 g) and potassium tert-butoxide (3 mL of a 1M solution in tetrahydrofuran) in N-methylpyrrolidinone (2 mL) was stirred at room temperature. After 1 h, aqueous citric acid was added and the mixture extracted with ethyl acetate. The organic solution was washed with water and brine and evaporated to dryness. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound as a white solid (0.027 g).
  • m/e 474 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.06 (1H, dd), 7.90 (1H, dd), 7.81 (1H, s), 7.60-7.40 (3H, m), 7.37 (1H, t), 7.29 (1H, t), 5.45 (2H, s), 4.64 (2H, s).
  • MP 145-146° C.
    • EXAMPLE 113 5-(2,3-Dichlorobenzenesuphonylamino)-6-methoxypyrazine-2-carboxylic acid, methyl ester
  • Figure US20100081670A1-20100401-C00140
  • N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (Example 8) (6.5 g) and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.7 g) in methanol (30 mL) and triethylamine (10 mL) was heated at 100° C. under an atmosphere of carbon monoxide (6 bar). After 5 h, the mixture was filtered and evaporated. The residue was dissolved in ethyl acetate. The organic solution was washed with brine, aqueous citric acid, dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound as a white solid (4.8 g).
  • m/e 392 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.13 (2H, dd), 7.95 (1H, dd), 7.60 (1H, t), 3.95 (3H, s), 3.82 (3H, s).
  • MP 120-121° C.
    • EXAMPLE 114 2,3-Dichloro-N-[5-(1-hydroxy-1-methylethyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00141
  • Methylmagnesium bromide (3 mL of a 3M solution in diethyl ether) was added over 3 minutes to a stirred solution of 5-(2,3-dichlorobenzenesuphonylamino)-6-methoxypyrazine-2-carboxylic acid, methyl ester (Example 113) (0.3 g) in tetrahydrofuran (10 mL) cooled in an ice/water bath. After a further 5 minutes, aqueous citric acid was added and the mixture extracted with ethyl acetate. The organic solution was evaporated to dryness. Chromatography on silica gel eluting with methanol/dichloromethane mixtures gave the title compound as a white solid (0.15 g).
  • m/e 392 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.40-11.30 (1H, br s), 8.07 (1H, dd), 7.93 (1H, d), 7.90-7.80 (1H, br s), 7.59 (1H, t), 5.10-5.05 (1H, br s), 3.88 (3H, s), 1.39 (6H, s).
  • MP 192-193° C.
    • EXAMPLE 115 N-4-[5-(2-Aminoethoxy)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide a) 2,3-Dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy-]-methyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00142
  • Prepared by the method of Example 66a using 2,3-dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide (Example 5) (7.0 g). Yield 9.8 g. Used directly.
  • Figure US20100081670A1-20100401-C00143
    • b) N-[5-(2-aminoethoxy)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • 2,3-Dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (Example 115a) (0.25 g) was added to a mixture of ethanolamine (0.05 mL) and sodium hydride (0.035 g of a 60% dispersion in oil) in 1,2-dimethoxyethane (15 mL) at room temperature. After 2 h, the mixture was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried (MgSO4) and evaporated to dryness. Chromatography on silica gel eluting with methanol/dichloromethane mixtures gave the title compound containing the SEM ([2-(trimethylsilyl)ethoxy]methyl) protecting group as an oil (0.14 g). Trifluoroacetic acid (1 mL) and dichloromethane (3 mL) were added. After 0.5 h at room temperature, toluene was added and the solution evaporated to dryness. HCl (4M in dioxane) was added and the mixture evaporated to dryness. The product was crystallised from diethyl ether (0.075 g).
  • m/e 393 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.90 (1H, br s), 8.07 (2H, br s), 7.99-7.92 (2H, m), 7.56 (1H, t), 7.49 (1H, s), 4.45 (2H, t), 3.84 (3H, s), 3.25-3.20 (2H, m).
  • MP 200-205° C.
    • EXAMPLE 116 N-{5-[(2-Aminoethyl)thio]-6-chloro-3-methoxy-2-pyrazinyl}-2,3-dichlorobenzenesulfonamide
  • Figure US20100081670A1-20100401-C00144
  • Prepared by the method of Example 101b using 2,3-dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (Example 66a) (0.27 g). Yield 0.055 g.
  • m/e 443 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.09 (1H, d), 7.90 (1H, d), 7.58 (1H, t), 3.95 (3H, s), 3.33 (2H, t), 3.14 (2H, t).
  • MP 185-190° C.
    • EXAMPLE 117 3-[(5-{[(2,3-Dichlorophenyl)sulphonyl]amino}-6-methoxy-2-pyrazinyl)thio]propanoic acid, methyl ester
  • Figure US20100081670A1-20100401-C00145
  • Prepared by the method of Example 101b using 2,3-dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (Example 115a) (0.25 g) and 3-mercaptopropionic acid, methyl ester (0.06 mL). Yield 0.1 g.
  • m/e 452 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.35 (1H, br s), 8.03 (1H, d), 7.93 (1H, d), 7.66 (1H, s), 7.57 (1H, t), 3.90 (3H, s), 3.58 (3H, s), 3.29 (2H, t), 2.72 (2H, t).
  • MP 146-148° C.
    • EXAMPLE 118 2,3-Dichloro-N-[5-bromo-3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide a) 6-Methyl-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00146
  • Dimethylzinc (100 mL of a 2M solution in toluene) was added dropwise over 0.5 h to a stirred solution of 6-chloro-2-pyrazinamine (12.9 g) and [1,3-bis(diphenylphosphino)propane]nickel(II) chloride (5.4 g) in dioxane (200 mL) under a nitrogen atmosphere. The reaction mixture was heated at reflux for 18 h, then cooled to room temperature and quenched cautiously with iso-propanol (30 mL) and methanol (50 mL). After removal of solvent in vacuo, the residue was partitioned between dichloromethane and aqueous ammonium chloride. The organic phase was filtered through celite, dried (MgSO4), filtered and evaporated to give the crude product as an orange solid. Chromatography on silica gel eluting with ethyl acetate/methanol mixtures gave the title compound (5.1 g). Used directly.
    • b) 3,5-Dibromo-6-methyl-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00147
  • A solution of bromine (1.85 g) in chloroform (5 mL) was added dropwise to a stirred solution of 2-amino-6-methylpyrazine (Example 118a) (0.6 g) in chloroform (50 mL). The reaction mixture was stirred at room temperature for 0.5 h, then washed twice with water, dried (MgSO4), filtered and evaporated to give the crude product as an orange solid. Chromatography on silica gel eluting with dichloromethane gave the title compound (0.95 g). Used directly.
    • c) 5-Bromo-3-methoxy-6-methyl-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00148
  • A solution of 3,5-dibromo-6-methyl-2-pyrazinamine (Example 118b) (0.9 g) was added to a solution of sodium (0.39 g) in methanol (30 mL) was heated at reflux for 18 h. After removal of solvent in vacuo, the residue was partitioned between water and dichloromethane, and the organic phase dried (MgSO4), filtered and evaporated to give the title compound as a pale yellow solid (0.58 g).
  • m/e 218/220 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 4.70 (2H, br s), 3.97 (3H, s), 2.40 (3H, s).
    • d) 2,3-Dichloro-N-[5-bromo-3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00149
  • Sodium hydride (0.5 g of a 60% dispersion in oil) was added to a solution of 5-bromo-3-methoxy-6-methyl-2-pyrazinamine (Example 118c) (0.55 g) in N-methylpyrrolidinone (25 mL). The resultant dark solution was stirred at room temperature for 0.5 h before a solution of 2,3-dichlorobenzenesulphonyl chloride (0.67 g) in N-methylpyrrolidinone (5 mL) was added dropwise. The reaction mixture was stirred at room temperature for 3 h, then quenched with aqueous ammonium chloride and partitioned between ethyl acetate and aqueous ammonium chloride (×5). the organic phase was dried (MgSO4), filtered and evaporated to give the crude product. Chromatography on silica gel eluting with dichloromethane/acetic acid (200:1) gave the title compound as a pale yellow solid (0.38 g).
  • m/e 424/426/428 (M−1−, 100%).
  • 1H NMR (CDCl3) δ 8.29 (1H, d), 7.69 (2H, d), 7.41 (1H, t), 4.01 (3H, s), 2.27 (3H, s).
  • MP 146-148° C.
    • EXAMPLE 119 5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-3-methylpyrazine-2-carboxylic acid, methyl ester
  • Figure US20100081670A1-20100401-C00150
  • Prepared by the method of Example 113 using 2,3-dichloro-N-[5-bromo-3-methoxy-6-methylpyrazinyl)benzenesulphonamide (Example 118) (0.35 g). Yield 0.27 g.
  • m/e 404/406 (M−1−, 100%).
  • 1H NMR (CDCl3) δ 8.32 (1H, br s), 8.10 (1H, br s), 7.70 (1H, d), 7.42 (1H, t) 4.06 (3H, s), 3.90 (3H, s), 2.50 (3H, br s).
  • MP 149-150° C.
    • EXAMPLE 120 2,3-Dichloro-N-[5-(hydroxymethyl)-3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00151
  • To a stirred solution of 5-(2,3-dichlorobenzenesulphonylamino)-6-methoxy-3-methylpyrazine-2-carboxylic acid, methyl ester (Example 119) (0.19 g) in tetrahydrofuran (10 mL) under an atmosphere of nitrogen was added a solution of lithium triethylborohydride (1.7 mL of a 1M solution in tetrahydrofuran). The reaction mixture was stirred at room temperature for 1 h, before quenching with aqueous ammonium chloride and extraction into dichloromethane. The organic phase was dried (MgSO4), filtered and evaporated to give the crude product as a colourless oil. Chromatography on silica gel eluting with dichloromethane/ethyl acetate/acetic acid (150:50:1) gave the title compound as a white solid (0.38 g).
  • m/e 378 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.31 (1H, br d), 7.77 (1H, br s), 7.68 (1H, d), 7.41 (1H, t), 4.55 (2H, d), 4.03 (3H, s), 3.12 (1H, br s), 2.13 (3H, br s).
  • MP 175-177° C.
    • EXAMPLE 121 2,3-Dichloro-N-[5,6-dichloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide a) 5,6-Dichloro-3-(3-pyridinylmethoxy)-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00152
  • To a stirred suspension of sodium hydride (1.20 g of a 60% dispersion in oil) in dry dimethoxymethane (40 mL) was added pyridine-3-methanol (2.18 g) in 1,2-dimethoxymethane (10 mL). The resulting suspension was stirred at room temperature for 0.5 h and then 3,5,6-trichloro-2-aminopyrazine (1.2 g) was added and the mixture stirred at 70° C. for 4 h. The reaction mixture was cooled and cautiously added to water (100 mL) and neutralised with 2M hydrochloric acid. The mixture was extracted with ethyl acetate (2×50 mL), dried (MgSO4), filtered and concentrated. The residue was purified by chromatography on silical gel eluting with ethyl acetate to afford the sub-titled compound as a white solid (0.29 g). 1H NMR (CDCl3) δ 8.73 (1H, s), 8.63 (1H, d), 7.8 (1H, d), 7.35 (1H, dd), 5.42 (2H, s), 4.92 (2H, br s).
    • b) 2,3-Dichloro-N-[5,6-dichloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00153
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5,6-dichloro-3-(3-pyridinylmethoxy)-2-pyrazinamine (Example 121a) (0.27 g) and 2,3-dichlorobenzenesulphonyl chloride (0.27 g). Yield 0.17 g.
  • m/e 479 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.8 (1H, s), 8.63 (1H, d), 8.11 (1H, d), 8.06 (1H, d), 7.58-7.52 (2H, m), 5.41 (2H, s).
    • EXAMPLE 122 3-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-fluorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00154
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-chloro-3-methoxy-2-pyrazinamine (0.16 g) and 3-chloro-2-fluorobenzenesulphonyl chloride (0.27 g). Yield 0.22 g.
  • m/e 354, 352 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 7.94-7.86 (2H, m), 7.82 (1H, s), 7.43 (1H, dt), 3.92 (3H, s).
  • MP 156-157° C.
    • EXAMPLE 123 3-Chloro-2-fluoro-N-[3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide a) 3-(3-Pyridinylmethoxy)-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00155
  • Prepared as for Example 121a using 3-chloro-2-aminopyrazine (0.5 g), pyridine-3-methanol (0.42 g) and sodium hydride (0.31 g of a 60% dispersion in oil) in N-methylpyrrolidinone (5 mL) to afford the sub-titled compound as a solid (0.62 g).
  • 1H NMR (CDCl3) δ 8.73 (1H, d), 8.60 (1H, d), 7.78 (1H, d), 7.60 (1H, d), 7.42 (1H, d), 7.32 (1H, dd), 5.43 (2H, s), 4.77 (2H, br).
  • MP 120-122° C.
    • b) 3-Chloro-2-fluoro-N-[3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00156
  • To a stirred solution of 3-(3-pyridinylmethoxy)-2-pyrazinamine (Example 122a) (0.404 g) in dichloromethane (5 mL) and pyridine (1 mL) was added iso-butylchloroformate (0.3 mL) and the resulting solution stirred for 20 hours. The reaction mixture was poured into water (20 mL) and extracted into ethyl acetate (2×20 mL). The combined extracts were dried (MgSO4), filtered and concentrated to afford an oil (0.51 g) that was used without further purification. A portion of the residue (0.15 g) was dissolved in 1,2-dimethoxymethane (2 mL) and sodium hydride (0.030 g of 60% dispersion in oil) added. The resulting suspension was stirred for 15 minutes and then 3-chloro-2-fluorobenzenesulfonyl chloride (0.137 g) in dimethoxymethane (1 mL) was added. The resulting solution was stirred at room temperature for 6 h. The reaction mixture was poured into water (20 mL) and extracted into ethyl acetate (2×20 mL). The combined extracts were dried (MgSO4), filtered and concentrated to afford an oil that was dissolved into methanol (5 mL) and water (2 mL) and sodium hydroxide (0.04 g) was added. The mixture was heated to 60° C. for 1 hour, cooled and was poured into water (20 mL) and extracted into ethyl acetate (2×20 ml). The combined extracts were dried (MgSO4), filtered and concentrated to afford an oil that was purified by chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures followed by ethyl acetate to afford the title compound (0.067 g) as a white solid.
  • m/e 395, 397 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.69 (1H, s), 8.62 (1H, d), 8.06 (1H, t), 7.78 (1H, d), 7.68 (1H, d), 7.69-7.60 (2H, m), 7.34 (1H, dd), 7.26 (1H, dd), 5.43 (2H, s).
    • EXAMPLE 124 3-{[(2,3-Dichlorophenyl)sulphonyl]amino}pyrazine-2-carboxylic acid, methyl ester
  • Figure US20100081670A1-20100401-C00157
  • To a stirred solution of 2,3-dichlorobenzenesulphonyl chloride (0.246 g) and methyl-3-s aminopyrazine-2-carboxylate (0.153 g) in 1,2-dimethoxymethane (3 mL) was added portionwise sodium hydride (0.1 g of a 60% dispersion in oil) over 1 hour. The mixture was stirred at room temperature for 20 h, was poured into water (20 mL) and extracted into ethyl acetate (2×20 mL). The combined extracts were dried (MgSO4), filtered and concentrated to afford an oil that was purified by chromatography on silica gel eluting with dichloromethane to afford the titled compound (0.085 g) as a white solid.
  • m/e 362/364 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 10.97 (1H, s), 8.32 (1H, dd), 8.31 (1H, d), 8.25 (1H, d), 7.68 (1H, dd), 7.42 (1H, t), 4.08 (3H, s).
  • MP 177-178° C.
    • EXAMPLE 125 N-(5-Bromo-6-chloro-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide a) 3-Methoxy-5-bromo-6-chloro-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00158
  • A stirred solution of 2-amino-6-chloropyrazine (2.0 g) and N-bromosuccinimide (13.71 g) in chloroform (100 mL) was heated to reflux for 20 hours. The reaction mixture was cooled and concentrated onto silica gel (20 g) and the residue loaded onto a column of silica gel (5 cm×2 cm) and the column was eluted with dichloromethane. Concentration afforded 3,5-dibromo-6-chloro-2-aminopyrazine that was dissolved into methanol (200 mL) and sodium methoxide (32 g of a 25% solution in methanol) added. The reaction was heated to 70° C. for 1.5 h, cooled and concentrated to approx. 50 mL capacity. The reaction mixture was poured into water (200 mL) and the sub-titled adduct (2.0 g) collected as an off-white solid.
  • m/e 235, 237 (M+1+, 100%).
    • b) N-(5-Bromo-6-chloro-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00159
  • Procedure as for Example 1 (reaction performed at room temperature) using 3-methoxy-5-bromo-6-chloro-2-pyrazinamine (Example 125a) (0.5 g) and 2,3-dichlorobenzenesulphonyl chloride (2.21 g). Yield 3.2 g.
  • m/e 445, 447 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.32 (1H, dd), 7.79 (1H, br), 7.72 (1H, dd), 7.45 (1H, t), 4.05 (3H, s).
  • MP 177-178° C.
    • EXAMPLE 126 3-Chloro-5-{[(2,3-dichlorophenyl)sulphonyl]amino}-6-methoxypyrazine-2-carboxylic acid, methyl ester
  • Figure US20100081670A1-20100401-C00160
  • Prepared by the method of Example 113 using N-(5-bromo-6-chloro-3-methoxypyrazin-2-yl)-2,3-dichlorobenzenesulfonamide (Example 125) (1.0 g). Yield 0.92 g.
  • m/e 426, 428 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.36 (1H, dd), 8.05 (1H, br), 7.73 (1H, dd), 7.47 (1H, t), 4.09 (3H, s), 3.92 (3H, s).
  • MP 200-201° C.
    • EXAMPLE 127 2,3-Dichloro-N-[6-chloro-5-(hydroxymethyl)-3-methoxypyrazin-2-yl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00161
  • Prepared as for Example 120 using 3-chloro-5-{[(2,3-dichlorophenyl)sulphonyl]amino}-6-methoxypyrazine-2-carboxylic acid, methyl ester (Example 126) (0.105 g). Yield 0.072 g.
  • m/e 397, 399 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.34 (1H, dd), 7.84 (1H, br), 7.74 (1H, dd), 7.45 (1H, t), 4.63 (2H, d), 4.07 (3H, s), 2.83 (1H, t).
  • MP 145-147° C.
    • EXAMPLE 128 2,3-Dichloro-N-{3-[(6-methoxy-3-pyridinyl)methoxy]-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00162
  • Prepared by the method of Example 28b using 2,3-dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (Example 28a) (0.338 g) and (6-methoxy-3-pyridinyl)methanol (0.21 g). Yield 0.23 g.
  • m/e 439, 440 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.28-8.26 (2H, m), 7.70-7.65 (3H, m), 7.60 (1H, br), 7.39 (1H, t), 6.80 (2H, d), 5.36 (2H, s), 3.97 (3H, s).
  • MP 187-188° C.
    • EXAMPLE 129 2,3-Dichloro-N-[6-chloro-3-methoxy-5-(methoxymethyl)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00163
  • To a stirred solution of 2,3-dichloro-N-[6-chloro-5-(hydroxymethyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide (Example 127) (0.1 g) in tetrahydrofuran (3 mL) was added manganese dioxide (0.131 g) and the resulting suspension was stirred for 20 h, filtered and concentrated. The residue was taken up into methanol (3 mL) and acetic acid (0.1 mL). To this solution was added ethylamine hydrochloride (0.081 g) and sodium cyanoborohydride (0.051 g). The resulting mixture was stirred for 20 h and concentrated onto silical gel (1 g) and eluting with methanol/dichloromethane mixtures to afford the titled compound (0.029 g) as a white solid.
  • m/e 412, 414 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.35 (1H, dd), 7.72 (1H, d), 7.45 (1H, t), 4.45 (2H, s), 4.05 (3H, s), 3.43 (3H, s).
  • MP 193-196° C.
    • EXAMPLE 130 2-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-3-fluorobenzenesulphonamide a) N-(5-Chloro-3-methoxy-2-pyrazinyl)-3-fluorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00164
  • By the method outlined in Example 1 (reaction performed at room temperature) using 5-chloro-3-methoxy-2-pyrazinamine (0.798 g) and 3-fluorobenzenesulphonyl chloride (1.17 g). Yield 0.64 g.
  • m/e 316 (M−1+, 100%).
    • b) 2-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-3-fluorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00165
  • A solution of N-(5-chloro-3-methoxy-2-pyrazinyl)-3-fluorobenzenesulphonamide (Example 130a) (0.159 g) in dry tetrahydrofuran (3 mL) was added to a stirred solution of lithium di-iso-propylamide (prepared from di-iso-propylamine (0.151 g) and n-butyl lithium (2.5M in hexanes)) in tetrahydrofuran (7.0 mL) at −78° C. The resulting solution was stirred at −78° C. for 15 minutes and then hexachloroethane (0.472 g) in tetrahydrofuran (2 mL) was added and the mixture allowed to attain room temperature over a 5 hour period. The reaction was quenched by the addition of 1N hydrochloric acid (10 mL) and extracted into ethyl acetate (2×20 mL). The combined extracts were dried (MgSO4), filtered and concentrated to afford an oil that was purified by chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the titled compound (0.086 g) as a white solid.
  • m/e 350, 352 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.16 (1H, dd), 7.81 (1H, br), 7.62 (1H, s), 7.48-7.37 (2H, m), 4.06 (3H, s).
  • MP 159-159.5° C.
    • EXAMPLE 131 2-Chloro-3-fluoro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide a) 3-Fluoro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00166
  • By the method outlined in Example 1 (reaction performed at room temperature) using 3-chloro-2-pyrazinamine (1.29 g), 3-fluorobenzenesulphonyl chloride (2.13 g). The crude adduct was reacted with a solution of sodium methoxide (10 mL of a 25% solution in methanol) in methanol (20 mL) to afford the sub-titled compound (2.36 g) as a solid.
  • m/e 284 (M+1+, 100%).
  • MP 142-143° C.
    • b) 2-Chloro-3-fluoro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00167
  • Prepared as for Example 130, 3-fluoro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide (Example 131a) (0.283 g), lithium di-iso-propylamide (prepared from di-iso-propylamine (0.30 g) and n-butyl lithium (0.96 mL of a 2.5M solution in hexanes)) and hexachloroethane (0.994 g) in anhydrous tetrahydrofuran (20 mL) afforded the titled compound (0.092 g) as a white solid after re-crystallisation from tent-butyl methylether.
  • m/e 318, 320 (M−1+, 100%).
  • 1H NMR (CD3OD) δ 8.11-8.08 (2H, m), 7.57 (1H, d), 7.57-7.50 (3H, m), 4.0 (3H, s).
  • MP 144-145° C.
    • EXAMPLE 132 2-Chloro-3-methoxy-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide a) 3-Methoxy-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00168
  • By the method outlined in Example 1 (reaction performed at room temperature) using 3-chloro-2-aminopyrazine (0.83 g), 3-methoxybenzenesulfonyl chloride (1.44 g). The crude adduct was reacted with a solution of sodium methoxide (10 mL of a 25% solution in methanol) in methanol (20 mL) to afford the sub-titled compound (1.41 g) as a solid.
  • m/e 296 (M+1+, 100%).
  • MP 133-134° C.
    • b) 2-Chloro-3-methoxy-N-(3-methoxypyrazin-2-yl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00169
  • Prepared as for Example 130, 3-methoxy-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide (Example 132a) (0.295 g), lithium di-iso-propylamide (prepared from di-iso-propylamine (0.30 g) and n-butyl lithium (0.96 mL of a 2.5M solution in hexanes)) and hexachloroethane (0.994 g) in anhydrous tetrahydrofuran (20 mL) afforded the titled compound (0.152 g) as a white solid after re-crystallisation from tent-butyl methylether.
  • m/e 328, 329 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 7.97 (1H, d), 7.92 (1H, br), 7.65 (1H, d), 7.60 (1H, d), 7.41 (1H, t), 7.15 (1H, t), 3.99 (3H, s), 3.91 (3H, s).
  • MP 151-152° C.
    • EXAMPLE 133 N-[5-Bromo-3-[(2S)-2-pyrrolidinylmethoxy]-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00170
  • Sodium hydride (0.026 g of a 60% dispersion in oil) was added to a mixture of 2,3-dichloro-N-(3,5-dibromo-2-pyrazinyl)benzenesulphonamide (Example 31a) (0.1 g) and 2-hydroxymethylpyrrolidine-1-carboxylic acid tent-butyl ester (0.088 g) in 1,2-dimethoxyethane (2 mL). After 0.5 h, the reaction mixture was partitioned between 2N hydrochloric acid and ethyl acetate. The organic solution was dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound protected with the BOC (tert-butoxycarbonyl) group (0.11 g) as an oil. This product was dissolved in dichloromethane (6 mL) and trifluoroacetic acid (2 mL). After 2 h, toluene was added and the solution evaporated to dryness. Crystallisation from diethyl ether gave the product as a white solid (0.083 g).
  • m/e 482 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.99 (1H, br), 8.65 (1H, br s), 8.13 (1H, d), 7.95 (1H, d), 7.84 (1H, s), 7.59 (1H, t), 4.57 (1H, dd), 4.39 (1H, t), 4.0 (1H, br s), 3.3 (2H, d), 2.20-2.05 (1H, m), 2.05-1.90 (2H, m), 1.85-1.75 (1H, m).
  • MP 199-200° C.
    • EXAMPLE 134 5-(2,3-Dichlorobenzenesulphonylamino)-6-(3-pyridinylmethoxy)pyrazine-2-carboxylic acid, methyl ester
  • Figure US20100081670A1-20100401-C00171
  • Prepared as for Example 113 using N-[5-bromo-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide (Example 34) (0.2 g) and bis(triphenylphosphine)palladium(II) dichloride (0.1 g). Yield 0.14 g.
  • m/e 469 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.83 (1H, s), 8.61 (1H, d), 8.15-8.05 (3H, m), 7.90 (1H, d), 7.60-7.50 (2H, m), 5.48 (2H, s), 3.82 (3H, s).
  • MP 209-210° C.
    • EXAMPLE 135 5-{[(2,3-Dichlorophenyl)sulphonyl]amino}-6-(3-pyridinylmethoxy)-2-pyrazinecarboxamide
  • Figure US20100081670A1-20100401-C00172
  • 5-(2,3-Dichlorobenzenesulphonylamino)-6-(3-pyridinylmethoxy)pyrazine-2-carboxylic acid, methyl ester (Example 134) (0.05 g) was heated at 60° C. in 7M ammonia in methanol for 4 days. The solution was evaporated to dryness and the product crystallised from methyl acetate. Yield 0.027 g.
  • m/e 453 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.72 (1H, s), 8.52 (1H, d), 7.99 (1H, d), 7.90 (1H, d), 7.83 (1H, s), 7.66 (1H, d), 7.56 (1H, s), 7.45-7.35 (2H, m), 5.49 (2H, s).
  • MP 174-178° C.
    • EXAMPLE 136 2,3-Dichloro-N-[5-(4-pyridinyl)-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide a) [5-Bromo-3-(3-pyridinylmethoxy)-2-pyrazinyl][(2,3-dichlorophenyl)sulphonyl]carbamic acid, 2-methylpropyl ester
  • Figure US20100081670A1-20100401-C00173
  • Sodium hydride (0.045 g of a 60% dispersion in oil) was added to N-[5-bromo-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide (Example 34) (0.5 g) in 1,2-dimethoxyethane (3 mL). Iso-butylchloroformate (0.15 mL) was added. After 2 h, the mixture was partitioned between water and ethyl acetate. The organic layer was dried (Na2SO4) and evaporated to yield the product (0.65 g). Used directly.
    • b) 2,3-Dichloro-N-[5-(4-pyridinyl)-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00174
  • [5-Bromo-3-(3-pyridinylmethoxy)-2-pyrazinyl][(2,3-dichlorophenyl)sulphonyl]carbamic acid, 2-methylpropyl ester (Example 136a) (0.11 g), 4-tributylstannanylpyridine (0.067 g) and tetrakis(triphenylphosphine)palladium(0) (0.05 g) in toluene (3 mL) was heated at 95° C. for 16 h. Chromatography on silica gel eluting with ethyl acetate/ethanol mixtures gave the title compound protected with the 2-methylpropylcarbonyl group (0.09 g). The compound was heated at 60° C. in methanol (2 mL) and 1M sodium hydroxide (0.36 mL) for 1 h. The solution was evaporated. Purification was by reverse phase preparative high pressure liquid chromatography. Yield 0.015 g.
  • m/e 488 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 9.05 (1H, s), 8.85 (2H, d), 8.78 (1H, d), 8.62 (1H, s), 8.44-8.39 (3H, m), 8.17 (1H, dd), 7.96 (1H, dd), 7.87-7.80 (1H, m), 7.64-7.57 (1H, m), 5.74 (2H, s).
  • MP 210° C. (dec.)
    • EXAMPLE 137 2,3-Dichloro-N-[5-(hydroxymethyl)-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00175
  • Lithium aluminium hydride (0.85 mL of a 1M solution in tetrahydrofuran) was added dropwise to 5-(2,3-dichlorobenzenesulphonylamino)-6-(3-pyridinylmethoxy)pyrazine-2-carboxylic acid, methyl ester (Example 134) (0.2 g) in tetrahydrofuran (10 mL) cooled to −65° C. The reaction mixture was allowed to warm to room temperature and stirred for 1 h. Aqueous acetic acid was added and the mixture extracted with ethyl acetate. The organic solution was dried (MgSO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/methanol mixtures gave the title compound (0.08 g).
  • m/e 441 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.73 (1H, s), 8.55 (1H, d), 8.06 (1H, dd), 7.95-7.85 (2H, m), 7.65 (1H, s), 7.56 (1H, t), 7.64-7.57 (1H, m), 5.41 (2H, s), 5.36 (1H, t), 4.41 (2H, d).
    • EXAMPLE 138 2,3-Dichloro-N-[5-(hydroxymethyl)-3-methoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00176
  • Prepared as for Example 120 using 5-(2,3-dichlorobenzenesuphonylamino)-6-methoxypyrazine-2-carboxylic acid, methyl ester (Example 113) (0.84 g). Yield 0.5 g.
  • m/e 364 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.21 (1H, dd), 7.79 (1H, dd), 7.59 (1H, s), 7.51 (1H, t), 4.50 (2H, s), 4.01 (3H, s).
  • MP 160-161° C.
    • EXAMPLE 139 N-(5-Allyloxy-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00177
  • Procedure as for Example 115 using N-(5-chloro-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-({2-[(trimethylsilyl)oxy]ethoxy}methyl)benzenesulphonamide (Example 115a) (0.25 g), allyl alcohol (0.06 g) and sodium hydride (0.035 g of a 60% dispersion in oil) in N,N-dimethylformamide (5 mL) stirred at room temperature for 5 days. Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures to give the title compound with SEM attached. Yield 0.18 g. This compound was dissolved in dichloromethane (4 mL) and trifluoroacetic acid (1 mL). After 2 h, toluene was added and the mixture evaporated to dryness. Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures to give the title compound. Crystallised for diethyl ether/iso-hexane mixtures. Yield 0.026 g.
  • m/e 390 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.81 (1H, s), 8.0-7.9 (2H, m), 7.53 (1H, t), 7.49 (1H, s), 6.07-7.02 (1H, m), 5.38 (1H, dd), 5.26 (1H, dd), 4.80 (2H, d), 3.82 (3H, s).
  • MP 120-121° C.
    • EXAMPLE 140 2,3-Dichloro-N-{3-methoxy-5-[(pyrazinyloxy)methyl]-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00178
  • Sodium hydride (0.022 g of a 60% dispersion in oil) was added to 2,3-dichloro-N-[5-(hydroxymethyl)-3-methoxy)-2-pyrazinyl]benzenesulphonamide (Example 138) (0.05 g) in N-methylpyrrolidinone (2 mL). After 0.5 h, chloropyrazine (0.013 mL) was added and the mixture heated at 60° C. for 3 h. Aqueous acetic acid was added and the mixture extracted with ethyl acetate. The organic solution was dried (Na2SO4) and evaporated. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound (0.012 g).
  • m/e 442 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.36 (1H, s), 8.23 (2H, d), 8.06 (1H, d), 7.87 (1H, d), 7.68 (1H, s), 7.54 (1H, t), 5.26 (2H, s), 3.86 (3H, s).
  • MP 155° C. (dec).
    • EXAMPLE 141 2,3-Dichloro-N-[5-(3-hydroxy-1-propynyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00179
  • A mixture of N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.52 g), propargyl alcohol (0.223 mL), copper(I)iodide (0.05 g) and bis(triphenylphosphine)palladium(II) chloride (0.1 g) in triethylamine (3 mL) was stirred at room temperature and under nitrogen for 16 h. The solvent was evaporated. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound containing the SEM ([2-(trimethylsilyl)ethoxy]methyl) protecting group (0.38 g). 0.074 g of this compound was dissolved in dichloromethane (2 mL) and trifluoroacetic acid (2 mL). After 1 h the solvent was evaporated. Chromatography on silica gel eluting with ethyl acetate/iso-hexane mixtures gave the title compound (0.043 g).
  • m/e 386 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.07 (1H, d), 7.93 (1H, d), 7.72 (1H, s), 7.58 (1H, t), 4.29 (2H, s), 3.90 (3H, s).
    • EXAMPLE 142 N-{3-[(5-Bromo-3-pyridinyl)methoxy]-5-chloro-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00180
  • Prepared by the method of Example 31 using (5-bromo-3-pyridinyl)methanol (0.2 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.25 g). Yield 0.17 g.
  • m/e 523 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.77 (1H, d), 8.71 (1H, d), 8.28 (1H, s), 8.07 (1H, dd), 7.92 (1H, d), 7.85 (1H, s), 7.55 (1H, t), 5.43 (2H, s).
  • MP 199-201° C.
    • EXAMPLE 143 2,3-Dichloro-N-[5-chloro-3-{[6-(hydroxymethyl)-2-pyridinyl]methoxy}-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00181
  • Prepared by the method of Example 31 using 2,6-bis(hydroxymethyl)pyridine (0.11 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.11 g) in N-methylpyrrolidinone (2 mL). Yield 0.043 g.
  • m/e 475 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 7.97 (1H, d), 7.83 (1H, t), 7.68 (1H, d), 7.43-7.35 (4H, m), 5.44 (1H, s), 5.32 (2H, s), 4.58 (2H, s).
  • MP 220° C.
    • EXAMPLE 144 2,3-Dichloro-N-{5-chloro-3-[(2-methyl-4-oxazolyl)methoxy]-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00182
  • Prepared by the method of Example 31b using (2-methyl-4-oxazolyl)methanol (0.08 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.26 g). Yield 0.083 g.
  • m/e 449 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.09 (1H, s), 8.03 (1H, dd), 7.94 (1H, dd), 7.85 (1H, s), 7.55 (1H, t), 5.23 (2H, s), 2.45 (3H, s).
  • MP 172-173° C.
    • EXAMPLE 145 2,3-Dichloro-N-{3-[(2-methyl-4-oxazolyl)methoxy]-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00183
  • Prepared by the method of Example 28 using (2-methyl-4-oxazolyl)methanol (0.3 g) and 2,3-dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (0.89 g). Yield 0.035 g.
  • m/e 412 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.06 (2H, dd), 7.92 (1H, dd), 7.85 (1H, br s), 7.70 (1H, br s), 7.56 (1H, t), 5.23 (2H, s), 2.41 (3H, s).
  • MP 207-209° C.
  • Examples 146-165 were prepared using the following procedure:
  • To a solution of N-(3,5-dibromo-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (Example 31) (0.003 g) and primary alcohol (0.026 mL of a 0.5M solution in N-methylpyrrolidinone) in N-methylpyrrolidinone (0.1 mL) was added potassium tert-butoxide (0.050 mL of a 1M solution in tetrahydrofuran). The solution was allowed to stand for 24 hours. The reaction mixture was diluted with acetic acid (0.010 mL) and water (0.10 mL) and the solvents were evaporated. The residue was redissolved in dimethylsulphoxide (0.5 mL) and purified by mass directed high pressure liquid chromatography. The solvent was evaporated to afford a solid.
    • EXAMPLE 146 N-[5-Bromo-3-(phenylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00184
  • m/e 489 (M+1+, 100%).
    • EXAMPLE 147 N-[5-Bromo-3-(2-cyclopropylethoxy)pyrazinyl]-2,3-dichlorobenzenesulphanamide
  • Figure US20100081670A1-20100401-C00185
  • m/e 467 (M+1+, 100%).
    • EXAMPLE 148 N-[5-Bromo-3-(3-thienylmethoxy)pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00186
  • m/e 495 (M+1+, 100%).
    • EXAMPLE 149 N-{5-Bromo-3-[(2-methyl-3-furanyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00187
  • m/e 493 (M+1+, 100%).
    • EXAMPLE 150 N-{5-Bromo-3-[(3-furanyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00188
  • m/e 479 (M+1+, 100%).
    • EXAMPLE 151 N-{5-Bromo-3-[(4-fluorophenyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00189
  • m/e 507 (M+1+, 100%).
    • EXAMPLE 152 N-{5-Bromo-3-[(3-fluorophenyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00190
  • m/e 507 (M+1+, 100%).
    • EXAMPLE 153 N-{5-Bromo-3-[3-(2-pyridinyl)propoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00191
  • m/e 518 (M+1+, 100%).
    • EXAMPLE 154 N-[5-Bromo-3-(pentyloxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00192
  • m/e 469 (M+1+, 100%).
    • EXAMPLE 155 N-[5-Bromo-3-(propyloxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00193
  • m/e 441 (M+1+, 100%).
    • EXAMPLE 156 N-[5-Bromo-3-(2-methoxyethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00194
  • m/e 457 (M+1+, 100%).
    • EXAMPLE 157 N-[5-Bromo-3-(2-ethoxyethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00195
  • m/e 471 (M+1+, 100%).
    • EXAMPLE 158 N-[5-Bromo-3-(2-fluoroethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00196
  • m/e 445 (M+1+, 100%).
    • EXAMPLE 159 N-{5-Bromo-3-[2-(1H-imidazol-1-yl)ethoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00197
  • m/e 493 (M+1+, 100%).
    • EXAMPLE 160 N-{5-Bromo-3-[3-(3-pyridinyl)propoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00198
  • m/e 516 (M−1+, 100%).
    • EXAMPLE 161 N-[5-Bromo-3-[2-(methylamino)ethoxy]-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00199
  • m/e 456 (M+1+, 100%).
    • EXAMPLE 162 N-{5-Bromo-3-[3-(4-hydroxyphenyl)propoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00200
  • m/e 533 (M+1+, 100%).
    • EXAMPLE 163 N-[5-Bromo-3-(2-phenoxyethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00201
  • m/e 517 (M−1+, 100%).
    • EXAMPLE 164 N-[5-Bromo-3-(cyclopropylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00202
  • m/e 453 (M+1+, 100%).
    • EXAMPLE 165 N-[5-Bromo-3-(3-phenoxypropoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00203
  • m/e 531 (M−1+, 100%).
    • EXAMPLE 166 2,3-Dichloro-N-(5-ethoxy-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00204
  • Prepared as for Example 56 using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.3 g) and sodium ethoxide (5 mL of a 0.5M solution in ethanol). Yield 0.1 g.
  • m/e 378 (M+1,100%).
  • 1H NMR (CDCl3) δ 8.22 (1H, d), 7.65 (1H, d), 7.49 (1H, s), 7.34 (1H, t), 7.30 (1H, s), 4.24 (2H, q), 3.95 (3H, s), 1.36 (3H, t).
  • MP 96-97° C.
    • EXAMPLE 167 2,3-Dichloro-N-[3-methoxy-5-([1,2,4]-1-triazolyl)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00205
  • Prepared as for Example 101b (reaction heated at 50° C.) using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.25 g) and [1,2,4]triazole (0.1 g). The intermediate product containing the SEM (2-[trimethylsilyl]ethoxymethyl) group was purified by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures. Deprotection as for Example 101b gave the title compound. Yield 0.035 g.
  • m/e 401 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.92 (1H, s), 8.34 (1H, d), 8.24 (1H, s), 8.08 (1H, s), 8.01 (1H, br s), 7.72 (1H, d), 7.43 (1H, t), 4.14 (3H, t).
  • MP 248-249° C.
    • EXAMPLE 168 2-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]-N-methylacetamide
  • Figure US20100081670A1-20100401-C00206
  • Prepared as for Example 101b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.4 g) and 2-mercapto-N-methylacetamide (0.1 g). The intermediate product containing the SEM (2-[trimethylsilyl]ethoxymethyl) group was purified by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures. Deprotection as for Example 101b gave the title compound. Yield 0.05 g.
  • m/e 437 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.25 (1H, dd), 7.76 (1H, s), 7.68 (1H, dd), 7.58 (1H, s), 7.40 (1H, t), 6.62 (1H, br s), 3.99 (3H, s), 3.69 (2H, s), 2.86 (3H, d).
  • MP 150-152° C.
    • EXAMPLE 169 2-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetamide
  • Figure US20100081670A1-20100401-C00207
  • Prepared as for Example 101b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.2 g) and 2-mercaptoacetamide (0.05 g). The intermediate product containing the SEM group was purified by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures. Deprotection as for Example 101b gave the title compound. Yield 0.03 g.
  • m/e 423 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 7.98 (1H, dd), 7.75 (1H, d), 7.46-7.42 (3H, m), 7.06 (1H, s), 3.83 (3H, s), 2.59 (2H, s).
  • MP 163-164° C.
    • EXAMPLE 170 2,3-Dichloro-N-[5-(4-fluorobenzylsulphanyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00208
  • Prepared as for Example 101b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-{[2-(trimethylsilanyl)ethoxy]methyl}benzenesulphonamide (Example 55a) (0.4 g) and (4-fluorophenyl)methanethiol (0.13 g). The intermediate product containing the SEM group was purified by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures. Deprotection as for Example 101b gave the title compound. Yield 0.2 g
  • m/e 474 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.25 (1H, dd), 7.73 (1H, s), 7.67 (1H, dd), 7.51 (1H, s), 7.38 (1H, t), 7.27 (2H, m), 6.92 (2H, m), 4.24 (2H, s), 4.01 (3H, s).
  • MP 119-120° C.
    • EXAMPLE 171 2,3-Dichloro-N-[5-cyanomethylsulphanyl-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00209
  • See example 172 for preparation.
  • m/e 403 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.28 (1H, dd), 7.84 (1H, s), 7.69 (1H, dd), 7.63 (1H, s), 7.38 (1H, t), 4.11 (3H, s), 3.78 (2H, s).
  • MP 158-159° C.
    • EXAMPLE 172 2,3-Dichloro-N-[3-methoxy-5-([1,2,4]-3-oxadiazolylmethylsulphanyl)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00210
  • Prepared as for Example 101b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.4 g), [1,2,4]-3-oxadiazolylmethanethiol (0.15 g) and cesium carbonate (0.5 g) at room temperature for 16 h. The intermediate products containing the SEM (2-[trimethylsilyl]ethoxymethyl) group was purified by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures. Deprotection as for Example 101b gave the title compound (0.09 g) and 2,3-dichloro-N-[5-cyanomethylsulphanyl-3-methoxy-2-pyrazinyl]benzenesulphonamide (Example 171) (0.1 g) which were separated by silica gel chromatography eluting with dichloromethane.
  • m/e 448 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.64 (1H, s), 8.26 (1H, dd), 7.76 (1H, s), 7.67 (1H, dd), 7.57 (1H, s), 7.37 (1H, t), 4.39 (2H, s), 4.04 (3H, s).
  • MP 154-156° C.
    • EXAMPLE 173 N-[5-(2-Aminoethylsulphanyl)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00211
  • Prepared as for Example 101b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.45 g) and 2-aminoethanethiol hydrochloride (0.2 g). Yield 0.03 g
  • m/e 409 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.02 (1H, dd), 7.94 (1H, dd), 7.87 (1H, s), 7.70 (1H, s), 7.58 (1H, t), 3.93 (3H, s), 3.48 (2H, br s), 3.28 (2H, t), 3.10-3.03 (2H, m).
  • MP 189-190° C.
    • EXAMPLE 174 2,3-Dichloro-N-[3-methoxy-5-(5-methyl-3-isoxazolylmethoxy))-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00212
  • Prepared as for Example 115b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.3 g) and (5-methyl-3-oxazolyl)methanol (0.13 g). The intermediate product containing the SEM (2-[trimethylsilyl]ethoxymethyl) group was purified by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures. Deprotection as for Example 115b gave the title compound. Yield 0.2 g
  • m/e 445 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.22 (1H, dd), 7.66 (1H, dd), 7.59 (1H, s), 7.38 (2H, t), 6.01 (1H, t), 5.31 (2H, s), 3.97 (3H, s), 2.43 (3H, s).
  • MP 142-143° C.
    • EXAMPLE 175 2,3-Dichloro-N-[5-(5-dimethylaminomethyl-2-furanylmethoxy)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00213
  • Prepared as for Example 115b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.3 g) and (5-dimethylaminomethyl-2-furanyl)methanol (0.2 g). After removal of the SEM (2-[trimethylsilyl]ethoxymethyl) group the title compound was purified by silica gel chromatography eluting with methanol/dichloromethane mixtures Yield 0.23 g
  • m/e 487 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.21 (1H, dd), 7.66 (1H, dd), 7.37 (2H, t), 6.39 (2H, s), 5.20 (2H, s), 4.00 (3H, s), 3.84 (2H, s), 2.51 (6H, s).
  • MP 114-115° C.
    • EXAMPLE 176 N-[5-Bromo-3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]-2,3-dichloro-benzenesulphonamide
  • Figure US20100081670A1-20100401-C00214
  • Prepared by the method of Example 31 using (5-dimethylaminomethyl-2-furanyl)methanol (0.2 g) and 2,3-dichloro-N-(3,5-dibromo-2-pyrazinyl)benzenesulphonamide (Example 31a) (0.2 g). Purified by silica gel chromatography eluting with methanol/dichloromethane mixtures and recrystallised from acetonitrile. Yield 0.058 g.
  • m/e 535 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 7.92 (1H, dd), 7.63 (1H, dd), 7.36 (2H, t), 6.71 (1H, d), 6.68 (1H, d), 5.22 (2H, s), 4.37 (2H, d), 2.75 (6H, s).
  • MP 206-207° C.
    • EXAMPLE 177 2,3-Dichloro-N-[5-(2-hydroxyethylsulphanyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00215
  • Prepared as for Example 101b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.2 g) and 2-mercaptoethanol (0.2 g). After removal of the SEM (2-[trimethylsilyl]ethoxymethyl) group the title compound was purified by silica gel chromatography eluting with methanol/dichloromethane mixtures. Yield 0.015 g
  • m/e 410 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.27 (1H, dd), 7.78 (1H, s), 7.67 (1H, dd), 7.61 (1H, s), 7.39 (1H, t), 4.04 (3H, s), 3.83 (2H, t), 3.24 (2H, t).
  • MP 180-181° C.
    • EXAMPLE 178 2,3-Dichloro-N-{5-[2-(ethylureido)ethylsulphanyl]-3-methoxy-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00216
  • Ethylisocyanate (0.016 g) was added to N-[5-(2-aminoethylsulphanyl)-3-methoxy-2-pyrazinyl]-2,3-dichloro-benzenesulphonamide (Example 173) (0.08 g) in dichloromethane (5 mL). After 1 h, the reaction mixture was evaporated to dryness. Purified by silica gel chromatography eluting with methanol/dichloromethane mixtures. Yield 0.015 g.
  • m/e 480 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.27 (1H, dd), 7.69 (1H, dd), 7.56 (1H, s), 7.39 (1H, t), 4.60 (1H, br s), 4.18 (1H, br s), 4.04 (3H, s), 3.40-3.30 (2H, m), 3.30-3.2 (2H, m), 3.25-3.20 (2H, m), 1.15 (3H, t).
    • EXAMPLE 179 2,3-Dichloro-N-[3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00217
  • Prepared by the method of Example 28 using (5-dimethylaminomethyl-2-furanyl)methanol (0.2 g) and 2,3-dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (Example 28) (0.4 g). Purified by silica gel chromatography eluting with methanol/dichloromethane mixtures. Yield 0.2 g.
  • m/e 455 (M−1+, 100%). 1H NMR (D6-DMSO) δ 7.96 (1H, dd), 7.66 (1H, dd), 7.40 (1H, t), 7.30 (1H, d), 7.24 (1H, d), 6.65 (1H, s), 6.64 (1H, d), 5.23 (2H, s), 4.25 (2H, s), 2.66 (6H, s).
    • EXAMPLE 180 2,3-Dichloro-N-[6-chloro-3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00218
  • Prepared by the method of Example 31 using (5-dimethylaminomethyl-2-furanyl)methanol (0.2 g) and N-(3-bromo-6-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (Example 98) (0.3 g). Purified by silica gel chromatography eluting with methanol/dichloromethane mixtures. Yield 0.11 g.
  • m/e 491 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.01 (1H, dd), 7.66 (1H, dd), 7.39 (1H, t), 7.11 (1H, s), 6.69 (1H, d), 6.67 (1H, d), 5.20 (2H, s), 4.39 (2H, s), 2.76 (6H, s).
  • MP 209-210° C.
    • EXAMPLE 181 2,3-Dichloro-N-[6-chloro-3-(5-methylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00219
  • Prepared by the method of Example 31 using (5-methylaminomethyl-2-furanyl)methanol (0.3 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.4 g). Purified by silica gel chromatography eluting with methanol/dichloromethane mixtures. Yield 0.03 g.
  • m/e 477 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.98 (2H, br), 7.92 (1H, d), 7.63 (1H, d), 7.35 (1H, t), 7.29 (1H, s), 6.67 (1H, d), 6.64 (1H, d), 5.20 (2H, s), 4.25 (2H, s), 2.59 (3H, s).
  • MP 211-212° C.
    • EXAMPLE 182 2,3-Dichloro-N-[5-chloro-3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00220
  • Prepared by the method of Example 31 using (5-dimethylaminomethyl-2-furanyl)methanol (0.3 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.4 g). Purified by silica gel chromatography eluting with methanol/dichloromethane mixtures. Yield 0.30 g.
  • m/e 491 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 7.93 (1H, dd), 7.65 (1H, dd), 7.36 (1H, t), 7.32 (1H, s), 6.71 (1H, d), 6.69 (1H, d), 5.23 (2H, s), 4.38 (2H, s), 2.75 (6H, s).
  • MP 209-210° C.
    • EXAMPLE 183 2,3-Dichloro-N-[3-(5-methylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00221
  • Prepared by the method of Example 28 using (5-methylaminomethyl-2-furanyl)methanol (0.2 g) and 2,3-dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (Example 28) (0.4 g). Purified by silica gel chromatography eluting with methanol/dichloromethane mixtures. Yield 0.12 g.
  • m/e 443 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.99 (2H, br s), 7.95 (1H, d), 7.62 (1H, d), 7.35 (1H, t), 7.24 (1H, d), 7.15 (1H, d), 6.88 (1H, d), 6.63 (1H, d), 5.20 (2H, s), 4.24 (2H, s), 2.58 (3H, s).
  • MP 198-199° C.
    • EXAMPLE 184 N-(5-Bromo-3-methoxypyrazinyl)-2-cyanobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00222
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.2 g) and 2-cyanobenzenesulphonyl chloride (0.24 g). Yield 0.059 g.
  • m/e 369/370 (M+1+), 307/309 (100%).
  • 1H NMR (D6-DMSO) δ 8.14 (1H, d), 8.09 (1H, d), 7.93-7.82 (3H, m), 3.93 (3H, s).
  • MP 190-191.5° C.
    • EXAMPLE 185 N-(5-Bromo-3-methoxypyrazinyl)-2,3-dichloro-4-fluorobenzenesulphonamide a) 2,3-Dichloro-4-fluorobenzenesulphonyl chloride
  • Figure US20100081670A1-20100401-C00223
  • Chlorosulphonic acid (12.1 mL) was added dropwise to a solution of 2,3-dichloro-4-fluorobenzene (5.0 g) in dichloromethane (12 mL) at −40° C. The solution was allowed to slowly warm to room temperature and was stirred for 3 days. The solution was poured onto crushed ice/water, extracted into dichloromethane and concentrated under reduced pressure. Purified by silica gel chromatography eluting with dichloromethane/iso-hexane mixtures. Yield 4.2 g
  • m/e 262/264 (M+), 163 (100%).
    • b) N-(5-Bromo-3-methoxypyrazinyl)-2,3-dichloro-4-fluorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00224
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 5-bromo-3-methoxy-2-pyrazinamine (0.2 g) and 2,3-dichloro-4-fluorobenzenesulphonyl chloride (Example 185a) (0.31 g). Yield 0.042 g.
  • m/e 430 (M−1−, 100%).
  • 1H NMR (D6-DMSO) δ 8.16-8.12 (1H, m), 7.81 (1H, s), 7.68-7.64 (1H, m), 3.92 (3H, s).
  • MP 208-211° C.
    • EXAMPLE 186 2,3-Dichloro-N-[3-methoxy-5-(4-morpholinylmethyl)-2-pyrazinyl]benzenesulphonamide a) 2,3-Dichloro-N-(5-formyl-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00225
  • Prepared as for Example 107a using 2,3-dichloro-N-[5-(hydroxymethyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide (Example 138) (0.6 g). Yield 0.53 g. Used directly.
    • b) 2,3-Dichloro-N-[3-methoxy-5-(4-morpholinylmethyl)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00226
  • Prepared as for Example 107b using 2,3-dichloro-N-(5-formyl-3-methoxy-2-pyrazinyl)benzenesulphonamide (Example 186a) (0.26 g) and morpholine (3.7 mL). Yield 0.057 g.
  • m/e 433 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.12 (1H, d), 7.94 (1H, d), 7.59 (1H, t), 4.20 (2H, s), 3.96 (3H, s), 3.85-3.65 (5H, m).
    • EXAMPLE 187 N-(3-Allyloxy-5-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00227
  • Prepared by the method of Example 31 using allyl alcohol (10 mL) as solvent and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.35 g). Yield 0.32 g.
  • m/e 393 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.80 (1H, br s), 8.08 (1H, dd), 7.96 (1H, dd), 7.82 (1H, dd), 7.58 (1H, t), 6.10-6.00 (1H, m), 5.49 (1H, dddd), 5.29 (1H, dddd), 4.86 (2H, dddd).
  • MP 145-146° C.
    • EXAMPLE 188 2,3-Dichloro-N-[5-chloro-3-(2-propynyloxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00228
  • Prepared by the method of Example 31 using propargyl alcohol (0.3 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.35 g). Yield 0.2 g.
  • m/e 390 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.08 (1H, dd), 7.95 (1H, dd), 7.86 (1H, s), 7.58 (1H, t), 5.02 (2H, d), 3.65 (1H, t).
  • MP 138-139° C.
    • EXAMPLE 189 2,3-Dichloro-N-[3-(2-propynyloxy)-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00229
  • Prepared by the method of Example 28 using propargyl alcohol as solvent (3 mL), 2,3-dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (Example 28) (0.3 g) and sodium hydride (0.2 g of a 60% dispersion in oil) at room temperature for 16 h. Yield 0.27 g.
  • m/e 356 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.67 (1H, br s), 8.10 (1H, dd), 7.94 (1H, dd), 7.85 (1H, br), 7.72 (1H, br), 7.59 (1H, t), 5.01 (2H, d), 3.56 (1H, t).
  • MP 153-154° C.
    • EXAMPLE 190 2,3-Dichloro-N-(5-cyano-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00230
  • Prepared as for Example 78 using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide (Example 8) (0.1 g). Yield 0.034 g.
  • m/e 357 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.15 (1H, s), 8.14 (1H, dd), 7.95 (1H, dd), 7.59 (1H, t), 3.96 (3H, s).
  • MP 239-240° C.
    • EXAMPLE 191 2,3-Dichloro-N-{3-methoxy-5-[(2S)-pyrrolidin-2-ylmethoxy]-2-pyrazinyl}benzenesulfonamide hydrochloride
  • Figure US20100081670A1-20100401-C00231
  • Procedure as for Example 115 using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-({2-[(trimethylsilyl)oxy]ethoxy}methyl)benzenesulphonamide (Example 55a) (0.5 g), tert-butyl (2S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (0.603 g) and sodium hydride (0.12 g of a 60% dispersion in oil) in N-methylpyrrolidinone (20 mL). The adduct was deprotected with HCl (4M in dioxane) to afford the titled adduct (0.241 g) as a white solid.
  • m/e 433, 435 (M−HCl++, 100%).
  • 1H NMR (D6-DMSO) δ 10.92 (1H, s), 9.45 (1H, br), 8.93 (1H, br), 7.98 (1H, d), 7.93 (1H, d), 7.57 (1H, d), 7.52 (1H, d), 4.53 (1H, dd), 4.37 (1H, dd), 3.94-3.86 (1H, m), 3.85 (3H, s), 3.22-3.18 (2H, m), 2.13-2.08 (1H, m), 1.99-1.86 (2H, m), 1.76-1.67 (1H, m).
    • EXAMPLE 192 2,3-Dichloro-N-{6-chloro-3-methoxy-5-[(2R)-2-pyrrolidinylmethoxy]-2-pyrazinyl}benzenesulphonamide Hydrochloride
  • Figure US20100081670A1-20100401-C00232
  • Procedure as for Example 115 using 2,3-dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (Example 66a) (0.29 g), tert-butyl (2S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (0.15 g) and sodium hydride (0.04 g of a 60% dispersion in oil) in N-methylpyrrolidinone (20 mL). The adduct was deprotected with HCl (4M in dioxane) to afford the titled adduct (0.2 g) as a white solid.
  • m/e 464 (M+H+, 100%).
  • 1H NMR (D6-DMSO) δ 11.24 (1H, br s), 9.46 (1H, br s), 8.99 (1H, br s), 8.01 (1H, d), 7.96 (1H, d), 7.59 (1H, m), 4.61 (1H, dd), 4.46 (1H, dd), 3.95 (1H, br s), 3.85 (3H, s), 3.19 (2H, br s), 2.16-2.07 (1H, br s), 2.03-1.94 (1H, br s), 1.92-1.85 (1H, br s), 1.81-1.72 (1H, br s).
  • MP 200-204° C.
    • EXAMPLE 193 2,3-Dichloro-N-[3-methoxy-5-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide Hydrochloride
  • Figure US20100081670A1-20100401-C00233
  • Procedure as for Example 115 using N-(5-chloro-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-({2-[(trimethylsilyl)oxy]ethoxy}methyl)benzenesulphonamide (Example 115a) (0.5 g), pyridine-3-methanol (0.11 g) and sodium hydride (0.05 g of a 60% dispersion in oil) in N-methylpyrrolidinone (5 mL). Yield 0.23 g.
  • m/e 438 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.9 (1H, br s), 8.7 (1H, br s), 8.12 (1H, t), 7.99-7.92 (2H, m), 7.74 (1H, d), 7.61 (1H, s), 7.63-7.53 (2H, m), 5.54 (2H, s), 3.73 (3H, s).
  • MP 180-183° C.
    • EXAMPLE 194 2,3-Dichloro-N-(3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide a) 3-Methoxy-6-methyl-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00234
  • To a solution of 5-bromo-3-methoxy-6-methyl-2-pyrazinamine (Example 118c) (0.8 g) and ammonium formate (0.4 g) in methanol (20 mL) was added palladium on carbon (0.2 g) and the reaction mixture heated at reflux for 5 h. After cooling to room temperature, the reaction mixture was filtered through a plug of celite, and the filtrate evaporated. The residue was partitioned between dichloromethane and water, and the organic phase dried (MgSO4), filtered and evaporated to give the title compound as a white solid (0.44 g).
  • 1H NMR (D6-DMSO) δ 7.10 (1H, s), 6.15 (2H, br s), 3.83 (3H, s), 2.14 (3H, s).
    • b) 2,3-Dichloro-N-(3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00235
  • A solution of 3-methoxy-6-methyl-2-pyrazinamine (Example 194a) (0.050 g) and 2,3-dichlorobenzenesulphonyl chloride (0.098 g) in pyridine (0.3 mL) was stirred at room temperature for 18 h. Solvent was evaporated to give a residue which was purified by chromatography on silica gel eluting with dichloromethane/ethyl acetate/acetic acid (200:4:1) giving the title compound as a pale orange solid (0.071 g).
  • m/e 348/350 (M+H+, 100%).
  • 1H NMR (D6-DMSO) δ 11.44 (1H, br s), 8.14 (1H, dd), 7.92 (1H, dd), 7.65 (1H, br s), 7.61 (1H, t), 3.85 (3H, s), 2.07 (3H, br s).
  • MP 50-60° C.
    • EXAMPLE 195 2,3-Dichloro-N-[3-methoxy-5-(1H-1,2,4-triazol-1-ylmethyl)-2-pyrazinyl]benzenesulphonamide a) 2,3-Dichloro-N-[5-(hydroxymethyl)-3-methoxy-2-pyrazinyl]-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00236
  • To a suspension of 2,3-dichloro-N-[5-(hydroxymethyl)-3-methoxy-2-pyrazinyl]-benzenesulphonamide (1.0 g) in dichloromethane (100 mL) was added diisopropylethylamine (0.57 mL) and 2-(trimethylsilyl)ethoxymethyl chloride (0.58 mL). The reaction mixture was stirred at room temperature for 0.5 h, then washed with water. The organic phase was dried (MgSO4), filtered and evaporated to give a yellow oil. This was purified by chromatography on silica gel eluting with dichloromethane/ethyl acetate mixtures to give the title compound as a colourless oil (0.8 g).
  • 1H NMR (CDCl3) δ 8.04 (1H, s), 7.99 (1H, d), 7.66 (1H, d), 7.28 (1H, t), 5.27 (2H, s), 4.74 (2H, d), 3.90 (3H, s), 3.78 (2H, m), 2.58 (1H, t), 0.85 (2H, m), 0.00 (9H, s).
    • b) 2,3-Dichloro-N-[3-methoxy-5-(1H-1,2,4-triazol-1-ylmethyl)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00237
  • To a solution of 2,3-dichloro-N-[5-(hydroxymethyl)-3-methoxy-2-pyrazinyl]-N-{[2-(trimethylsilyl)ethoxy]methyl}benzenesulphonamide (Example 195a) (0.1 g) and triethylamine (0.056 mL) in dichloromethane (5 mL) at 0° C. was added methanesulphonyl chloride (0.019 mL) and the reaction mixture stirred at 0° C. for 1 h and room temperature for 1 h. The solution was filtered through a plug of silica washing with ethyl acetate and concentrated in vacuo to give a colourless oil (0.082 g). This was dissolved in N,N-dimethylformamide (0.5 mL) and 1,2,4-triazole (0.013 g) and sodium carbonate (0.026 g) added. The reaction mixture was heated at 60° C. for 18 h, then partitioned between ethyl acetate and saturated aqueous ammonium chloride (5×). The organic phase was dried (MgSO4), filtered and evaporated. The residue was dissolved in trifluoroacetic acid (2 mL) and dichloromethane (2 mL). After 20 min, removal of solvent in vacuo gave a residue which was purified by chromatography on silica gel eluting with ethyl acetate/acetic acid mixtures to give the title compound a pale yellow solid (0.011 g).
  • m/e 413/415 (M−H−, 100%).
  • 1H NMR (CDCl3) δ 8.27 (2H, m), 8.0 (1H, br s), 7.94 (1H, s), 7.68 (1H, d), 7.58 (1H, br s), 7.41 (1H, t), 5.25 (2H, s), 3.97 (3H, s).
  • MP 95-105° C.
    • EXAMPLE 196 N-(3-(5-Aminomethyl-2-furanylmethoxy)-5-chloro-2-pyrazinyl)-2,3-dichloro-benzenesulphonamide
  • Figure US20100081670A1-20100401-C00238
  • Prepared by the method of Example 31 using (5-aminomethyl-2-furanyl)methanol (0.2 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.3 g). Purified by silica gel chromatography eluting with methanol/dichloromethane mixtures. Yield 0.1 g.
  • m/e 463 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.25 (2H, br s), 7.92 (1H, dd), 7.61 (1H, dd), 7.35 (1H, t), 7.27 (1H, s), 6.66 (1H, d), 6.57 (1H, d), 5.19 (2H, s), 4.14 (2H, s).
  • MP 201-202° C.
    • EXAMPLE 197 N-(3-(5-Aminomethyl-2-furanylmethoxy)-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00239
  • Prepared by the method of Example 28 using (5-aminomethyl-2-furanyl)methanol (0.2 g) and 2,3-dichloro-N-(3-chloro-2-pyrazinyl)benzenesulphonamide (Example 28) (0.3 g). Purified by silica gel chromatography eluting with methanol/dichloromethane mixtures. Yield 0.2 g.
  • m/e 427 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.40 (2H, br s), 7.96 (1H, dd), 7.60 (1H, dd), 7.35 (1H, t), 7.24 (1H, d), 7.15 (1H, d), 6.64 (1H, d), 6.57 (1H, d), 5.20 (2H, s), 4.13 (2H, s).
  • MP 199-201° C.
    • EXAMPLE 198 2,3-Dichloro-N-[3-methoxy-5-(2-propyn-1-yloxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00240
  • Procedure as for Example 115 using 2,3-dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-N-({2-[(trimethylsilyl)oxy]ethoxy}methyl)benzenesulphonamide (Example 115a) (0.25 g), propargyl alcohol (0.025 mL) and sodium hydride (0.035 g of a 60% dispersion in oil) in N,N-dimethylformamide (5 mL). Yield 0.05 g.
  • m/e 388 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.90 (1H, s), 7.98-7.94 (2H, m), 7.55 (1H, t), 7.51 (1H, s), 4.97 (2H, d), 3.85 (3H, s), 3.56 (1H, t).
  • MP 110-112° C.
    • EXAMPLE 199 {[5-(2,3-Dichlorophenylsulfonylamino)-6-methoxy-2-pyrazinyl]oxy}acetic acid, methyl ester
  • Figure US20100081670A1-20100401-C00241
  • Procedure as for Example 115 using 2,3-dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-N-({2-[(trimethylsilyl)oxy]ethoxy}methyl)benzenesulphonamide (Example 115a) (0.26 g), methyl glycolate (0.075 mL) and sodium hydride (0.035 g of a 60% dispersion in oil) in N,N-dimethylformamide (5 mL). Yield 0.1 g
  • m/e 422 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 10.89 (1H, s), 7.99-7.92 (2H, m), 7.58-7.53 (2H, m), 4.92 (2H, s), 3.75 (3H, s), 3.68 (3H, s).
  • MP 185-190° C.
    • EXAMPLE 200 N-[5-(2,3-Dichlorophenylsulphonylamino)-6-methoxy-2-pyrazinyl]-2-hydroxyacetamide
  • Figure US20100081670A1-20100401-C00242
  • Procedure as for Example 115 using 2,3-dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-N-({2-[(trimethylsilyl)oxy]ethoxy}methyl)benzenesulphonamide (Example 115a) (0.25 g), glycolamide (0.066 g) and sodium hydride (0.035 g of a 60% dispersion in oil) in N,N-dimethylformamide (5 mL). Yield 0.075 g.
  • m/e 407 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.23 (1H, br s), 9.77 (1H, s), 8.36 (1H, s), 8.05 (1H, dd), 7.94 (1H, dd), 7.58 (1H, t), 4.04 (2H, s), 3.86 (3H, s).
  • MP 153-155° C.
    • EXAMPLE 201 6-(2,3-Dichlorophenylsulphonylamino)-5-methoxy-2-pyrazinecarboxylic acid, methyl ester a) 6-chloro-3-methoxy-2-pyrazinamine
  • Figure US20100081670A1-20100401-C00243
  • A mixture of 5-bromo-6-chloro-3-methoxy-2-pyrazinamine (Example 125a) (0.6 g), triethylamine (0.72 mL), 10% palladium on carbon (0.05 g) and ethyl acetate (50 mL) were hydrogenated at 0.5 bar until reaction was complete as judged by hydrogen uptake. The reaction mixture was filtered and washed with water (25 mL), dried (MgSO4), filtered and evaporated to afford the sub-titled compound (0.33 g). Used Directly.
    • b) 6-Amino-5-methoxypyrazine-2-carboxylic acid methyl ester
  • Figure US20100081670A1-20100401-C00244
  • Prepared as for Example 113 using 6-chloro-3-methoxy-2-pyrazinamine (Example 201a) (0.35 g) heated at 120° C. for 3 h. Yield 0.3 g.
  • m/e 184 (M+1+, 100%).
    • c) 6-(2,3-Dichlorophenylsulphonylamino)-5-methoxy-2-pyrazinecarboxylic acid, methyl ester
  • Figure US20100081670A1-20100401-C00245
  • Prepared by the method of Example 1 (reaction performed at room temperature) using 6-amino-5-methoxypyrazine-2-carboxylic acid methyl ester (Example 201b) (0.3 g) and 2,3-dichlorobenzenesulphonyl chloride (0.4 g). Yield 0.15 g.
  • m/e 392 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.39 (1H, s), 8.25 (1H, dd), 7.93 (1H, dd), 7.65 (1H, t), 3.99 (3H, s), 3.77 (3H, s).
  • MP 90-92° C.
    • EXAMPLE 202 2,3-Dichloro-N-[6-(hydroxymethyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00246
  • Prepared as for example 120 using 6-(2,3-dichlorophenylsulphonylamino)-5-methoxy-2-pyrazinecarboxylic acid, methyl ester (Example 201) (0.12 g). Yield 0.03 g.
  • m/e 364 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.5 (1H, br s), 8.13 (1H, dd), 7.92 (1H, dd), 7.77 (1H, br s), 7.59 (1H, t), 5.25 (1H, br s), 4.19 (2H, s), 3.87 (3H, s).
  • MP 153-155° C.
    • EXAMPLE 203 2,3-Dichloro-N-(5-methanesulphonyl-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00247
  • Oxone (potassium peroxymonosulphate) (0.6 g) was added to 2,3-dichloro-N-(3-methoxy-5-methylsulphanyl-2-pyrazinyl)benzenesulphonamide (Example 80) (0.3 g) in methanol (40 mL) and water (10 mL) and the mixture heated at 50° C. for 4 h. After cooling, the mixture was filtered and evaporated. Purified by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures containing 1% acetic acid to give the title compound. Yield 0.2 g.
  • m/e 411 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.33 (1H, s), 8.30 (1H, s), 8.23 (1H, br s), 7.72 (1H, dd), 7.47 (1H, t), 4.14 (3H, s), 3.11 (3H, s).
  • MP 237-238° C.
    • EXAMPLE 204 2-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinyloxy]-N,N-diethyl-acetamide
  • Figure US20100081670A1-20100401-C00248
  • Prepared as for Example 115b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-[{2-(trimethylsilanyl)ethoxy}methyl]benzenesulphonamide (Example 55a) (0.35 g) and N,N-diethyl-2-hydroxyacetamide (0.13 g). Yield 0.2 g
  • m/e 463 (M+1+, 100%).
  • 1H NMR (CDCl3) δ 8.22 (1H, dd), 7.68 (1H, dd), 7.52 (1H, s), 7.46 (1H, s), 7.37 (1H, t), 4.88 (2H, s), 3.92 (3H, s), 3.38 (2H, q), 3.30 (2H, q), 1.20 (3H, t), 1.11 (3H, t).
  • MP 117-118° C.
    • EXAMPLE 205 2,3-Dichloro-N-{5-[2-(dimethylamino)ethylsulphanyl]-3-methoxy-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00249
  • Prepared as for Example 101b using N-(5-bromo-3-methoxy-2-pyrazinyl)-2,3-dichloro-N-{[2-(trimethylsilanyl)ethoxy]methyl}benzenesulphonamide (Example 55a) (0.3 g) and 2-(dimethylamino)ethanthiol hydrochloride (0.2 g). Yield 0.25 g.
  • m/e 435 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.05 (1H, dd), 7.95 (1H, dd), 7.71 (1H, s), 7.58 (1H, t), 3.98 (3H, s), 3.47 (2H, m), 3.28 (2H, m), 2.77 (6H, s).
  • MP 117-118° C.
    • EXAMPLE 206 2,3-Dichloro-N-(5-difluoromethyl-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00250
  • (Diethylamino)sulphur trifluoride (DAST) (0.15 g) and 2,3-dichloro-N-(5-formyl-3-methoxy-2-pyrazinyl)benzenesulphonamide (Example 186a) (0.3 g) in dichloromethane (20 mL) was stirred at room temperature for 4 h and then evaporated. Purified by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures to give the title compound. Yield 0.06 g.
  • m/e 382 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.14 (1H, dd), 7.96 (1H, dd), 7.84 (1H, s), 7.60 (1H, t), 6.80 (1H, t), 3.95 (3H, s).
  • MP 117-118° C.
    • EXAMPLE 207 2,3-Dichloro-4-fluoro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00251
  • Sodium hydride (0.4 g of a 60% dispersion in oil) was added to a solution of 3-methoxy-2-pyrazinamine (0.25 g) in N-methylpyrrolidinone (10 mL). After 0.5 h, 2,3-dichloro-4-fluorobenzenesulphonyl chloride (Example 185a) (0.63 g) was added. After 16 h at room temperature the reaction mixture was quenched with 2M aqueous HCl, extracted with ethyl acetate, dried (MgSO4) and evaporated. Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures. Yield 0.16 g.
  • m/e 350/352 (M−1−, 100%).
  • 1H NMR (D6-DMSO) δ 8.16 (1H, dd), 7.78 (1H, br s), 7.68 (1H, t), 7.62 (1H, br s), 3.9 (3H, s).
  • MP 192-194° C.
    • EXAMPLE 208 2,3-Dichloro-N-{5-chloro-3-[1-(cyclopropyl)ethoxy]-2-pyrazinyl}benzenesulphonamide
  • Figure US20100081670A1-20100401-C00252
  • Prepared by the method of Example 31b using 1-(cyclopropyl)ethanol (0.1 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.1 g). Yield 0.04 g.
  • m/e 422 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 11.70-11.50 (1H, br s), 8.07 (1H, dd), 7.94 (1H, dd), 7.77 (1H, s), 7.59 (1H, t), 4.60-4.50 (1H, m), 1.33 (3H, d), 1.1-1.0 (1H, m), 0.6-0.3 (4H, m).
  • MP 161-162° C.
    • EXAMPLE 209 2,3-Dichloro-N-[5-chloro-3-(5-formyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide a) [5-(1,3-Dimethyl-2-imidazolidinyl)-2-furanyl]methanol
  • Figure US20100081670A1-20100401-C00253
  • 5-hydroxymethylfuran-2-carbaldehyde (5.0 g) and N,N′-dimethylethane-1,2-diamine (3.8 g) in toluene (100 mL) was heated under reflux using a Dean and Stark apparatus. After 12 h, the toluene was evaporated to give an oil. Yield 8.3 g. Used directly.
    • b) 2,3-Dichloro-N-[5-chloro-3-(5-formyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
  • Figure US20100081670A1-20100401-C00254
  • Prepared by the method of Example 31b (reaction heated at 60° C. for 4 h) using [5-(1,3-dimethyl-2-imidazolidinyl)-2-furanyl]methanol (2.3 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (3.0 g). The reaction was quenched with 2M hydrochloric acid and left for 16 h. The solid product was collected. Purified by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures to give the title compound. Yield 2.5 g.
  • m/e 460 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 9.64 (1H, s), 8.06 (1H, dd), 7.94 (1H, dd), 7.87 (1H, s), 7.57 (2H, d+t), 6.93 (1H, d), 5.47 (2H, d).
    • EXAMPLE 210 2,3-Dichloro-N-[5-chloro-3-(5-cyclopropylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]-benzenesulphonamide
  • Figure US20100081670A1-20100401-C00255
  • Prepared by the method of Example 107b using 2,3-dichloro-N-[5-chloro-3-(5-formyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide (Example 209) (0.3 g) and cyclopropylamine (0.1 g). Yield 0.1 g.
  • m/e 503 (M−1+, 100%).
  • 1H NMR (D6-DMSO) δ 7.93 (1H, dd), 7.63 (1H, dd), 7.36 (1H, t), 7.30 (1H, s), 6.66 (1H, d), 6.63 (1H, d), 5.21 (2H, s), 4.34 (2H, s), 2.71 (1H, m), 0.76 (4H, m).
  • MP 175-176° C.
    • EXAMPLE 211 N-[5,6-bis-(Hydroxymethyl)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide a) 2,3-Dichloro-N-(5,6-dicyano-3-methoxy-2-pyrazinyl)benzenesulphonamide
  • Figure US20100081670A1-20100401-C00256
  • Prepared by the method outlined in Example 1 using 5-amino-6-chloro-2,3-dicyanopyrazine (1.8 g) and 2,3-dichlorobenzenesulfonyl chloride (2.7 g). The adduct was reacted by the method outlined in example 31b using sodium methoxide to afford the sub-titled compound that was used directly.
  • m/e 382, 383 (M−1+, 100%).
    • b) 5-{[(2,3-Di chlorophenyl)sulphonyl]amino}-6-methoxypyrazine-2,3-dicarboxylic acid, dimethyl ester
  • Figure US20100081670A1-20100401-C00257
  • The crude product from above (Example 211a) was dissolved in 10% aqueous sodium hydroxide solution and heated under reflux for 10 hours. The reaction mixture was cooled, concentrated and the residue was treated with thionyl chloride (30 mL) and refluxed for 1 hour, cooled and concentrated, azeotroping with dry toluene. The resulting residue was dissolved in methanol (30 mL) and allowed to stand for 10 hours and concentrated to afford the sub-titled compound that was used directly.
  • m/e 448, 450 (M−1+, 100%).
    • c) N-[5,6-bis-(Hydroxymethyl)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00258
  • To a solution of 5-{[(2,3-dichlorophenyl)sulphonyl]amino}-6-methoxypyrazine-2,3-dicarboxylic acid, dimethyl ester (Example 211b, 0.5 g) dissolved in anhydrous tetrahydrofuran (20 mL) at 0° C. was added a solution of lithium triethylborohydride (Super Hydride®) (5.55 mL of a 1M solution in tetrahydrofuran) and the resulting solution was stirred for 1 hour. The reaction was quenched by the addition of 1N hydrochloric acid (10 mL) and extracted into ethyl acetate (2×20 mL). The combined extracts were dried (MgSO4), filtered and concentrated to afford an oil that was purified by chromatography on silica gel eluting with ethyl acetate/dichloromethane mixtures to afford the titled compound (0.201 g) as a foam.
  • m/e 392, 394 (M−1+, 100%).
  • 1H NMR (CDCl3) δ 8.30 (1H, d), 7.91 (1H, br s), 7.71 (1H, d), 7.46 (1H, t), 4.59 (2H, s), 4.50 (2H, s), 4.0 (3H, s).
    • EXAMPLE 212 N-[3-[(2-amino-4-oxazolyl)methoxy]-5-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide a) (4-Hydroxymethyl-2-oxazolyl)carbamic acid tent-butyl ester
  • Figure US20100081670A1-20100401-C00259
  • Prepared by the method of Example 120 using 2-{bis[(1,1-dimethylethoxy)carbonyl]amino}-4-oxazolcarboxylic acid, ethyl ester (0.65 g) and sodium triethylborohydride (5.5 mL of a 1M solution in tetrahydrofuran). Yield 0.24 g. Used directly.
    • b) N-[3-[(2-amino-4-oxazolyl)methoxy]-5-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
  • Figure US20100081670A1-20100401-C00260
  • Prepared by the method of Example 112 using (4-hydroxymethyl-2-oxazolyl)carbamic acid tert-butyl ester (Example 212a) (0.12 g) and 2,3-dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (Example 74) (0.21 g). Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures to give the title compound with the BOC (tert-butyl carbonyl) attached (0.11 g). This compound was dissolved in trifluoroacetic acid (1.5 mL) and dichloromethane (1.5 mL). After 2 h, the solution was evaporated. Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane mixtures to give the title compound. Yield 0.08 g.
  • m/e 450 (M+1+, 100%).
  • 1H NMR (D6-DMSO) δ 8.04 (1H, dd), 7.91 (1H, dd), 7.80 (1H, s), 7.55 (1H, t), 7.49 (1H, s), 6.71 (2H, br s), 5.10 (2H, s).
  • MP 137° C.
    • Pharmacological Analysis FMAT Whole Cell Binding Assay Cells
  • CHO-K1 cells stably expressing the human recombinant CCR4 receptor (Euroscreen; Brussels, Belgium) were cultured in NUT.MIX.F—12(HAM) medium with glutamax-1, containing 10% (v/v) foetal bovine serum and 400 μg ml−1 geneticin.
  • Cells were harvested at approximately 70% confluence by treatment with a cell dissociation buffer, and seeded at 5×103 cells/1000 culture medium into wells of a black Costar clear-bottomed 96-well microtitre plates. Plates were incubated overnight at 37° C. in 5% CO2 and used the following day.
    • Assay
  • Before use, the cell plates were washed twice with 100 μl Hanks balanced salt solution (HBSS). To each well was then added 650 of HBSS, 10 μL of 10% DMSO in HBSS test compound and then 25 μL of 2.8 nM FB-MDC (Applied Biosystems). This fluorescent probe was prepared from a 10 μM stock in 0.08% (v/v) TFA/16% (v/v) acetonitrile, diluted into HBSS.
  • After two hours incubation in the dark at room temperature, the plates were analysed in an FMAT8100 reader (Applied Biosystems) to measure fluorescence that was associated with binding of FB-MDC to the cells. Compound activity was determined as an pIC50 [log(concentration of compound that results in 50% inhibition)], comparing fluorescence in control and background wells.
    • Typical Data
  • Fluorescence (ctrl)=1200
    Fluorescence (bkg)=0
  • The compounds of the examples all have a pIC50 of greater than 5.0.
  • Data for specific compounds is given below.
  • Mean
    Example 112 pIC50 9.5
    Example 119 pIC50 7.2
    Example 186 pIC50 6.2

Claims (15)

1. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:
Figure US20100081670A1-20100401-C00261
in which:
R1, R2 and R3 are independently hydrogen, halogen, cyano, CF3, OCF3, OC1-6 alkyl or C1-6 alkyl;
R4 is halogen, CO2R12,
C1-6 alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
C3-6 alkenyloxy or C3-6 alkynyloxy where either may be optionally substituted with hydroxy or NR14R15;
OC1-6 alkyl-X—C1-6 alkyl where the alkyl groups may form a 3-6 membered saturated ring;
OC1-6 alkylR11, or OC2-6 alkyl-X—R11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR14R15, SR13, S(O)2R13, S(O)R13 or COR13;
OC1-6 alkylR16;
R5 and R6 are independently hydrogen, cyano, halogen, CO2R12, CONR14R15;
C1-6 alkyl optionally substituted by hydroxy, NR14R15, or 1-3 fluorines;
C1-6 alkylR11 or XCH(R11)C1-6 alkyl or XCH(R16)C1-6 alkyl where the alkyl group may be optionally substituted with 1-3 groups selected from hydroxy, and NR14R15;
NR14R15; N(R11)R11; X—(CH2)qNR14R15; (CH2)nNR14R15; NHC(O)C1-6 alkyl optionally substituted by one or more hydroxy groups,
C3-6 alkynyl or C3-6 alkenyl optionally branched and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and ═O;
R11; X—R11; X—R12; X—C1-6 alkylR16; X—R16; X—(CH2)nCO2R12; X—(CH2)nCONR14R15;
X—(CH2)nR11; X—(CH2)nCN; X—(CH2)qOR12; (CH2)nOR12;
(CH2)n-X—R11; X—(CH2)qNHC(O)NHR12; X—(CH2)qNHC(O)R12;
X—(CH2)qNHS(O)2R12; X—(CH2)qNHS(O)2R11; X—C3-6 alkenyl; X—C3-6 alkynyl;
n is 1, 2, 3, 4 or 5;
q is 2, 3, 4, 5 or 6;
X is NR13, O, S, S(O), S(O)2;
R11 is an aryl group or a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur each of which can be optionally substituted by 1-3 groups selected from halogen, C(O)NR14R15, C(O)OR12, hydroxy, ═O, ═S, CN, NO2, COR13, NR14R15, X(CH2)qNR14R15, (CH2)nNR14R15, (CH2)nOH, SR13, S(O)R13, S(O)2R13, C1-6 alkyl-X—C1-6 alkyl, C1-6 alkyl or C1-6 alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR14R15, SR13, S(O)R13, S(O)2R13;
R12 and R13 are independently hydrogen or C1-6 alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;
R14 and R15 are independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl or (CH2)qOH,
or R14 and R15 together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C1-6 alkyl, C1-6 alkyl-OH, or hydroxy; and
R16 is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and ═O,
provided that:
when R4 is halogen or C1-4alkoxy and R5 is hydrogen, halogen, C1-4alkyl, C1-2alkoxy, C1-2alkylthio, trifluoromethyl or ethynyl and when one R1, R2, or R3 is C1-6alkyl or C1-6alkoxy and is meta to the sulphonamide group then the group ortho to both the sulphonamide group and the C1-6alkyl or C1-6alkoxy group is not hydrogen,
when R4 is halogen or C1-4alkoxy and R5 is hydrogen, halogen, C1-4alkyl, C1-2alkoxy, C1-2alkylthio, trifluoromethyl, or ethynyl and when one of R1, R2 or R3 is C1-6alkyl or C1-6alkoxy and is ortho to the sulphonamide group then the group ortho to the C1-6Alkyl or C1-6alkoxy and also meta to the sulphonamide group is not hydrogen,
when two of R1, R2, R3 are hydrogen and the other is a methyl group para to the sulphonamide and R4 is methoxy then R5 is not hydrogen or bromo, and
when R5 is methyl and R6 is methoxy and one of R1, R2 or R3 is bromo or iodo and the other two are both hydrogen, then the bromo or iodo group is not ortho to the sulphonamide group.
2. The compound according to claim 1 in which one of R1, R2 and R3 is hydrogen and the other is chloro, bromo or methyl.
3. The compound according to claim 1 or in which R4 is C1-6 alkoxy such as methoxy, 2-furanylmethoxy, bromo, chloro, 2-methoxyethoxy, (5-methyl-3-isoxazolyl)methoxy, pyridylmethoxy, 3-pyridazinylmethoxy, methoxy, 2-(1-imidazolyl)ethoxy, (2-methyl-4-oxazolyl)methoxy and 4-methoxyphenylmethoxy.
4. The compound according claim 1 in which R5 is hydrogen, halogen such as bromo and chloro, phenyl, —C1-6 alkyl such as methyl, CH2OH, cyano and
2-aminothanethiol
5. The compound according to claim 1 in which R6 is hydrogen,
C1-6 alkyl, CH2OH and halogen.
6. The compound according to claim 1 which is:
2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide
N-(6-Chloro-3-methoxy-2-pyrazinyl)-2,3,4-trifluorobenzenesulphonamide
3-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-methylbenzenesulphonamide
2,3-Dichloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,5-dichlorobenzenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-3,5-dichlorobenzenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,4-dichlorobenzenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-3,4-dichlorobenzenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-4-chlorobenzenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-3-chlorobenzenesulphonamide
N-(3-Methoxy-5-methyl-2-pyrazinyl)-2-fluorobenzenesulphonamide
N-(3-Methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
N-(3-Methoxy-5-methyl-2-pyrazinyl)-2-iodobenzenesulphonamide
N-(3-Methoxy-5-methyl-2-pyrazinyl)-3-fluorobenzenesulphonamide
2-[[(3-Methoxy-5-methyl-2-pyrazinyl)amino]sulphonyl]benzonitrile
N-(5-Bromo-3-methoxy-2-pyrazinyl)benzenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-2-iodobenzenesulphonamide
2,3-Dichloro-N-[3-(2-furanylmethoxy)-5-methyl-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-methyl-3-(5-methyl-3-isoxazolylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-methyl-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-methyl-3-(6-methyl-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-methyl-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-methyl-3-(4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-methyl-3-(3-methyl-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-methyl-3-(3-pyridazinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
N-[5-Bromo-3-(2-pyrazinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(1-methyl-6-oxo-1,6-dihydro-3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(3-pyridazinyllmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(5-pyrimidinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Chloro-3-(5-pyrimidinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
2-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
4-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
N-(6-Chloro-3-methoxy-2-pyrazinyl)-2,4-dichlorobenzenesulphonamide
N-(6-Chloro-3-methoxy-2-pyrazinyl)-3,4-dichlorobenzenesulphonamide
3-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-2-methylbenzenesulphonamide
2-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
3-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
4-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
2,4-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
3,4-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-2-trifluoromethoxybenzenesulphonamide
3-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-methylbenzenesulphonamide
2-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
3-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
4-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
N-(5-Chloro-3-methoxy-2-pyrazinyl)-2,4-dichlorobenzenesulphonamide
2,3-Dichloro-N-[3-methoxy-5-(4-morpholinyl)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[3,5-dimethoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[3-methoxy-5-(1-pyrrolinyl)-2-pyrazinyl]benzenesulphonamide
3-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-2-methylbenzenesulphonamide
2,3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
2-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
3-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
4-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
2,4-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
3,4-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-(3-methoxy-5,6-dimethyl-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-(6-chloro-3,5-dimethoxy-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-[6-chloro-3-methoxy-5-(4-morpholinyl)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[6-chloro-5-(2-hydroxyethylamino)-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[6-chloro-5-dimethylamino-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[6-chloro-3-methoxy-5-(2-methoxyethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[6-chloro-5-hydroxy-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[6-methoxy-5-([2,2′]bipyrazinyl)]benzenesulphonamide
4-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinyloxy]benzoic acid
2,3-Dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-{6-chloro-3-methoxy-5-([2-methoxyethyl)amino]-2-pyrazinyl}benzenesulphonamide
N-{2-[3-Chloro-5-(2,3-dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylamino]ethyl}acetamide
2,3-Dichloro-N-[5-(4-hydroxymethyl-1-piperidinyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-cyano-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-(6-chloro-3-methoxy-5-methylamino-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-(3-methoxy-5-methylsulphanyl-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-[5-(2,4-difluorophenyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetic acid methyl ester
[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetic acid
2,3-Dichloro-N-[5-(2-chlorobenzylsulphanyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[6-chloro-5-(3-hydroxy-1-azetidinyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-methyl-3-(1-oxy-3-pyrazinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(1-oxy-4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(2-methylsulphanylethoxy)-2-pyrazinyl]benzenesulphonamide
N-(3-Butoxy-5-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(2-methyl-3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(6-methyl-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(1-oxy-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
3-Chloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-methylbenzenesulphonamide
3-Chloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-fluorobenzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(4-methoxyphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
N-[5-Bromo-6-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-[6-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[6-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
N-[5-(2-Aminoethylsulphanyl)-3-(2-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(6-methoxy-3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
N-[3-(3-Bromophenylmethoxy)-5-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
3-[6-Chloro-3-(2,3-dichlorobenzenesulphonylamino)-2-pyrazinyloxymethyl]benzoic acid methyl ester
3-[6-Chloro-3-(2,3-dichlorobenzenesulphonylamino)-2-pyrazinyloxymethyl]benzoic acid
2,3-Dichloro-N-[5-chloro-3-(3-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(3-methylaminomethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-{3-([2-hydroxyethylamino]methyl)phenylmethoxy}-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(4-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-{4-([2-hydroxyethylamino]methyl)phenylmethoxy}-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[3-(4-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(2-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
5-(2,3-Dichlorobenzenesuphonylamino)-6-methoxypyrazine-2-carboxylic acid, methyl ester
2,3-Dichloro-N-[5-(1-hydroxy-1-methylethyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
N-[5-(2-Aminoethoxy)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-{5-[(2-Aminoethyl)thio]-6-chloro-3-methoxy-2-pyrazinyl}-2,3-dichlorobenzenesulfonamide
3-[(5-{[(2,3-Dichlorophenyl)sulphonyl]amino}-6-methoxy-2-pyrazinyl)thio]propanoic acid, methyl ester
2,3-Dichloro-N-[5-bromo-3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide
5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-3-methylpyrazine-2-carboxylic acid, methyl ester
2,3-Dichloro-N-[5-(hydroxymethyl)-3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-[5,6-dichloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
3-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-fluorobenzenesulphonamide
3-Chloro-2-fluoro-N-[3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
3-{[(2,3-Dichlorophenyl)sulphonyl]amino}pyrazine-2-carboxylic acid, methyl ester
N-(5-Bromo-6-chloro-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
3-Chloro-5-{[(2,3-dichlorophenyl)sulphonyl]amino}-6-methoxypyrazine-2-carboxylic acid, methyl ester
2,3-Dichloro-N-[6-chloro-5-(hydroxymethyl)-3-methoxypyrazin-2-yl]benzenesulphonamide
2,3-Dichloro-N-{3-[(6-methoxy-3-pyridinyl)methoxy]-2-pyrazinyl}benzenesulphonamide
2,3-Dichloro-N-[6-chloro-3-methoxy-5-(methoxymethyl)-2-pyrazinyl]benzenesulphonamide
2-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-3-fluorobenzenesulphonamide
2-Chloro-3-fluoro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
2-Chloro-3-methoxy-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
N-[5-Bromo-3-[(25)-2-pyrrolidinylmethoxy]-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
5-(2,3-Dichlorobenzenesulphonylamino)-6-(3-pyridinylmethoxy)pyrazine-2-carboxylic acid, methyl ester
5-{[(2,3-Dichlorophenyl)sulphonyl]amino}-6-(3-pyridinylmethoxy)-2-pyrazinecarboxamide
2,3-Dichloro-N-[5-(4-pyridinyl)-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-(hydroxymethyl)-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-(hydroxymethyl)-3-methoxy)-2-pyrazinyl]benzenesulphonamide
4-Amino-2,3-dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
N-(5-Allyloxy-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-[5-(3-hydroxy-1-propynyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
N-{3-[(5-Bromo-3-pyridinyl)methoxy]-5-chloro-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-{[6-(hydroxymethyl)-2-pyridinyl]methoxy}-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-{5-chloro-3-[(2-methyl-4-oxazolyl)methoxy]-2-pyrazinyl}benzenesulphonamide
2,3-Dichloro-N-{3-[(2-methyl-4-oxazolyl)methoxy]-2-pyrazinyl}benzenesulphonamide
N-[5-Bromo-3-(phenylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(2-cyclopropylethoxy)pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(3-thienylmethoxy)pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[(2-methyl-3-furanyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[(3-furanyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[(4-fluorophenyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[(3-fluorophenyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[3-(2-pyridinyl)propoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(pentyloxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(propyloxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(2-methoxyethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(2-ethoxyethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(2-fluoroethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[2-(1H-imidazol-1-yl)ethoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[3-(3-pyridinyl)propoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-[2-(methylamino)ethoxy]-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[3-(4-hydroxyphenyl)propoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(2-phenoxyethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(cyclopropylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(3-phenoxypropoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-(5-ethoxy-3-methoxy-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-[3-methoxy-5-([1,2,4]-1-triazolyl)-2-pyrazinyl]benzenesulphonamide
2-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]-N-methylacetamide
2-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetamide
2,3-Dichloro-N-[5-(4-fluorobenzylsulphanyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-cyanomethylsulphanyl-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[3-methoxy-5-([1,2,4]-3-oxadiazolylmethylsulphanyl)-2-pyrazinyl]benzenesulphonamide
N-[5-(2-Aminoethylsulphanyl)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-[3-methoxy-5-(5-methyl-3-isoxazolylmethoxy))-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-(5-dimethylaminomethyl-2-furanylmethoxy)-3-methoxy-2-pyrazinyl]benzenesulphonamide
N-[5-Bromo-3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]-2,3-dichloro-benzenesulphonamide
2,3-Dichloro-N-[5-(2-hydroxyethylsulphanyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-{5-[2-(ethylureido)ethylsulphanyl]-3-methoxy-2-pyrazinyl}benzenesulphonamide
2,3-Dichloro-N-[3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[6-chloro-3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[6-chloro-3-(5-methylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[3-(5-methylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
N-(5-Bromo-3-methoxypyrazinyl)-2-cyanobenzenesulphonamide
N-(5-Bromo-3-methoxypyrazinyl)-2,3-dichloro-4-fluorobenzenesulphonamide
2,3-Dichloro-N-[3-methoxy-5-(4-morpholinylmethyl)-2-pyrazinyl]benzenesulphonamide
N-(3-Allyloxy-5-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(2-propynyloxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[3-(2-propynyloxy)-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-(5-cyano-3-methoxy-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-{3-methoxy-5-[(2S)-pyrrolidin-2-ylmethoxy]-2-pyrazinyl}benzenesulfonamide hydrochloride
2,3-Dichloro-N-{6-chloro-3-methoxy-5-[(2R)-2-pyrrolidinylmethoxy]-2-pyrazinyl}benzenesulphonamide Hydrochloride
2,3-Dichloro-N-[3-methoxy-5-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide Hydrochloride
2,3-Dichloro-N-(3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-[3-methoxy-5-(1H-1,2,4-triazol-1-ylmethyl)-2-pyrazinyl]benzenesulphonamide
N-(3-(5-Aminomethyl-2-furanylmethoxy)-5-chloro-2-pyrazinyl)-2,3-dichloro-benzenesulphonamide
N-(3-(5-Aminomethyl-2-furanylmethoxy)-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-[3-methoxy-5-(2-propyn-1-yloxy)-2-pyrazinyl]benzenesulphonamide
{[5-(2,3-Dichlorophenylsulfonylamino)-6-methoxy-2-pyrazinyl]oxy}acetic acid, methyl ester
N-[5-(2,3-Dichlorophenylsulphonylamino)-6-methoxy-2-pyrazinyl]-2-hydroxyacetamide
6-(2,3-Dichlorophenylsulphonylamino)-5-methoxy-2-pyrazinecarboxylic acid, methyl ester
2,3-Dichloro-N-[6-(hydroxymethyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-(5-methanesulphonyl-3-methoxy-2-pyrazinyl)benzenesulphonamide
2-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinyloxy]-N,N-diethyl-acetamide
2,3-Dichloro-N-{5-[2-(dimethylamino)ethylsulphanyl]-3-methoxy-2-pyrazinyl}benzenesulphonamide
2,3-Dichloro-N-(5-difluoromethyl-3-methoxy-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-4-fluoro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
2,3-Dichloro-N-{5-chloro-3-[1-(cyclopropyl)ethoxy]-2-pyrazinyl}benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(5-formyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-chloro-3-(5-cyclopropylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]-benzenesulphonamide
N-[5,6-bis-(Hydroxymethyl)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[3-[(2-amino-4-oxazolyl)methoxy]-5-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide and pharmaceutically acceptable salts and solvates thereof.
7. A process for the preparation of a compound of formula (I) as claimed in claim 1 which comprises:
(a) reaction of a compound of formula (II):
Figure US20100081670A1-20100401-C00262
where R4, R5 and R6 are as defined in claim 1 or are protected derivatives thereof with a compound of formula (III):
Figure US20100081670A1-20100401-C00263
where R1, R2 and R3 are as defined in claim 1 or are protected derivatives thereof and LG is a leaving group, or
(b) for compounds where R4 is C1-6 alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
C3-6 alkenyloxy or C3-6 alkynyloxy where either may be optionally substituted with hydroxy or NR14R15;
OC1-6 alkyl-X—C1-6 alkyl where the alkyl groups may form a 3-6 membered saturated ring;
OC1-6 alkylR11, or OC2-6 alkyl-X—R11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR14R15, SR13, S(O)2R13, S(O)R13; or
OC1-6 alkylR16;
treating a compound of the formula (VI), where LG is a leaving group:
Figure US20100081670A1-20100401-C00264
with a compound of formula

R4—H  (V)
(V) in the presence of a suitable base, or
(c) for compounds of structure (I), where R5 is an optionally substituted aryl or heteroaryl ring as defined above, reacting a compound of formula (XI) or (VII) where LG is a leaving group with an aryl or heteroaryl boronic acid in the presence of a palladium catalyst and a suitable base at elevated temperature:
Figure US20100081670A1-20100401-C00265
and optionally thereafter process (a), (b) or (c)
removing any protecting groups,
converting a compound of formula (I) to a further compound of formula (I)
forming a pharmaceutically acceptable salt.
8. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
9. A process for the preparation of a pharmaceutical composition as claimed in claim 8 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.
10. (canceled)
11. A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a therapeutically effective amount of a compound of formula (IB), or a pharmaceutically acceptable salt or solvate thereof:
Figure US20100081670A1-20100401-C00266
in which:
R1, R2 and R3 are independently hydrogen, halogen, cyano, CF3, or C1-6 alkyl;
R4 is halogen, CO2R12,
C1-6 alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
C3-6 alkenyloxy or C3-6 alkynyloxy where either may be optionally substituted with hydroxy or NR14R15;
OC1-6 alkyl-X—C1-6 alkyl where the alkyl groups may form a 3-6 membered saturated ring;
OC1-6 alkylR11, or OC2-6 alkyl-X—R11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR14R15, SR13, S(O)2R13, S(O)R13;
OC1-6 alkylR16;
R5 and R6 are independently hydrogen, cyano, halogen, CO2R12, CONR14R15;
C1-6 alkyl optionally substituted by hydroxy, NR14R15, or 1-3 fluorines;
C1-6 alkylR11 or XCH(R11)C1-6 alkyl or XCH(R16)C1-6 alkyl where the alkyl group may be optionally substituted with 1-3 groups selected from hydroxy, and NR14R15;
NR14R15; N(R11)R11; X—(CH2)qNR14R15; (CH2)nNR14R15;
C3-6 alkynyl or C3-6 alkenyl optionally branched and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and ═O;
R11; X—R11; X—R12; X—C1-6 alkylR16; X—R16; X—(CH2)nCO2R12; X—(CH2)nCONR14R15;
X—(CH2)nR11; X—(CH2)nCN; X—(CH2)qOR12; (CH2)nOR12;
(CH2)n-X—R11; X—(CH2)qNHC(O)NHR12; X—(CH2)qNHC(O)R12;
X—(CH2)qNHS(O)2R12; X—(CH2)qNHS(O)2R11; X—C3-6 alkenyl; X—C3-6 alkynyl;
n is 1, 2, 3, 4 or 5;
q is 2, 3, 4, 5 or 6;
X is NR13, O, S, S(O), S(O)2;
R11 is an aryl group or a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur each of which can be optionally substituted by 1-3 groups selected from halogen, C(O)NR14R15, C(O)OR12, hydroxy, ═O, ═S, CN, NO2 NR14R15, X(CH2)qNR14R15, (CH2)nNR14R15, (CH2)nOH, SR13, S(O)R13, S(O)2R13C1-6 alkyl-X—C1-6 alkyl, C1-6 alkyl or C1-6 alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR14R15, SR13, S(O)R13, S(O)2R13;
R12 and R13 are independently hydrogen or C1-6 alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;
R11 and R15 are independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl or (CH2)qOH,
or R14 and R15 together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C1-6 alkyl, C1-6 alkyl-OH, or hydroxy; and
R16 is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and ═O,
12. The method according to claim 11 in which the chemokine receptor belongs to the CCR chemokine receptor subfamily.
13. The method according to claim 11 in which the chemokine receptor is the CCR4 receptor.
14. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (IB), or a pharmaceutically acceptable salt or solvate thereof, as defined in claim 11.
15. The method according to claim 14, wherein the disease is asthma.
US12/435,864 2002-01-16 2009-05-05 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases Abandoned US20100081670A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/435,864 US20100081670A1 (en) 2002-01-16 2009-05-05 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SE0200119A SE0200119D0 (en) 2002-01-16 2002-01-16 Novel compounds
SE0200119-6 2002-01-16
SE0201857-0 2002-06-17
SE0201857A SE0201857D0 (en) 2002-06-17 2002-06-17 Novel compounds
PCT/SE2003/000041 WO2003059893A1 (en) 2002-01-16 2003-01-14 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
US10/501,510 US7662825B2 (en) 2002-01-16 2003-01-14 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
US12/435,864 US20100081670A1 (en) 2002-01-16 2009-05-05 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/501,510 Continuation US7662825B2 (en) 2002-01-16 2003-01-14 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
PCT/SE2003/000041 Continuation WO2003059893A1 (en) 2002-01-16 2003-01-14 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases

Publications (1)

Publication Number Publication Date
US20100081670A1 true US20100081670A1 (en) 2010-04-01

Family

ID=26655657

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/501,510 Expired - Fee Related US7662825B2 (en) 2002-01-16 2003-01-14 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
US12/435,864 Abandoned US20100081670A1 (en) 2002-01-16 2009-05-05 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/501,510 Expired - Fee Related US7662825B2 (en) 2002-01-16 2003-01-14 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases

Country Status (22)

Country Link
US (2) US7662825B2 (en)
EP (1) EP1467976B1 (en)
JP (1) JP4504021B2 (en)
KR (1) KR20040073566A (en)
CN (1) CN100357275C (en)
AR (1) AR038179A1 (en)
AT (1) ATE534635T1 (en)
AU (1) AU2003201802A1 (en)
BR (1) BR0306922A (en)
CA (1) CA2472204A1 (en)
CO (1) CO5640137A2 (en)
ES (1) ES2375107T3 (en)
HK (1) HK1068885A1 (en)
IL (1) IL162678A0 (en)
IS (1) IS7348A (en)
MX (1) MXPA04006806A (en)
NO (1) NO20043370L (en)
NZ (1) NZ533750A (en)
PL (1) PL371432A1 (en)
RU (1) RU2312105C9 (en)
TW (1) TWI328007B (en)
WO (1) WO2003059893A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673908B2 (en) 2008-11-10 2014-03-18 Kyowa Hakko Kirin Co., Ltd. Kynurenine production inhibitor
US20160164361A1 (en) * 2013-07-09 2016-06-09 Hisayoshi Fukuyanagi Large output, high efficiency, single phase, multi-polar power generator

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1541563A4 (en) * 2002-07-10 2007-11-07 Ono Pharmaceutical Co Ccr4 antagonist and medicinal use thereof
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
WO2004018435A1 (en) 2002-08-24 2004-03-04 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
SE0301653D0 (en) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0302304D0 (en) * 2003-08-27 2003-08-27 Astrazeneca Ab Novel compounds
JPWO2005023771A1 (en) * 2003-09-05 2006-11-02 小野薬品工業株式会社 Chemokine receptor antagonist and its pharmaceutical use
GB0401269D0 (en) * 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
WO2006020830A2 (en) * 2004-08-12 2006-02-23 Amgen Inc. Bisaryl-sulfonamides
WO2006024823A1 (en) 2004-08-28 2006-03-09 Astrazeneca Ab Pyrimidine sulphonamide derivatives as chemokine receptor modulators
TW200800921A (en) * 2005-09-19 2008-01-01 Astrazeneca Ab Novel compounds
EP1956009A1 (en) * 2005-12-02 2008-08-13 Mitsubishi Tanabe Pharma Corporation Aromatic compound
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
TW200730512A (en) * 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
GB0526255D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
PL2170848T3 (en) 2007-06-27 2015-02-27 Astrazeneca Ab Pyrazinone derivatives and their use in the treatment of lung diseases
EP2276731A1 (en) * 2008-04-09 2011-01-26 Boehringer Ingelheim International GmbH 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10
JP2012524789A (en) * 2009-04-22 2012-10-18 アクシキン ファーマシューティカルズ インコーポレーテッド 2,5-disubstituted arylsulfonamide CCR3 antagonist
TWI535442B (en) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
KR101840503B1 (en) * 2010-12-16 2018-03-20 알러간, 인코포레이티드 Novel 1,2-bis-sulfonamide derivatives as chemokine receptor modulators
EP2781517B1 (en) 2011-11-09 2017-10-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
CN106008418A (en) * 2016-05-20 2016-10-12 厦门大学 Method for synthesizing 5-aminomethyl-2-furfuryl alcohol
HUE069276T2 (en) * 2018-01-26 2025-02-28 Rapt Therapeutics Inc Chemokine receptor modulators and uses thereof
CN113069446B (en) * 2021-03-01 2022-12-02 中山亿维迪科技有限公司 Application of EL102 in preparation of medicine for treating diseases caused by novel coronavirus

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026957A1 (en) * 1994-03-31 1995-10-12 Zeneca Limited N-heterocyclyl sulphonamide derivatives and their use as endothelin antagonists
WO2000001389A1 (en) * 1998-07-06 2000-01-13 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US20020143024A1 (en) * 1998-07-06 2002-10-03 Natesan Murugesan Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US20060122195A1 (en) * 2003-06-05 2006-06-08 Richard Harrison Sulphonamide compounds that modulate chemokine receptor activity (ccr4)
US20060128723A1 (en) * 2003-06-04 2006-06-15 Antonio Mete Sulptionamide compounds that modulate chemokine receptor activity (CCR4)
US20060189613A1 (en) * 2003-06-05 2006-08-24 David Cheshire Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4)
US20070093491A1 (en) * 2003-08-27 2007-04-26 Andrew Baxter Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases
US7410972B2 (en) * 2001-12-18 2008-08-12 Astrazeneca Ab Compounds
US20080293742A1 (en) * 2005-12-12 2008-11-27 David Cheshire Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US143024A (en) * 1873-09-23 Improvement in clothes-pins
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
CA2162630C (en) 1994-11-25 2007-05-01 Volker Breu Sulfonamides
GB2295616A (en) * 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
EP1237888B1 (en) * 1999-12-15 2006-09-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
EP1541563A4 (en) 2002-07-10 2007-11-07 Ono Pharmaceutical Co Ccr4 antagonist and medicinal use thereof
TW200800921A (en) 2005-09-19 2008-01-01 Astrazeneca Ab Novel compounds

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026957A1 (en) * 1994-03-31 1995-10-12 Zeneca Limited N-heterocyclyl sulphonamide derivatives and their use as endothelin antagonists
WO2000001389A1 (en) * 1998-07-06 2000-01-13 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US20020143024A1 (en) * 1998-07-06 2002-10-03 Natesan Murugesan Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US7410972B2 (en) * 2001-12-18 2008-08-12 Astrazeneca Ab Compounds
US20060128723A1 (en) * 2003-06-04 2006-06-15 Antonio Mete Sulptionamide compounds that modulate chemokine receptor activity (CCR4)
US20060122195A1 (en) * 2003-06-05 2006-06-08 Richard Harrison Sulphonamide compounds that modulate chemokine receptor activity (ccr4)
US20060189613A1 (en) * 2003-06-05 2006-08-24 David Cheshire Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4)
US20070093491A1 (en) * 2003-08-27 2007-04-26 Andrew Baxter Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases
US20080293742A1 (en) * 2005-12-12 2008-11-27 David Cheshire Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673908B2 (en) 2008-11-10 2014-03-18 Kyowa Hakko Kirin Co., Ltd. Kynurenine production inhibitor
US20160164361A1 (en) * 2013-07-09 2016-06-09 Hisayoshi Fukuyanagi Large output, high efficiency, single phase, multi-polar power generator

Also Published As

Publication number Publication date
TW200303308A (en) 2003-09-01
US20060025423A1 (en) 2006-02-02
EP1467976A1 (en) 2004-10-20
CA2472204A1 (en) 2003-07-24
KR20040073566A (en) 2004-08-19
HK1068885A1 (en) 2005-05-06
PL371432A1 (en) 2005-06-13
BR0306922A (en) 2004-11-09
CN1639132A (en) 2005-07-13
IS7348A (en) 2004-07-08
CN100357275C (en) 2007-12-26
RU2004119966A (en) 2005-06-10
RU2312105C9 (en) 2008-06-10
NO20043370L (en) 2004-09-28
EP1467976B1 (en) 2011-11-23
IL162678A0 (en) 2005-11-20
TWI328007B (en) 2010-08-01
JP2005521650A (en) 2005-07-21
AR038179A1 (en) 2005-01-05
RU2312105C2 (en) 2007-12-10
US7662825B2 (en) 2010-02-16
NZ533750A (en) 2006-03-31
MXPA04006806A (en) 2004-12-06
ATE534635T1 (en) 2011-12-15
JP4504021B2 (en) 2010-07-14
CO5640137A2 (en) 2006-05-31
AU2003201802A1 (en) 2003-07-30
ES2375107T3 (en) 2012-02-24
WO2003059893A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
US20100081670A1 (en) N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
US7410972B2 (en) Compounds
US20060122195A1 (en) Sulphonamide compounds that modulate chemokine receptor activity (ccr4)
US8106063B2 (en) Pyrimidyl sulphone amide derivatives as chemokine receptor modulators
US7482355B2 (en) Pyrimidine derivatives as modulators of chemokine receptor activity
EP1708996B1 (en) Fused heteroyral derivatives for use as p38 kinase inhibitors
US8293917B2 (en) Pyrazole compounds as CCR1 antagonists
US8153818B2 (en) Triazolyl phenyl benzenesulfonamides
US8722883B2 (en) Pyrimidine sulphonamide derivatives as chemokine receptor modulators
US20070161673A1 (en) P38 kinase inhibitors
EP1660461B1 (en) Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases
EP1202984A1 (en) Novel diphenyl-piperidine derivate
ZA200405260B (en) N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载